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Abstract 
NICOLA HELEN CARTWRIGHT 
CYTOKINE PROFILES AND THEIR RELEVANCE TO HUMAN 
TRANSPLANTATION 
The aim of this project was to develop an in vitro functional assay for the prediction of 
allograft rejection following renal transplantation. This assay was also used to study 
acute GVHD following identical sibling bone marrow transplantation. Lymphocyte 
cytokine profiles were measured by ELISA (protein secretion) and flow cytometry 
( cytokine expression) following mitogen stimulation and MLR. In normal individuals, 
considerable inter-individual variations were found in both protein secretion (IL-2, IL-
4, IL-10 and IFN-y) and cytokine expression (IL-2 and IFN-y). Strong relationships 
were found between IL-2 protein and expression, IL-2 and IL-10 protein, and IL-10 
and IFN-y protein secretion. Analysis of cytokine gene polymorphisms showed no 
correlation between IFN-y protein secretion, frequency or gene polymorphism. 
?re-transplant MLRs were set up between renal transplant patient/donors pairs and 
cytokine protein secretion (IL-2, IL-4, IL-6, IL-10 and IFN-y) measured by ELISA. 
Analysis was performed to ascertain predictive factors of allograft rejection. Inter-
individual variations were found for all cytokine profiles. Significant correlations were 
found between individual cytokine protein profiles including IL-10 and IFN-y. In 
addition, a correlation was found between HLA-DR mismatching and both IL-10 and 
IFN-y protein secreted in the MLR.Primary univariate analysis revealed that HLA and 
HLA-DR mismatching, female donor sex, MLR-stimulated IL-10, MLR-stimulated 
IFN-y and spontaneous IL-4 secretion were associated with an increased risk of 
rejection. Multivariate analysis showed the strongest correlations for predicting risk of 
rejection to be female donor sex, HLA mismatching and MLR-stimulated IL-l 0 
secretion. A combination of high HLA mismatching and high IL-l 0 secretion in MLR 
gave the highest risk of rejection (RR=25.5). Finally, cytokine secretion decreased 
when measured post-transplant. Prediction of graft survival could not be analysed due 
to the low number (n=6) of patients that suffered graft failure in the group. 
Cytokine protein secretion (IL-2, IL-4, IL-10 and IFN-y) in MLR was also studied for 
prediction of GVHD after bone marrow transplantation. There was a very low MLR . 
response by all BMT pairs, therefore analysis could not be performed. 
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1.1. History of transplantation 
1.1.1. Early experiments 
Transplantation may be described as "the removal or partial detachment of a 
part of the body and its implantation to the body of the same or different individual". 
Accounts of transplantation date back as far as 250AD with the famous legend of 
Cosmas and Damian. This legend describes transplantation as one of the miraculous 
feats of these two medical martyrs, where they performed numerous healings until 
their deaths in 287 AD. 
Later, in 348AD, the miracle of the black leg occurred, whereby an elderly 
parishioner lay sleeping with a gangerous leg. It is believed that saints came and 
removed his leg with a saw, and replaced the destroyed tissue with a fresh leg obtained 
from a Moor buried that day. The man awoke to find himself free of pain and able to 
walk with his new healthy black leg (Kahan, 1983 ). 
A new Western tradition of transplantation surgery arose during the 
Renaissance in Bologna, where the 16th century anatomist and surgeon Gasparo 
Tagliacozzi developed his technique for reconstruction using a flap of skin from the 
inner side of the upper arm. He carved the flap of skin into the shape of the patients 
nose and stitched it to the forehead and inner surface of the cheek, leaving a slender 
attachment to the arm to maintain the blood supply. After three weeks of healing, the 
attachment was severed. The technique is currently still in use, and is known as the 
Tagliacotian flap or Italian method (Converse and Casson, 1968). 
The Scottish surgeon John Hunter (1728-1793) is also famous for his 
experimental procedures in transplantation. One of his grafts includes the transplant of 
a cocks claw to its comb. Not only did the claw survive, but actually grew towards the 
beak of the animal. John Hunter managed to revive the practice of transplanting teeth, 
which had been utilized in ancient Egypt, Greece, Rome, Arabia and pre-Columbian 
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America, as well as by Ambrose Pare of Paris in the 16th century (Converse and 
Casson, 1968). 
1.1.2. Organ transplantation in the twentieth century 
During the early years of this century, it had been shown that 
autotransplantation (where donor and recipient are the same individual) was virtually 
always successful and homo- (donor and recipient of the same species) and 
heterotransplantation (donor and recipient are of different species) were always 
unsuccessful. Organ transplantation has developed during the 20th century, with 
transplantation of organs including the kidney, liver, heart, lungs and intestine being 
performed. 
One of the first autotransplants was performed in 1902 by Emmerich Ullmann 
where he removed both the kidneys of a dog, and replanted one of them. The 
interruption of the blood circulation did not interfere with the function of the kidney, 
and from this experiment, it was viewed that grafting of an organ was a possibility 
(Carrel, 1908). Homotransplantation using the same technique was not as successful. 
The recognition that blood vessel anastomosis was required in order to move major 
vascularised organs such as the kidney from one animal to another was made by Alex 
Carrel in 1902. His method has been used since that time, with few modifications 
(Carrel, 1908). Later, in 1936, a Ukranian surgeon, Yu Yu Voronay treated six patients 
with renal failure by the transplantation of a human kidney. However, these transplants 
were unsuccessful (reviewed by Brent and Sells, 1989). The first successful human 
renal transplant in modern times was performed by Hufnagel and colleagues, who, in 
1946, transplanted a cadaveric kidney to the arm of a woman suffering from 
septicaemia. The kidney was rejected after three days (Hufnagel, 194 7). 
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Transplantation of long-tenn surviving kidneys was finally put into practice in 
1954 by Murray and Colleagues in Boston, Massachusetts. A kidney was transplanted 
between identical twin brothers, and immediate function was seen. The organ 
continued to function for a further eight years (Merrill, 1956). Following their success, 
the group had many cases of renal failure where non-identical relatives offered to 
donate kidneys. 
1.1.3. The second set response 
Although there was some success in transplantation, it was soon realised that 
the loss of the grafted organ was due to something quite distinct from processes such 
as infection or inflammation. The tenn "rejection" indicated a process by which the 
new host was refusing to grant the "right of abode" to the transplanted organ. 
Following these observations, during World War II, the British Medical Council 
focused on the problems of skin grafting. Or Peter Medawar, a British Lebanese, was 
asked to work with a plastic surgeon, Or Thomas Gibson in order to perfect skin 
grafting. It was noticed that if a skin graft was placed from one animal to another, it 
survived for about one week. Then, if a second set of skin was applied in exactly the 
same fashion, the second set of skin rejected in about half that period of time. This was 
tenned the "second set response", which now has major historical importance in 
transplantation science (Converse and Casson, 1968). 
1.1.4. Clinical immunosuppression 
Since 1962, all tissue transplantations between unrelated individuals have been 
carried out with the patient under the influence of a chemical reagent to suppress the 
immune system of the recipient to the graft. Many investigators were studying whole 
body or whole graft irradiation as a means of immunosuppression. The breakthrough 
32 
came when Schwartz and Dameshek made clinical observations on the effect of a 
compound called 6-mercaptopurine on protein. They discovered that by radioactively 
labelling albumin given to a laboratory animal, it was possible to study its 
disappearance curve. It was rapidly removed from the blood system by circulating 
antibodies, but when the animals were given 6-mercaptopurine, the foreign protein had 
a normal half-life in the body fluids of the recipient (Schwartz and Dameshek, 1959). 
A young surgeon, Mr Roy Calne, followed these findings by applying 6-
mercaptopurine to the kidney graft model. Following the success of his experiments, a 
derivative of this drug, now known as azathioprine, was developed. Improved graft 
survival in kidney transplants was demonstrated (Ca1ne et a/, 1978), and organ 
transplantation was considered to be the treatment of choice for a wide variety of end 
stage diseases. 
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1902 First successful experimental (canine autograft) transplantation 
1912 Alexis Carrel awarded Nobel Prize for describing techniques on organ grafting 
1933 First human allograft kidney transplant performed by Yu Yu Voronay, Russia 
1943 Rejection observed by Medawar and Gibson and recognition of "second set 
response" 
1946 First functioning human allograft performed in Boston, USA 
to 1953 First long term surviving human renal isograft performed in Paris, France 
1960 Observation of effectiveness of 6-mercaptopurine in canine renal tranplantation 
1962 Widespread use of azathioprine and steroids in renal transplantation 
1967 Machine hypothermic perfusion of kidneys providing seventy two hours of 
storage 
1967 Clinical introduction of anti-lymphocyte globulin for prophylaxis against 
rejection in Denver, USA 
1968 Brain death criteria determined by committee ofHarvard Medical School 
1968 First prospective histocompatibility locus antigen matching of cadaver kidney 
recipients in Melbourne, Australia 
1969 Cold storage of kidneys for twenty four hours 
1978 First clinical use of cyclosporin in Cambridge, England 
1981 First clinical use of mouse monoclonal anti-CD3 antibody (OKT3) 
1990 First clinical use ofFKS06 in Pittsburgh, USA 
Table 1.1. Experimental chronology of transplantation in the twentieth century 
(adapted from Alien and Chapman "A Manual of Renal Transplantation"; 1993). 
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1.2. Allogeneic renal transplantation in man 
1.2.1. Introduction 
Kidney transplantation is now considered the treatment of choice for a variety 
of end-stage renal diseases. There are several steps which have to be taken before the 
transplant can take place. Not all patients receiving dialysis are suitable for 
transplantation. Careful assessment of potential renal transplant recipients both by 
those who are responsible for their long term care and by the team responsible for 
transplantation is essential for all renal units. The patient needs to consider both the 
options available and to meet those involved. The process of assessment is critical to a 
successful outcome of the transplant. 
1.2.2. Procedure 
Explicit clinical criteria are applied when determining a patients' suitability for 
transplantation. A full pre-operative assessment is made of the potential renal 
transplant recipient, including a notification of full medical history eg; history of renal 
disease, family history, allergies etc. A physical examination is also carried out 
together with routine laboratory and clinical investigations, including full blood 
counts, cross-matching, chest X-ray and electrocardiogram (ECG). When the patient 
goes into theatre, he/she is anaesthetised. The donor kidney is prepared and 
transplanted in a heterotopic position in one or other of the iliac fossa, with vascular 
anastomoses to the recipient iliac vessels, and ureter anastomosis to the urinary 
bladder (Belzer, 1991, Ha yes, 1993). Once transplantation has been performed, if the 
patient is in a stable respiratory and cardiovascular state, they may be transferred 
directly to the transplant ward where they will be monitored for cardiopulmonary and 
transplant function, and started on immunosuppressive therapy as soon as possible. 
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1.2.3. Indications for renal transplantation 
The causes of end stage renal failure may include glomerulonephritis ( 15.7% of 
total) (Heafet a/, 1999, Couser, 1999), diabetes mellitus (9.5%) (Klein et a/, 1999), 
reflux nephropathy (15.5%) (Vallee et al, 1999), polycystic disease (9.3%) (Kohno and 
Yunoki, 1999), hypertension (5.3%) (Dasgupta et a/, 1999) and renal vascular disease 
(2.6%) (Christensson, 1999). According to the UK renal registry report, other causes, 
either uncertain (34%) or causes with no information (24%) may be associated (Ansell 
and Feest, 1999). Viral infections may be associated, for example, Hepatitis C has 
been shown to be associated with glomerulonephritis (Okada et a/, 1996). 
Transplantation is contraindicated in the presence of malignancy or active infection. 
There are few situations where transplantation is not possible, and in some there are 
difficulties. Oxalosis represents a relative contra-indication, although this condition 
may be considered to be rare (Farreli et a/, 1997, Gluck et a/, 1998). However, it has 
been shown that patients with this condition may be transplanted successfully if 
perioperative management is applied (Alien et a/, 1996). Conditions such as Fabry's 
Disease (Sirvent et a/, 1997, Wuthrich et a/, 1998) and amyloidosis (Druecke et a/, 
1995) may also be considered contraindications for transplantation. Although 
transplantation is not strictly a contra-indication in patients with renal amyloidosis, it 
carries high post-operative risks such as cardiac complications (Turkrnen et a/, 1998, 
Kaaroud et a/, 1999). Age may also be classed as a relative contra-indication. Patients 
up to the age of seventy are now being regularly transplanted, although mortality in the 
years after transplantation is much greater, primarily due to cardiovascular disease. 
However, more recently, it is thought that chronological age is not a major factor in 
determining the short term (<five years) survival of grafts because an increase in 
deaths with a functioning graft is counterbalanced by a lower rejection rate in the 
elderly (Cameron et a/, 1994, Cantarovich et a/, 1994, Tesi et a/, 1994, Sanchez-
36 
Fructuoso et a/, 1998). A worse graft survival, however, has been shown in older 
patients when receiving a kidney from an older donor, possibly due to a series of 
changes characterised by glomerular, vascular and tubular senescence, which may be 
aggravated by artherosclerosis, hypertension, or diabetes, which are highly prevalent 
in older individuals (Basar et a/, 1999). 
1.2.4. Preservation 
Effective preservation is essential in all kidney transplant programmes. In the 
course of renal transplantation, the kidney, once removed from the donor, starts to cool 
towards room temperature. Damage may be caused to the organ, termed ischaemia. It 
is the length of ischaemia time that is said to determine the long term behaviour of the 
organ (Ca1ne, 1965). This can be reduced either by continuous perfusion on a machine 
or by flushing with one of several appropriate solutions and then storage in ice, which 
will allow preservation for at least twenty four hours (Matsuno et a/, 1996, Kozaki et 
a/, 1997). Solutions used are usually citrate-based, which contain high concentrations 
of potassium, phosphate and mannitol. This process may cause injury to the organ, and 
has been reviewed that this may even be associated with decreased graft survival 
and/or rejection (Szabo and Heeman, 1998, Chandraker, 1999). However, despite 
methods employed to minimize damage to the kidney (Brasile et a/, 1997), it remains 
essential that the renal transplantation is performed as quickly as possible. 
1.2.5. Live versus cadaveric transplantation 
The use of organs donated from live related (and unrelated) donors has been 
suggested as a solution to the shortage of cadaveric organ donation (Thiel, 1998). The 
limitation of cadaveric donation is due to the availability of cadaveric donors, which is 
falling due to improvements in road safety and changes in medical practice, with the 
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added complication of the continued refusal for organ donation (between 20 and 30%). 
Therefore the need continues for donation by living donors (Terasaki et a/, 1997, Foss 
et a/, 1998, Haberal et a/, 1998, Cecka, 1999). There has been a great improvement in 
short-temi survival in organ allografts. Recent transplant registry data shows that five 
year graft survival for recipients of first cadaveric kidneys has increased to over 60% 
(Cecka, 1998). These advances resulted from a combination of factors including more 
powerful and less toxic immunosuppressive drugs, better tissue matching and 
improved surgical techniques (Gorski, 1996). In previous years, the expected half life 
of a cadaveric allograft that remained functional for twelve months was an additional 
eight and half years, a duration that has not changed appreciably since (Turka, 1998). 
Donation from live related or unrelated donors can be considered an effective 
alternative to cadaveric donation (Alfani et a/, 1996, 1998, Peters et a/, 1999). 
Registry data also shows that graft survival at five years is higher in recipients 
receiving grafts from living donors compared to cadaveric donors (Cecka, 1998). Long 
term observations reveal that survival and function of kidneys transplanted from 
living-related donors are better than cadaveric kidneys (Stryjecka-Rowinska and 
Wataszewski, 1996, Fangmann et a/, 1999). This may be due to several factors: 
a) Better immunological compatibility between donor and recipient 
b) Better pre-operative preparation of donor and recipient 
c) Application of less aggressive immunosuppressive protocols 
d) The possibility of immunizing the future recipient with the donors' blood 
Despite a substantial increase in the number of living donor transplants 
performed in recent years, graft survival rates are still superior to all but HLA-
identical cadaver transplants (Cecka, 1997). Allograft survival at ten years have been 
recently shown to be over 70% for HLA-identical sibling transplants, and 55% for 
other living donor transplants (eg; HLA-non-identical) and cadaveric transplants 
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(Cecka, 1997). Slightly earlier data also showed an improved graft survival rate at both 
five and ten years in live-related transplants (5=87%; 10=85%) compared to cadaveric 
transplants (5=75%; 1 0=57%; Mouquet et a!, 1996). (Figure l.l ). Both patient and 
graft survival has also been shown to be up to 10% higher in live donor transplants 
compared to cadaveric (Recio et a!, 1996, Cecka, 1998). 
As well as the long term survival in live-related transplants being better than 
cadaveric, first acute rejection episodes have been shown to be lower in live related 
transplants compared to cadaveric (Cecka and Terasaki, 1993, Cecka, 1998, Offner, 
1994). This may not primarily be due to a better HLA compatibility in live related 
transplants, but the higher extent of graft tissue damage in cadaveric grafts might 
contribute to the susceptibility to alloimmune reactions leading to more rejection 
episodes. A higher rate of chronic rejection has also been shown in cadaveric grafts 
compared to live related (Fangmann et a!, 1999). Although the number of rejection 
episodes are lower in live-related transplantation, immunosuppressive therapy remains 
necessary for the prevention of allograft rejection. 
1.2.6. Complications of renal transplantation 
1.2.6.1. Technical 
The majority of the senous technical complications are either vascular or 
urological. Renal artery or vein thrombosis occurs within the first week after 
transplantation, and generally within the first forty eight hours (Ghekiere et a!, 1998). 
It may be suggested that this complication may not arise very often, a 5% incidence 
has been reported and that these are occurring due to the increased use of cyclosporin 
therapy (Beyga and Kahan, 1998). Presentation of thrombosis involves painful 
enlargement of the renal transplant, haematuria · followed by graft rupture and 
hypotension. The transplant itse1fpresents as being enlarged, oedematous and is 
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Years post-transplant 
Figure 1.1. Graft survival in live related and cadaveric transplantation (data from 
Mouquet et al, 1996). 
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surrounded by fresh blood clots (Hussein et a/, 1999). However, early diagnosis of 
vascular thrombosis may enable graft salvage by surgical or thrombolytic treatment 
{lsmail et a/, 1997). 
Renal artery stenosis has been reported to develop in quite a low percentage of 
patients of patients (Merkus et a/, 1993, Lopes et a/, 1998). This complication can 
occur anytime between three months and years after transplantation. The occurrence of 
this complication is technical in origin, although it may reflect initial damage during 
the nephrectomy or perfusion (Rigg, 1995, Preston and Epstein, 1997). In general, the 
patient will present with hypertension and deteriorating renal function. Surgery is 
usually the approach to correct this complication (Henry et a/, 1999, Sekkarie, 1999, 
Dowling et a/, 1999). 
Urinary tract complications comprise of either urinary leaks or obstructions. 
Urine leaks (or ureteric stenoses) generally occur from the lower end of the ureter 
which may have necrosed during ischaemia. This ischaemia is almost inevitably 
related to damage to the blood supply to the ureter during removal of the kidney. The 
incidence of urological complications following renal transplantation is 2-10%, and 
most of these complications occur within the first year, leading to a deterioration of 
renal function (Maier et a/, 1997). Surgery may be performed to reconstruct the ureter, 
as with renal artery stenosis (Insall et a/, 1995, Peregrin and Lacha, 1998). 
Obstruction of the ureter in the early period after transplantation is uncommon, 
but can be associated with kinking when a redundant length of ureter has been used. It 
may also be caused from external compression by a transplant lymphocele, which may 
be treated with omentorplasty/omentopexy (Bry et a/, 1990, Ovnat et a/, 1995). 
Urinary tract haemorrhages are common in the first week post-transplant, but are an 
uncommon cause of impaired renal function. A bleeding vessel may be found at the 
end of the ureter, or in the bladder wall (Jaskowski et a/, 1987, Shoskes et a/, 1995). 
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1.2.6.2. Infections 
Infection of any form is common in immunosuppressed transplant recipients 
and has non-specific effects on transplant function. During the first month post-
transplant infections are mostly conventional bacterial including wound infections, 
pneumonia and urinary tract infection (Schrnaldienst and Horl, 1998), with the only 
viral infection occurring during this time being herpes simplex virus (Schlupen et a/, 
1995, Gomez et a/, 1999). 
Cytomegalovirus (CMV) is now considered to be one of the most important 
infectious complication after organ transplantation (Daniel, 1999). A variety of clinical 
manifestations such as fever, leucopenia, hepatitis, ureteritis and glomerulopathy have 
been described (Rao et a!, 1994, Zhang and Chan, 1994, Moudgil et a/, 1997, Yeung et 
a/, 1998). The infection is usually treated with the anti-viral agent ganciclovir, either 
orally (Ahsan et al, 1997) or intravenously (Sancho et a/, 1999). An association 
between either acute or chronic rejection and CMV infection has been reported in 
renal (Kashyap et a/, 1999, Yeung et a/, 1998) and liver transplantation 
(Lautenschlager et a!, 1997, Rosen et a/, 1998). However, there is evidence to suggest 
that enhancement, but not induction of rejection is associated with CMV in heart 
transplantation (Boriskin et a/, 1996, Decoene et a/, 1996). 
Interestingly, some reports suggest that increased HLA class II antigen 
expression is associated with increased CMV infection, in particular HLA-DR7 
(Blancho et a!, 1992, Kraat et a!, 1993, 1994), thus triggering the anti-allograft 
response. However, other work has suggested this not to be the case (Gomez et a/, 
1993). Several in vitro studies have supported the latter (Sedrnak et a!, 1994, Ng-
Bautista and Sedrnak, 1995, Knight et a/, 1997, Scholz et a/, 1997). It has also been 
reported that glycoproteins encoded by the CMV genome exhibit homology with both 
HLA class I (Bankier et a/, 1991) and class II antigens (Fujinami et a/, 1988, Plachter 
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et a/, 1993). Rejection is known to precede clinical evidence ofCMV, and this may be 
explained by the long incubation time of several weeks, with the virus being of donor 
origin and received within the graft at the moment of transplantation (Grundy et a/, 
1988, Lauzurica et a/, 1992, Costa et a/, 1994). It has also been shown in murine 
models that latent CMV may be reactivated by allogeneic stimulation and 
immunosuppression (Bruning et a/, 1989, Bruggeman, 1993, Yagku et a/, 1994). In 
contrast, there is now evidence to suggest that factors like immunosuppression may 
not be associated with CMV reactivation, but instead cytokines such as tumour 
necrosis factor (TNF) may be responsible (Koffron et a/, 1999). It therefore appears 
that association with CMV infection and rejection is involved with HLA antigens and 
the immune response against those antigens. 
1.2.6.3. Long term 
Hypertension IS common after transplantation and the prevalence of 
hypertension has increased with the use of immunosuppression (Gerhardt et a/, 1999, 
Taler et a/, 1999). Immunosuppressants like tacrolimus have been shown to induce 
less hypertension than drugs like cyclosporin (Canzanello et a!, 1998, Taylor et a/, 
1999). It has been suggested that cardiovascular complications are the major cause of 
morbidity following renal transplantation (Kasiske et a/, 1996, Aker et a/, 1998, 
Aakhus et a!, 1999). Drugs such as angiotensin converting enzyme (ACE) inhibitors 
and beta blockers are highly effective in reducing blood pressure and may help to 
preserve graft function in the long term (Grekas et a/, 1996, Hausberg et a!, 1999). 
The prevalence of all types of cancer is increased in patients on 
immunosuppressive therapy after transplantation. The most common cancers include 
squamous cell carcinomas (Shafqat et a/, 1997, Hiesse et a/, 1997), lymphomas 
(Johnson and Herzig, 1999) and even cervical cancer (ter Haar-van Eck et a/, 1995). 
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Human papilloma virus infections are associated with both skin and cervical cancers 
(Mansat-Krzyanowska et a/, 1997, Ozsaran et a/, 1999), whilst Epstein Barr virus 
infections are mainly affiliated with skin lymphomas (Chai et a/, 1999). In the early 
stages of the lymphoma (termed post-transplant lymphoproliferative disease or PTLD), 
the B cell proliferation is polyclonal and diffuse (Tessler et a/, 1998). This disorder is 
potentially reversible on reduction of immunosuppression (Balfour et a/, 1999, Rees et 
a/, 1998). 
1.3. Immunosuppressive therapy 
1.3.1. Introduction 
In an ideal clinical situation, all organ donor-recipient pairs would be HLA-
identical, and therefore the incidence of rejection would be small (de Mattos et a/, 
1999). However, this is rarely the case due to the shortage of donors combined with 
the difficulty of HLA matching. Therefore, donor-recipient pairs usually exhibit a 
degree of HLA incompatibility, and therefore acute rejection may occur (Reisaeter et 
a/, 1998). Immunosuppressive therapy is used to try and prevent or reverse acute 
rejection by setectively abrogating the patients' reactivity to the allograft (Keown, 
1998). Immunotherapy should, preferably, be donor specific and targeted to minimise 
the risks of non-specific immunosuppression. An ideal immunosuppressant would 
specifically block the activities of only the small population of antigen-specific cells 
actually engaged in the events of rejection, for instance, Basiliximab (Onrust and 
Wiseman, 1999, discussed later). There are perhaps four key needs which, if not met, 
could marginalise transplantation as a form of therapy: i) Achieving logical 
immunosuppression (striking a balance between maximizing therapeutic effectiveness 
and minimizing side effects) ii) overcoming chronic rejection iii) new therapeutic 
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targets and iv) increasing the number of organ donations. However, although the ideal 
immunosuppressant has not been found as of yet, great progress has been made. 
1.3.2. Cyclosporin/Sandimmune 
1.3 .2.1. Mode of action 
This drug was originally isolated from two strains of fungi imperfecti by the 
Department of Microbiology at Sandoz in Basle, Switzerland as an antifungal agent of 
limited activity. The compound increased in interest when Bore! and colleagues 
discovered that it exerted pronounced immunosuppressive activity in vivo without 
causing myelotoxicity or other severe side effects (Bore! et a/, 1976). Following 
Borels' initial description of the immunosuppressive properties of this drug, it was 
then described to suppress rejection of vascularised organ allografts in a variety of 
species (Morris, 1981 ). Clinical trials of the drug in renal transplantation began in 
Cambridge in 1978 (Calne et a/, 1979) and when cyclosporin became generally 
available in the early 1980's, it quickly became the major immunosuppressive drug 
used in organ transplantation. 
Cyclosporin is a fat soluble cyclic peptide antibiotic derived from the fungus 
Tolypodadium Injlatum. Of the eleven amino acids, seven are non-methylated and one 
is a unique derivative of threonine (Verheyden et a/, 1994). Due to its lipophilic 
properties, cyclosporin readily diffuses across cell membranes and binds to two 
intracellular proteins, calmodulin and cyclophilin. Calcineurin, a calciurnlcalmodulin-
dependent serine/threonine phosphatase has been shown to be inhibited by the 
complex of cyclosporin and its receptor, cyclophilin (Li and Handschumacher, 1993, 
I very, 1999). Cyclosporin inhibits early stages of lyrnphocyte proliferation in response 
to a variety of activation signals. It specifically blocks the activation of not only IL-2 
production (Matsuda et a/, 1998), but also IL-2 receptor at the mRNA level (Li et a/, 
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1992), thus inhibiting IL-2 gene transcription and subsequent protein secretion. The 
decrease in IL-2 production has been shown to cause a shift towards tolerance 
inducing cytokines, thus attempting to dampen down the allogeneic rejection response 
(Van den Berg, 1998). The drug appears to affect CD4+ T cells in particular (Fischer 
et a/, 1991), as CD4 plays a major role in IL-2 induction (Oyaizu et a/, 1992) although 
some effects on CTL activity, B cell differentiation and HLA antigen expression has 
been shown (Roelen et a/, 1993, Vaessen et a/, 1994) 
New formulations of cyclosporin have been made, attempting to improve 
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adsorption and decrease side effects. One such formulation is known as Neoral and has 
been subjected to many random double blind studies to establish its safety and 
tolerability (Barone et a/, 1996, Feutren et a/, 1996). Neoral is a novel microemulsion 
formulation of cyclosporin, and all studies performed have shown there to be an 
improved outcome with this new formulation, not only with tolerability, but also with 
decreased incidence of acute rejection (Keown, 1996, Warrens et a/, 1996, Cossu et a/, 
1998). 
1.3.2.2. Side effects 
The major side effect of cyclosporin is nephrotoxicity, which is ironic in the 
sense that the clinical features distinguishing cyclosporin kidney toxicity from other 
causes of graft dysfunction are not clearly established (Barone et a/, 1996). Although 
pharmacokinetic considerations have been taken into account in tailoring dosage of 
cyclosporine (Kahan, 1996), inter-individual differences in drug sensitivity can still 
lead to chronic nephropathy (Povlsen et a/, 1991 ). This side effect has been defined as 
a clinicopathologic entity produced by exposure of a patient to cyclosporin (Bennett et 
a/, 1996). Cyclosporin vasoconstricts the vessels of the kidney, and as these are much 
more sensitive to the constrictive effects of cyclosporine compared to non-renal blood · 
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vessels, this leads to renovascular injury (Curtis, 1996). The potent vasoconstriction 
seen after administration is mediated by reduction in vasodilatory prostaglandins and 
nitric oxide, leading to subsequent systemic hypertension (Bobadilla et a/, 1998). 
Surprisingly, although this drug is used as part of an anti-rejection regimen, 
extensive use of cyclosporin may be one of the leading causes of long-term renal 
allograft failure due to its nephrotoxicity (Vanrenterghem and Peeters, 1996). It has 
even been shown that in some transplants, there has been an increased frequency in 
kidney allograft rejection due to this risk factor (Bowes et a/, 1990), with cyclosporin 
monotherapy leading to increased risk of rejection compared to combined 
cyclosporine-steroid immunosuppression (Oppenheimer et a/, 1994). 
1.3.3. Corticosteroids 
1.3.3.1. Mode of action 
Corticosteroids remain one of the main classes of drugs used for induction, 
maintenance and rescue therapy. Steroids have been shown to lead to a better 
histological and functional outcome in transplant recipients (Rush et a/, 1998). 
Synthetic compounds (prednisone, prednisolone or methylprednisolone) are the most 
widely prescribed agents, and are usually given in combination with other 
immunosuppressive agents (Opelz, 1995, Lafferty et a/, 1997). Corticosteroids bind to 
intracellular, cytoplasmic high affinity receptors with which they form corticosteroid-
receptor complexes that interact with DNA and modulate gene expression. mRNA 
concentrations are modified and protein synthesis is consequently initiated or blocked 
(Bach and Viard, 1993). Corticosteroids provide the proximal block in the T cell 
activation cascade. They are able to do this by interfering with T cell proliferation 
through blocking the activation of the IL-l and II:.-6 genes (Vella and Sayegh, 1997). 
The fever associated with allograft rejection is probably caused by the secretion of IL-
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l, and therefore the ability of steroids to prevent fever in septic states almost certainly 
derives from the blocking of IL-l release. As IL-2 release is dependent upon IL-l 
stimulated IL-6 release, corticosteroids also indirectly block IL-2 production 
(Crabtree, 1989, Brattsand and Linden, 1996). 
The anti-inflammatory effects of corticoids are probably mediated by proteins 
of the lipocortin family, which are synthesised by macrophages in response to natural 
and synthetic corticosteroids (Almawi et a!, 1996). Lipocortin is an inhibitor of 
phospholipase A2, an enzyme involved in transmembrane signal transduction and in 
the synthesis of inflammatory mediators such as prostaglandins and platelet activating 
factor (Flower, 1990). Corticosteroids preferentially affect CD4+ T cells, inhibiting 
cytokine synthesis. 8 cells appear to be more resistant. 
Glucocorticoids have broad non-specific immunosuppressive and anti-
inflammatory effects (Cohn, 1997). Glucocorticoids have been suggested to inhibit the 
production of Th l type cytokines, and in turn, enhance the production of Th2 type 
cytokines (Almawi et a!, 1998, 1999, Ramirez, 1998). Besides their effects on 
cytokines they reduce the migration of monocytes to sites of inflammation . A major 
drawback to these drugs is that they inhibit the entire immune system, which can lead 
to some undesirable side effects. 
1.3.3.2. Side effects 
Due to the initial high dose protocols, inflammatory and phagocytic capacities 
are decreased, resulting in increased susceptibility to infection, impaired wound 
healing, hyperglycaemia, increased capillary fragility, osteoporosis in adults and 
growth suppression in children. 
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1.3.4. Azathioprine (lmuran) 
1.3.4.1. Mode of action 
Azathioprine has been shown to be successful in reducing acute rejection 
episodes after transplantation (Bergan et a/, 1998), with azathioprine monotherapy 
being safe and effective (Bartucci et a/, 1999). Azathioprine is an anti-metabolite and 
is a derivative of 6-mercaptopurine. It has non-specific effects on the immune system, 
but is known to have an anti-proliferative effect on lymphocytes and exerts a toxic 
effect on endothelial cells after metabolism by vascular endothelium (Weigel et al, 
1999). The main active metabolite of azathioprine, thionosinic acid, inhibits purine 
synthesis via a complex mechanisms involving numerous enzymes. However, T cells 
appear to be the major target of this drug, although, unlike 6-mercaptopurine, 
azathioprine inhibits proliferation by a mechanism independent of purine 
ribonucleotide depletion (Dayton et at, 1992). The imidazole ring of azathioprine is 
probably involved in its mode of action, perhaps through fixation of the drug to certain 
amino acid residues of membrane proteins. High concentrations of azathioprine tends 
to decrease the number of migratory cells such as neutrophils by inhibition of IL-8-
activated chemotaxis (Elferink et al, 1997). Early reports suggest that lymphocyte 
blast transformation and natural killer cell activity is inhibited (Ramsey et al, 1984, 
Musiani et al, 1985). As a result, the number of circulating monocytes capable of 
differentiating into macrophages is decreased. 
1.3.4.2. Side effects 
The major side effect of azathioprine is myelotoxicity, leading to severe 
leucopenia and depression of the bone marrow. Among the other possible deleterious 
effects of azathioprine administration· are thrombocytopenia, gastrointestinal 
disturbances~ fever, hepatotoxicity and an increased risk of neoplasia (Heaf, 1993). 
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1.3 .5. Tacrolimus/FK506/ProGraf 
1.3.5.1. Mode of action 
FK506 is a macrolide antibiotic of fungal origin which possesses similar 
immunosuppressive properties to cyclosporin, which although used in lower doses, 
may lead to an increased risk of infection (Cao et al, 1999). FK506 has been used 
since 1989 as a primary immunosuppressive agent in both adult and pediatric renal 
transplantation (Shapiro et al, 1996). This drug has been suggested to have the 
additional advantage over cyclosporin of permitting the tapering and, in some cases, 
the cessation of steroid therapy allowing for FK506 monotherapy in up to 40% of 
patients (Jordan et a/, 1996). The mechanism of action is similar to that of cyclosporin, 
with the blockade of calcineurin-mediated T cell receptor signal transduction (Salowe 
and Hermes, 1998). It also has the advantage of being more water soluble than 
cyclosporin, and therefore is less dependent on bile salts for adsorption. 
In vivo, like cyclosporin, FK506 inhibits allograft rejection, delayed type 
hypersensitivity reactions, and antibody production against thymus-dependent 
antigens. FK506 has been reported to affect the production of cytokines, including IL-
4 and IL-l 0 (Wang, 1992), by inhibiting cytokine gene transcription. The number of 
IL-2 producing cells are lower with FK506 compared to cyclosporin, which may 
explain the higher efficiency in vivo (Rostaing et a/, 1999a). 
1.3.5.2. Side effects 
FK506 can cause hypertension and late renal insufficiency. FK506 can also 
cause nephrotoxicity, similar to that of cyclosporin (Finn, 1999). One potential benefit 
of FK506, however, is as rescue therapy (Jordan et a/, 1996). This study reported how 
FK506 was able to be used as rescue therapy of rejecting allografts under primary 
cyclosporin immunosuppression. 
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1.3.6. Mycophenolate mofetil 
1.3.6.1. Mode of action 
Mycophenolate ts a morpholinoethyl ester of mycophenolic acid. 
Mycophenolate has the ability to reduce the incidence of acute rejection, in particular 
if used in conjunction with other therapies (Kim et a/, 1999, Puig et a/, 1999). The 
drug has a selective effect on lymphocyte activation. Mycophenolate mofetil causes 
the inhibition of purine synthesis, followed by the selective inhibition of the 
proliferation ofT and B cells, which subsequently inhibits antibody formation and the 
generation of CTLs (Sollinger and Rayhill, 1997). Multi centre studies have shown the 
effect of mycophenolate on graft and patient survival, renal function etc to be similar 
to drugs such as azathioprine (US Renal Transplant Mycophenolate Mofetil Study 
Group, 1999). Studies have also demonstrated mycophenolate as rescue therapy for 
biopsy-proven acute rejection in patients (Sollinger et a/, 1992, Birkeland, 1996). 
1.3.6.2. Side effects 
It is not classed as a nephro- or hepatotoxic drug, although it can cause some 
bone marrow toxicity. In studies of liver transplant patients, major side effects of 
mycophenolate observed included gastrointestinal problems, which usually manifest as 
gastritis and diarrhoea (McDiarmid, 1996, Hebert et a/, 1999). 
1.3. 7. Monoclonal antibodies 
1.3.7.1. Mode of action (0KT3) 
These drugs offer a more sophisticated approach to immunosuppressive 
protocols. The constant domains of the T cell receptor (TCR) complex is directly 
targeted for therapy by the use of monoclonal antibodies. OKT3 is a monoclonal 
antibody which is directed at the CD3 antigen on the surface of the T cell. This acts as 
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a transducer of signal from the T cell receptor, in conjunction with eo-stimulatory 
molecules, to intracellular activation events (Alegre et a/, 1995, Kawaguchi and 
Eckels, 1995). When the agent binds to the TCR, each of the latter's six proteins is 
stripped from the cell surface, either by shedding or internalization. OKT3-treated T 
cells therefore become literally blinded to the antigens of the allograft, and the 
rejection process comes to a halt. Studies have undertaken experiments and have 
suggested that the mechanism of inter-T cell bridging occurs, and therefore leads to 
cell mediated cytolysis (Wong et a/, 1990, Lwin et a/, 1995) The CD3+ T cells rapidly 
disappear from the circulation (Chatenoud et a/, 1990, Reinke et a/, 1997). T cells 
bearing the usual array of cell surface molecules ie; CD2, CD4, CD8 reappear but 
these cells are devoid of the CD3 molecule, therefore become immunoincompetent 
(Callait-Zucman et a/, 1990, Norman, 1995). Anti-CD3 monoclonal antibodies, 
together with anti-CD2 antibody, have been shown to induce alloantigen specific 
tolerance (Punch et a/, 1998). OKT3 is a powerful immunosuppressant and if used for 
the treatment of steroid-resistant allograft rejection, the drug has been shown to 
reverse a high percentage of acute rejection episodes (Jogose et a/, 1997), although 
this is not the case in every study (Rowe et a/, 1994). Much interest has been shown in 
targeting particular antigens or receptors as selective immunosuppressive therapy. One 
recent approach has been to target the IL-2 receptor, which is upregulated during a 
rejection response. 
1.3.7.2. Mode of action (anti-IL-2 receptor) 
Humanized monoclonal antibodies that recognize the alpha (a) chain of the IL-
2 receptor have been used to prevent allograft rejection, since the chain is expressed by 
T cells participating in allograft rejection but not by resting T cells. The high affinity 
IL-2 receptor is composed of three distinct membrane components, including the 55 
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K.Da IL-2 receptor-a chain, CD25 (Taniguchi, 1992, Minami et a/, 1993). Antibodies 
to the IL-2 receptor inhibit proliferation of antigen-activated T cells and prevent the 
generation of cytotoxic T cells (Yasuda et a/, 1998). Examples of these types of drugs 
include Daclizumab (Waldmann and O'Shea, 1998, Nashan et a/, 1999) and 
Basiliximab (Nashan et a/, 1997, Onrust and Wiseman, 1999). The approval of the 
new antibody was based on evidence that its use could reduce the rate of rejection 
episodes to about 20% (Auchincloss and Wood, 1998). 
Although anti-IL-2 receptor directed therapy has been used with considerable 
success, there are limitations. Antibodies to the IL-2 receptor alpha subunit do not 
inhibit IL-2 mediated activation of natural killer (NK) cells. In their resting state, NK 
cells do not express IL-2 receptor alpha but do express the other subunits, IL-2 
receptor-WIL-15 receptor-~ and y (Waldmann and Tagaya, 1999). Therefore, these 
antibodies do not inhibit the action of IL-15. Anti-IL-2 receptor a antibodies alone do 
not provide the complete immunosuppression ofT cell function that could be achieved 
if the actions of all of the cytokines that stimulate T cells were inhibited. A recent trial 
however, has attempted to administer an anti-IL-2 receptor drug which is specific for 
all three subunits, and was shown to be capable of suppressing the induction of CTLs 
and NK cells, resulting in prolongation of graft survival (Yasuda et a!, 1998). 
1.3.7.3. Side effects 
In particular for OKT3, within a few hours of the first dose, fever, chills, and 
general malaise can be seen. This response is thought to be due to the release of TNF 
from lysed T cells, with toxicity increasing with drug dosage (Parlevliet et a!, 1995, 
Richards et a!, 1999). This is usually treated with intravenous anti-histamines. The 
major side effect is an influenza-like syndrome (Embrey and Geist, 1995). Nausea may 
also be suffered. 
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OKT3 has been used as an induction regime as a cyclosporin sparing drug, 
although this has been proved to have no long term benefit. This approach provides a 
window of immunosuppression until graft function is established, followed by the 
introduction into the therapeutic protocol (Vanderwerf, 1996). 
1.3.8. Polyclonal antibodies 
1.3.8.1. Mode of action 
Due to the frequency and severity of adverse events as well as high costs of 
these drugs, they are only usually applied after treatment with methylprednisolone 
(Hilbrands et a/, 1996). Polyclonal antilymphocyte globulin (ALG) or antithymocyte 
globulin (ATG) preparations available for use in organ transplantation since the 
1970's, have proved effective for reversing renal allograft rejection (Burdick, 1986, 
Thibaudin et a/, 1998). ALG therapy has even been shown to be more effective that 
OKT3 when used concomitantly with cyclosporin (Grino et a/, 1992). Such polyclonal 
immune globulins are obtained by injecting animals (eg; horses or rabbits) with human 
lymphoid cells and then separating the resulting immune sera to obtain purified 
gamma globulin fractions. Polyclonal immune globulins represent a heterogeneous 
group of antibodies, only a minority of which are specific to T cells. 
There are several possible mechanisms by which globulins may exert an 
immunosuppressive effect. These include classic complement mediated lysis of 
lymphocytes, resulting in the decrease in T cell numbers (Strom, 1994, Lange et a/, 
1999). The specific antibodies bind to lymphocytes, and this usually results in a 
prompt and profound lymphopenia. In short, the resolution of cell-mediated graft 
rejection results from the elimination of circulating T cells (main cellular target), and 
the subsequent inhibition of proliferative responses maintains the immunosuppressive 
effect (Burdick, 1986). 
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1.3.8.2. Side effects 
As mentioned, because the specific antibodies bind to lymphocytes, 
lymphopenia may occur. Fever, chills, rash and increased susceptibility to infection 
may also occur (Min and Monaco, 1991). Anaphylactic shock may occur in a few 
cases due to the formation of xenogeneic serum protein antibodies, but this is 
extermely rare. Minimising the toxicity of these antibodies is being discussed (Pascual 
et at, 1996). 
1.3.9. Multiple drug protocols 
A regimen of azathioprine and prednisone in combination was the standard 
treatment for recipients with organ allografts prior to the introduction of cyclosporin. 
Almost all protocols have included adjunctive steroid treatment. Triple therapy is now 
used, consisting of cyclosporin, prednisone and azathioprine and has been shown to be 
more beneficial to the patient (Pfaff et at, 1996). Quadruple therapy has also shown to 
be beneficial after renal transplantation (Hiesse et at, 1999). Results have shown 
quadruple therapy to be more effective at reducing the incidence of allograft rejection 
compared to triple therapy (Cantarovich et at, 1998). One practical advantage of 
multiple drug therapy is that it permits more flexible immunosuppression. The dosage 
of the individual components can be altered to minimize complications or adverse 
effects while maintaining adequate overall immunosuppression. 
The use of intravenous immunoglobulins (lvlg) have recently come into use in 
patients receiving the basic cyclosporin regimen either for prevention of infectious 
complications or as an additional prophylaxis of GVHD. The addition oflvlg has been 
shown to cause a cyclosporin sparing effect, therefore leading to a possible combined 
immunosuppressive ·protocol (Schanz et at, 1996). In another study, lvlg was used as 
rescue therapy of renal allograft recipients on the standard cyclosporin protocol 
55 
(Casadei et a/, 1997). It revealed that 84% of the patient sample biopsies obtained after 
intravenous Ig treatment showed no evidence of rejection. However, Ivig may induce 
adverse effects such as hyperviscosity and renal insufficiency (Nydegger and 
Sturzenegger, 1999). The exact mechanism of Ivig action is still unknown, but it may 
involve anti-idiotypic antibodies that are present. These anti-idiotypic antibodies block 
anti-HLA antibodies, which may explain the ability of lvig to reverse a positive cross-
match. 
Other combinations of drugs have been investigated to attempt to improve the 
clinical outcome, including a combination of anti-CD4 and anti-IL-2 receptor therapy 
in addition to the usual regimen (Mousson et a/, 1995, Racadot et a/, 1995). Even 
adding additional drugs to further block the calcium channel along with cyclosporin 
have been attempted, with no significant improvement (Citterio et a/, 1996). In 
conclusion, immunosuppression significantly improves both patient and graft survival, 
although a drug which is able to completely inhibit the rejection response has not yet 
been found. 
1.4. Graft rejection 
1.4.1. Introduction 
The immune response to an allograft (a graft between animals of the same 
species, but of different genotype) will almost invariably result in rejection if not 
prevented by the appropriate treatment (Morris, 1989). Not only are grafts lost in the 
early weeks or months after transplantation, but in surviving grafts the lesions 
frequently caused by early rejection reactions may lead to permanent damage and to a 
gradual deterioration of function, months to years later (Morris, 1989). 
Rejection remains the major cause of transplant failure regardless of the tissue 
or organ grafted. Numerous host, donor and clinical factors can affect the level and 
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type of reactions to allografts (Sanfillipo et a/, 1984). In organ transplants such as 
kidney transplantation, functional decline is usually the first sign of a rejection 
reaction. It is important to establish a prompt diagnosis either of rejection or of any 
unrelated complication that might be the cause of deteriorating function, so that 
prompt and appropriate treatment can be commenced to reverse the process. The 
principles of diagnosis are essentially a deterioration of organ function accompanied 
by appropriate histological changes of rejection. 
Several types of rejection have been recognised for many years, namely 
hyperacute, acute and chronic. These terms are essentially based on the timing of the 
rejection and the immunological mechanisms causing the rejection. 
1.4.2. Hyperacute rejection 
Hyperacute rejection may be seen within minutes to hours after surgery. The 
kidney may become swollen and cyanotic, with renal circulation therefore being 
compromised. Within an hour of revascularization, the kidney becomes blue and 
flabby, and if a biopsy was taken, there would be evidence of widespread 
polymorphonuclear leucocyte infiltration (Wada et a/, 1998). Subsequent glomerular 
and arterial thromboses would also be evident (Bakir et a/, 1996). Histologically, 
severe vascular damage is typical and includes thrombosis (as mentioned), congestion 
and necrosis. 
1.4.3. Acute rejection 
This is the most frequent type of rejection seen after kidney transplantation. 
Acute rejection may develop between one week and three/six months post-transplant. 
Since the eta of cyclosporin A, reactions may now be seen within two to four weeks of 
transplantation and manifest by a moderate rise in serum creatinine (Castro et a/, 
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1998) and often, but not always, a moderate fever (Toogood et a/, 1994), usually with 
some swelling and tenderness of the kidney (Chung et a/, 1991). What now 
complicates the diagnosis of rejection is the acute cyclosporin nephrotoxicity that can 
become evident at the same time. As can be seen in Table 1.2, cyclosporin 
nephrotoxicity may also be associated with a rise in serum creatinine. Cellular 
infiltration of the graft is the most characteristic histopathological feature of the acute 
process (Vanrenterghem, 1995). As infiltration can also occur in well functioning 
grafts, it has been determined that it is the degree of cellular infiltration that provides a 
diagnostic indication of rejection (McWhinnie et a/, 1985). This has been used to 
distinguish between clinical and subclinical rejection (Grimm et a!, 1999). Cellular 
infiltration is discussed later. When inflammation is widespread and prolonged, blood 
flow is compromised and ischaemic tissue damage results, therefore acute graft 
rejection causes many of the pathological signs that is characteristic of tissue 
ischaemia (Orosz and VanBuskirk, 1998). Numbers of acute rejection episodes have 
been shown to among the best predictors of allograft survival (Tesi et a!, 1993). 
Unusually, in this study, traditional measures of immunological risk eg; HLA 
mismatches and panel reactive antibodies did not correlate with long term graft 
survival. HLA mismatching has been widely implicated as being a significant 
contributing factor towards increased acute rejection (discussed later). A more recent 
study has shown that in adult renal transplant recipients, the co-variate that best 
predicts the impact of acute rejection on graft survival is not the number of acute 
rejection episodes, but instead the impact of acute rejection on graft function (Cosio et· 
a!, 1997). Recent work has also shown there to be a significant association between 
delayed graft function and acute rejection (Troppmann et a!, 1995), and that acute 
rejection remains a risk factor not only associated with the allograft outcome (Peeters 
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Acute Rejection CsA Toxicity 
Serum creatinine Elevated Elevated 
Urine output Falling Unchanged 
Temperature Elevated Normal 
Graft Swollen and Unchanged 
tender 
Biopsy Cellular infiltrate Normal or minimal 
cellular infiltrate 
Oedema 
Vascular changes: 
fibrinoid necrosis Vacuolization of 
interstitial haem tubules 
thrombosis 
Giant cell 
mitochondria 
Arteriolar thrombosis 
Immunohistology HLA class II Normal class II 
induction expression 
Cyclosporin trough 
levels Low High 
Table 1.2. Distinguishing features of acute rejection and cyclosporin nephrotoxicity 
(information adapted from Morris, 1989). 
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et al, 1995) but also for incidence of chronic rejection (Matas, 1998, Matas et a!, 
1999). 
1.4.4. Chronic rejection 
Chronic rejection is the designated term for the slow, progressive and 
uncontrollable loss of renal transplant function. This stage presents as insidious 
deterioration in renal function at any time from six months to many years post-
transplant, and there is little or no response to additional treatment with high dose 
steroids. The histological picture shows interstitial fibrosis, marked intimal fibrosis of 
arteries and arterioles and minimal to moderate cellular infiltration (Hayry, 1996). 
Studies in rat models have shown cellular infiltration to include macrophages by 
preventing changes in the pathophysiology of chronic rejection by using specific 
macrophage inhibitors (Leendert et al, 1992, Heemann et al, 1993, Azuma et a/, 1995, 
Ishibashi et al, 1995). Macroscopically, the surface of the kidney is pale, and with 
increasing time after transplantation, the kidney becomes smaller. Risk factors for the 
incidence of chronic rejection have been discussed (Azuma and Tilney, 1994), 
including both immunologic and non-immunologic factors (Mourad et a/, 1996, 
Kasiske, 1997), including ischamia time and re-perfusion. Previous studies have 
implied, however, that the main cause of chronic rejection is the extensive damage 
caused by earlier episodes of acute rejection (Almond 1993a, 1993b, Koskinen et al, 
1996, Matas et al, 1999). 
Cyclosporin toxicity has also been linked to chronic rejection (Bennett et al, 
1996, Pascual et al, 1998). The histopathological lesions of chronic CsA toxicity share 
similarities with that of chronic rejection, although chronic CsA toxicity 
predominantly affects small vessels, whereas rejection affects·Jarger arteries (Curtis, 
1996). General criteria used to classify graft rejection may be found in Table 1.3. 
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1.5. Graft versus host disease 
1.5 .I. Introduction 
Graft versus host disease (GVHD) is the clinical manifestation of the graft 
versus host reaction. Human GVHD is composed of two distinct clinical entities, acute 
and chronic GVHD; with both of these conditions having a different pathogenesis 
(Parkman, 1998). There are three requirements for the development ofGVHD: 
I. The graft must contain immunocompetent cells capable of recognising and reacting 
against host antigens 
2. The host must be immunocompetent and incapable of rejecting the donor graft 
3. Alloantigenic differences must exist between donor and recipient, and these must 
be capable of inducing an allogeneic response. 
These criteria were first described more than thirty years ago in lethally 
irradiated mice given homologous (allogeneic) spleen cells (Billingham, 1966). 
Human GVHD was first observed in patients with primary immunodeficiences 
following whole blood or maternal-fetal transfusions which led to the patients' death 
(Walknowska et al, 1969). 
Factors involved in GVHD have been investigated both in animal (Shenoy et 
a/, 1998, Drobyski et al, 1999) and human studies (Przepiorka et al, 1999, Quaranta et 
al, 1999, Liem et al, 1999). Extensive fibrotic changes in the skin is characteristic for 
GVHD, and is known to be continuing major complication in transplantation, 
especially with the increasing use of related and mismatched donors (Vogelsang and 
Hess, 1994). 
It is now felt that GVHD is more complex than simple alloreactivity and is now 
suggested that even cytokines may play a role in mediating many of the clinical and 
experimental manifestations of GVHD (Jadus and Wepsic, 1992, Ferrara et al, 1993, 
Krenger et al, 1997, Ferrara and Krenger, 1998). 
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1.5.2. Acute GVHD 
Acute GVHD can manifest within the first one hundred days post-transplant. Acute 
GVHD is produced by the attack. of donor immunocompetent T or null cells against 
recipient histocompatibility antigens. It is characterised clinically by dysfunction of 
the skin, liver and gastrointestinal tract (Ghosh et a/, 1998). The most frequent clinical 
manifestation is an erythrematous skin rash (Moreb et a/, 1997). In more severe cases, 
generalised erythroderma can occur (Symington and Storb, 1989, Suzuki et a/, 1993). 
Liver involvement is manifested by hepatocellular enzymes and an increase in alkaline 
phosphatase. GVHD of the gastrointestinal tract presents as diarrhea. Cells, 
presumably of donor origin are found in the epidermis, with epithelial cells displaying 
signs of cellular damage including basal cell vacuolization and dyskeratosis, thus 
supporting the hypothesis that acute GVHD is a lymphocyte mediated disorder 
(Kohler et a/, 1997). 
Acute GVHD is usually graded (grades 0-IV) by the pattern of organ 
involvement using the classic Glucksberg-Seattle criteria (Glucksberg et a!, 1974). A 
new severity index has now has been developed by re-grouping the patterns of organ 
involvement into five indeces, 0, A, 8, C and D (Martino et a/, 1999). These can be 
seen in Table 1.4. 0 represents no acute GVHD, grades A and 8 represent the early 
stages ofGVHD (equivalent to the former grades 1-11). Grade A is usually mild, with 
grade 8 being moderatley severe. Grades C and D represent the advanced stages, 
equivalent to former grades Ill and IV, with C representing severe multi-organ GVHD, 
and D being life-threatening. 
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Classification Kinetics TargetStnictilreS 
1. Hyperacute Minutes/hours Vascular (large 
post-transplant and small) 
2. Acute: Rapid onset Vessels{large 
an<hmall) 
3.·C~ronic: Late post-transplant Vessels (large 
and small)· 
Table 1.3. Cla8sifi~ation ot rejection. 
I'· ' 
Iminune.·l\f:«!diators 
·Humoral· 
'. 
. Celiui3!, hillnoral 
·.· 
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lll.flammlltory Pa_tt~rn. 
.Fibnnoid necrosis 
~ul'ocytic i.nflittation 
Monocyte; Granulocytic, 
Mononuclear celLinfiltrate 
Ischeriiic damage' · 
1.5.3. Chronic GVHD 
Chronic GVHD is caused by immunocompetent cells that differentiate in the 
recipient (Parkman, 1998). Chronic GVHD is a multi-organ, autoimmune-like 
disorder with clinical manifestations including malar erythema, photosensitivity, oral 
ulcers, polyserositis and sicca (Sjorgen's) syndrome (Sullivan et a/, 1981, Sherer and 
Shoenfeld, 1998). Chronic GVHD can be classified as limited or extensive. Limited 
chronic GVHD involves localised skin involvement or hepatic dysfunction due to 
chronic GVHD. Extensive chronic GVHD involves either i) Generalized skin 
involvement ii) Localized skin involvement and/or hepatic dysfunction due to 
chronic GVHD, plus positive liver histology, eye biopsy, positive salivary gland or 
oral mucosa biopsy or involvement of any other target organ (Shulman et a!, 1980, 
Woo et a/, 1997). If untreated, after six to eighteen months, dermal thickening, 
scleroderma and joint contractures will develop (Chosidow et a/, 1992). The absence 
of clinical imd pathological renal disease resembling lupus or scleroderma kidney is 
another significant difference. Although chronic GVHD features common to 
naturally occurring autoimmune disorders, several differences can be clearly defined. 
1.6. Overview of the immune system 
1.6.1. Introduction 
Transplant rejection occurs due the recognition of foreign molecules and 
activation of various components of the immune system. The immune system in 
mammals has evolved to protect the host from pathogens and is dependent on the 
ability to recognise foreign molecules, especially proteins. The immune system has 
two functional divisions that are involved in a normal reaction to foreign antigens, 
non-specific (innate) immunity and specific (acquired) immunity. The two 
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Grade Skin Liver Gut .Functional 
impairment 
0 (none) 0 0 0 0 
A (mild) +to++ 0 0 0 
B (moderate) +to+++ + + + 
C (severe) ++to+++ ++to+++ ++to+++ ++ 
D (life- ++to++++ ++to++++ ++to++++ +++ 
threatening) 
Table 1.4. Severity index developed by the IBMTR (Martino et al, 1999) 
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systems work in unison, and it is known that many cellular and soluble components 
function in both systems (Carroll and Prodeus, 1998). Innate immunity is the initial 
non-specific response to tissue injury produced by the body in response to stimuli. 
Acquired immunity is a mechanism provided for the body to selectively detect and 
eliminate foreign antigens. It could be said that activation of innate immunity is a 
prerequisite for an adaptive immune response (Parish and O'Neill, 1997). Antigens 
may either be exogenous eg; pathogens or endogenous eg; damaged cells. A response 
is provoked when the body detects components recognised as "non-self'. Acquired 
immunity consists of a humoral component (antibodies) and a cellular component 
(lymphocytes ). 
1.6.2. Cellular effectors of the immune system 
The cells involved in the immune response are derived from the bone 
marrow, probably from a common precursor. These include the granulocytes 1e; 
neutrophils, eosinophils and basophils, the mononuclear cells 1e; 
monocytes/macrophages and the lymphocytes ie; B cells, T cells and NK cells. The 
different cell types can be determined by cell surface markers used to divide the cells 
into different phenotypes. These cell surface markers have been conventionally 
defined by CD (cluster of differentiation) numbers as agreed by 6th International 
Worshop (Sixth International Workshop and Conference on Human Leucocyte 
Differentiation Antigens, 1996). 
1.6.3. Granulocytes 
Polymorphonuclear granulocytes mainly consist of neutrophils (95%) which 
are released from the bone marrow at a rate of approximately seven million per ml of 
blood. Granulocytes make up about 70% of the total blood leucocytes, and like 
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monocytes (discussed later), can adhere to endothelial cells lining the blood vessels 
and extravasate by squeezing between the endothelial cells to leave the circulation 
(Jagels et a/, 1999). This process is known as diapedesis. 
1.6.3.1 Neutrophils 
These cells are involved in acute inflammation. They possess phagocytotoic 
activity and are granular. These granules contain substances such as lysozyme, 
antibiotic proteins, and myeloperoxidase (Tapper, 1996). They exhibit chemotactic 
activity and express high levels of receptors for a family of chemoattractants known 
as chemokines eg; IL-8 (Siddiqui et a/, 1999). Products from the complement system, 
products of bacteria and factors from fibrinolytic systems may act as chemotactic 
agents. Chemotactic stimuli results in neutrophil margination (adhesion to 
endothelial cells) and diapedesis. 
1.6.3.2. Eosinophils 
These cells comprise approximately 2-5% of blood leucocytes. They also 
exhibit phagocytotic activity. Their mode of activity may be by release of their 
granular content into the surrounding area or by production of toxic reactive oxygen 
intermediates (Fabian et a/, 1992). Eosiniophils are attracted by chemotactic factors 
such as ECF-A (eosinophil chemotactic factor of anaphylaxis), which is released 
from T cells, mast cells and basophils. Eosinophils also release histaminase, which 
inactivates the mast cell products histamine and the slow reactive substance of 
anaphylaxis (SRS-A) (Abelson et al, 1995). 
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l.6.3.3.Basophils and mast cells 
Basophils are found in very small numbers in the circulation, approximately 
making up 0.2% of the leucocyte population. This cell type is indistuinguishable from 
the mast cell in a number of properties. 
Mast cells may be found near blood vessels in all connective tissues, and 
contain randomly distributed granules which contain SRS-A, histamine and ECF-A. 
The stimulus for basophil or mast cell degranulation is IgE-mediated and is enhanced 
by cytokines such as IL-4 (Bischoff et at, 1999). Degranulation can only be effective 
if allergen (an antigen causing an allergic reaction) cross-links IgE molecules bound 
to the surface of the cell via its high affinity Fe receptors for IgE (Fc&Rl). Mediators 
of allergy such as histamine are released by degranulation. 
1.6.4. Monocytes/Macrophages 
Macrophages mature from circulating monocytes. Macrophages may be 
found in the tissue or as migratory cells. They secrete inflammatory intermediates 
including nitric oxide. Macrophages secrete a variety of pro-inflammatory cytokines, 
including tumour necrosis factor alpha (TNF -a, IL-l and IL-6), with these cells 
being involved in the early stages of inflammation known as the acute phase 
response (Koj, 1996). 
As with dendritic cells, macrophages are able to express HLA class I and 
class II molecules (Laupeze et at, 1999). This only occurs during an inflammatory 
reaction, so that autoimmunity does not develop. 
1.6.5 Endothelial cells and adhesion molecules 
The main immunological role of the endothelium is to aid the migration of 
cells and proteins to the sites of inflammation. The movement ofleucocytes from the 
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blood circulation into sites of inflammation requires co-operative interaction between 
signalling and adhesion molecules (McEver, 1992). The selectin family (L-, P- and 
E-selectin) mediate the initial rolling contacts of leucocytes with the endothelium. 
Following activation, integrins (COil, CD18) strengthen adhesion by binding to 
members of the immunoglobulin super gene family-intercellular adhesion molecule 
(ICAM)-1 and ICAM-2 (Malik, 1993). 
The other important adhesive interaction between leucocytes and the 
endothelium involves binding of selectins to their endothelium carbohydrate counter-
receptors on leucocytes. The latter molecules also facilitate transendothelial 
migration, diapedesis and migration along connective tissue (Penberthy et a/, 1997). 
As well as adhesion molecules, endothelial cells also express cytokines including IL-
l, IL-6 and IL-8 (Krishnaswamy et a/, 1999). Adhesion molecule expression may be 
induced by cytokines such as IL-l and TNF-a (Krishnaswamy et a/, 1999), 
transcription factors like NF-kappa-B (NF-KB) and AP-1 (Ledebur and Parks, 1995) 
and lipopolysaccharides (Fries et a/, 1993). 
1.6.6. Lymphocytes 
The lymphocyte population consists of NK cells and null cells, with the two 
main kinds of lymphocytes being T and B cells. T and B cells express antigen 
receptors and other surface molecules or markers important for their different 
functions. 
1.6.6.1. T cells and the TCR 
The T cell population is primarily derived from the bone marrow and matures 
m the thymus, which· has recently been shown in adults (Poulin et a/, 1999). 
Discrimination from self and non-self antigens and HLA molecules is achieved by 
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negative and positive selection (von Boehmer and Kisielow, 1990). T cells may be 
divided into two subsets, CD4 and CD8. Cells expressing CD4 cell surface marker are 
known to recognise peptide associated with HLA class II molecules. CD8+ T cells are 
known to recognise peptide associated with HLA class I molecules (l<rensky, 1997). 
This difference in expression allows the differentiation ofT cells into their two major 
subsets. CD4 cells function as helper cells while CD8 cells function as cytotoxic 
cells. The main panT cell marker is, however, CD3. 
T helper cells (CD4+), after recognition of a HLA class II associated peptide, 
undergo clonal proliferation. These clones activate B cells, cytotoxic T cells (CD8+) 
and other effector cells by the secretion of soluble mediators known as cytokines. T 
helper cells may be divided into two subpopulations, T helper (Th) 1 and Th2, which 
are determined by the secretion of certain cytokines (Mossman and Coffman, 1989) 
(discussed in detail later). Th 1 responses are associated with the activation of a cell 
mediated immune response. This, in turn, activates cells such as macrophages and 
cytotoxic T cells. Th2 responses activate a B cell, and an anti-inflammatory response. 
Cytotoxic (CD8+) T cells, on association with HLA class I, produce IL-2 and 
stimulate the T cell surface molecule, CD28 (Hornell et a/, 1999). The CTLs initiate 
apoptosis and lysis of altered cells by the activation of soluble effector mediators. 
T cells recognise antigen by their heterodimeric T cell receptor (TCR). This 
receptor always occurs in close association with the CD3 complex of molecules 
which are important in intracellular signalling. The TCR recognises short peptides in 
association with HLA molecules, and due to significant structural differences in the 
TCR between different T cell clones, it has a wide range of specificity for different 
peptides (Litman et a/, 1999). Like immunoglobulin (section 1.6.6.2), the TCR 
consists of a and~ chains (or y and o chains), which are linked by disulphide bonds, 
which has been analysed by X-ray crystallography (Fields and Mariuzza, 1996, 
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Garcia et a/, 1996, Garboczi et a/, 1996). The genes encoding these chains undergo 
similar rearrangement as immunoglobulin during T cell maturation which leads to a 
diverse family ofTCRs (Shortman and Wu, 1996). 
1.6.6.2. 8 cells and immunoglobulin 
8 cells mature in the bone marrow and are defined by the presence of 
immunoglobulin on their surface. 8 cells also express HLA class 11 on their surface, 
which is important for interactions with T cells, and therefore may act as antigen 
presenting cells (APC). Immunoglobulin is constitutively produced and are inserted 
into the cell surface membrane, where they act as specific antigen receptors. The 
majority of human 8 cells in peripheral blood express two isotypes, IgM and lgD, 
and when mature, have been shown to migrate back to the bone marrow 
(Paramithiotis and Cooper, 1997). Interaction between antigen and receptor induces 
proliferation of both plasma and memory 8 cells, and the activation of kinases and 
the phosphorylation of proteins. It is the plasma cell population that can produce the 
soluble form of immunoglobulin (antibody). CDI9, CD20 and CD22 are the main 
markers currently used to identify human 8 cells (Paloczi et a/, 1998). 
Diversity and heterogeneity are the characteristic features of immunoglobulin 
molecules. Like the TCR, there is extensive gene rearrangements which generate 
immunoglobulins capable of recognising many different antigens (Rao et a/, 1999). 
The basic structure of all immunoglobulin molecules is a unit consisting of two 
identical light polypeptide chains and two heavy polypeptide chains containing 
variable and constant regions. The chains are linked by disulphide bonds. The class 
and subclass of immunoglobulins are determined by its heavy chain. 
Imrnurloglobulins are a complex multigene family of proteins specified by 
genes encoding variable (V), diversity (D), joining (J) and constant (C) domains 
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(Marchalonis et a/, 1993). Diversity in immunoglobulin antigen receptors is 
generated in part by V(D)J recombination (Sollbach and Wu, 1995). Recombination 
activation genes (RAG)- I and RAG-2 gene products are known to be responsible for 
the activation of V(D)J recombination (Silver et a/, 1993). Immunoglobulins are also 
known to have the ability to switch classes or isotypes in the presence of external 
factors eg; in the presence of IL-4, lgM may class switch to IgE (Hikida et a/, 1999). 
1.6.6.3. Natural killer (NK) cells 
NK cells belong to a group known as null cells whereby neither T nor B cell 
markers are expressed. NK cells may become activated during an immune response 
via the secretion of cytokines including IL-2 and IL-12. These cytokines are thought 
to activate NK activity by enhancing the expression of lymphocyte-specific 
chemokines called single cysteine motif (SCM)-1 a and SCM-113 (Hennemann et a/, 
1999). Human NK cells express receptors for HLA class I encoded by the killer cell 
inhibitory receptor (KIR) gene family present on chromosome 19q 13.4 (Lanier, 
1998). If the KIR receptor recognises HLA class I molecule, this then suppresses NK 
activity, hence preventing autoimmunity. If HLA class I expression is lost, then 
cytotoxicity may occur (Lopez-Botet et a/, 1995). Functional studies of NK cells 
have revealed that in addition to KIR, another type of receptor is responsible for 
recognition of HLA class I (Houchins et a/, 1997). This receptor, designated 
CD94/NKG2, is a heterodimer composed of a CD94 glycoprotein that is disulphide 
bonded to an NKG2 subunit. NK cells also express a number of activating receptors, 
which are regulated by the inhibitory receptors. These include p46, which is known 
to cooperate with other triggering receptors to induce NK activity (Sivori et a/, 
1997). 
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1.7. The major histocompatibility complex 
1. 7 .1. Introduction 
The major histocompatibility complex (MHC) is a set of genes found in all 
mammalian species. It encodes for the expression of a group of cell surface 
molecules, termed the human leucocyte antigen (HLA) system in humans. This 
system plays an important role in the initiation of the immune response and also in 
rejection responses in allograft transplantation. 
1.7.2. History 
The definition of the MHC locus of man, HLA, is intertwined with the 
evolution of typing and crossmatching for human blood donor selecton. The work of 
Landsteiner during the first four decades of this century with erythrocyte ABO and 
rhesus antigens was a necessary basis for blood banking and blood transfusion which 
came into extensive use during and after World War II (Landsteiner, 1901). The 
development of blood transfusion contributed to progress with the problem of graft 
rejection in three ways. Firstly, the A and 8 erythrocyte antigens are widely 
distributed in tissues and are transplantation antigens that must be considered in the 
selection of tissue and donor organs. Second, by analogy with typing and cross-
matching for blood donor selection, one of the major approaches to the problem of 
graft rejection has been tissue compatibility testing. Thirdly, the serum of patients 
who have received multiple blood transfusions frequently contains antibodies to 
human leucocytes, now known as HLA antibodies. 
Some of the first experiments to describe transplantation antigens were 
performed by Gorer and colleagues (1937), in which he illustrated the genetic basis 
of tumour rejection in mice, with the identification of anti-sera specific for MHC 
antigens. He discovered an erythrocyte antigen present on both normal and tumour 
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cells, which was associated with tumour rejection. This was named "antigen 11". 
Later, in 1944, Medawar and colleagues illustrated the classical study in which it was 
shown that the intradermal injection of buffy coat evoked homograft sensitivity 
(Medawar, 1944). Seventeen years later, Rapaport and colleagues confirmed these 
findings in man (Rapaport et al, 1961 ). In 1948, Snell and colleagues described the 
histocompatibility system in mice. In this work, he showed that tumours will grow 
progressively in mice carrying certain dominant genes present in the stock of origin 
(Snell, 1948). In these experiments, he discovered a locus which determined 
allogeneic tumour graft rejection. He termed this the H-locus. This locus was then 
found to be responsible for the coding of antigen ll previously discovered (Gorer et 
al, 1948). Medawar and colleagues had previously described that allografts were 
rejected as a result of an immune event (Medawar and Gibson, 1943). The suggestion 
that graft rejection was due to cell-mediated immunity was strengthened by the 
subsequent work of Mitchinson. Using a system now known as 'adoptive transfer', 
he transferred lymphocytes from previously sensitized recipients into non-immunized 
animals. The results of these experiments showed that specific immunity could be 
transferred with cells from lymph nodes draining from the grafted tissue (Mitchinson, 
1954). 
The serological identification of transplantation antigens began in 1952 when 
Dausset discovered a leucocyte antigen responsible for transfusion reaction (Dausset, 
1954). These findings prompted a more extensive study, where sera of great 
specificity were prepared by serial transfusions into normal male recipients, using 
graded doses of blood from the same donor. The recipients produced high titres of 
leucocyte antibodies which agglutinated leucocytes from the blood donor as well as 
cells obtained from randomly selected individuals. This pioneering work of leucocyte 
grouping was confirmed and extended by many others, notably by Payne (1957) and 
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van Loghem .et a/ ( 1958). The hypothesis of the "second set response" was put 
forward (section 1.1.3) by Gorer and colleagues, whereby the presence of circulating 
antibodies against the H2 antigens were present after graft rejection (Gorer and 
Gorman, 1956), with earlier findings by Amos and colleagues ( 1953) demonstrating 
the presence of leucocyte agglutinins after skin grafts in mice, thus proving that skin 
and leucocytes share antigens. On the basis of his own work in 1954, Dausset was 
able, by immunizing a number of recipients with leucocytes from single donors, to 
produce agglutinins which, even though they were not pure, seemed to recognise the 
same antigen. This antigen, termed Mac (now known as HLA-A2) occurred in about 
60% of the French population (Dausset, 1958). In 1962, a study of renal 
homotransplant recipients was performed, demonstrating that "a close genetic 
relationship increased the probability of graft tolerance, presumably as a result of an 
increase in the number of identical transplantation antigens in the recipient and 
donor" (Hamburger et a/, 1962). 
In 1964, the first International Workshop on Histocompatibility was 
organized by D Bemard Amos in Durham, North Carolina. In the same year, Payne 
reported the first clear evidence that these leucocyte antigens segregated in families 
as a genetic system. Whereas the original serological identification of transplantation 
antigens was done by leucoagglutination, Terasaki introduced a much more sensitive 
and specific microlymphocytotoxicity test (Terasaki and McClelland, 1964). Also in 
the same year, work by Colambani et a/ (1964) and Walford et a/ (1964) 
demonstrated similar findings to that of earlier work by Amos (1953) and Gorer 
( 1956) in man. Indirect evidence that leucocyte antigens and transplantation antigens 
are related was also provided by the work by Van Roods group (Rapaport et a/, 
l964) whereby microsomal fractions containing the transplantation antigens also 
contained leucocyte antigens. The following year, studies illustrated that injection of 
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white cell extracts sensitised an individual against grafts of foreign skin (Rappaport 
et a!, 1965). In the same year, Dausset and colleagues showed t,hat by skin grafting of 
six randomly chosen volunteers that at least five identifiable leucocyte antigens or 
antigen complexes affect the survival of skin grafts (Dausset et a!, 1965). Attention 
therefore focused on analysing the iso-antigen systems of human white cells. 
The history of the discovery of leucocyte antigens has been reviewed by Van 
Rood and colleagues (1966). In the same year, sera was prepared from forty five 
multiparous women, two polytransfused patients and three post-graft volunteers in 
order to further investigate the complex system they had now termed Hu-1 (Dausset 
et a!, 1966). In this study, they managed to define ten leucocyte antigen using 
adsorption studies and complex statistical analyses. In 1967, isoantisera was also 
prepared by immunizing voluteers with a series of small skin grafts, with adsorptions 
of isoantisera carried out as previously described (Batchelor and Chapman, 1966). 
From the seventy four individuals screened, twenty six antigens were able to be 
recognised (Batchelor and Chapman, 1967). Studies on the inheritance of these 
antigens in eighteen families have shown that a large proportion are inherited en bloc 
in a manner similar to that of the H-2 antigens of the mouse. It was concluded from 
this work that most of the antigens detected belong to a single pseudo-allelic system. 
In 1968, Morris and colleagues used the method of leucocyte typing in 
cadaver renal transplantation (Morris et a!, 1968). Leucocytes were typed from donor 
and recipient in twenty seven renal allotransplants. They reported that twenty two of 
the mismatched recipients underwent moderate to severe rejection episodes, and 
found that the remaining five patients who were matched for eight of the presently 
defined antigens fared better. Influence of HLA incompatibility in renal 
transplantation was also examined by Batchelor and Joysey ( 1969). Fifty two cases 
were studied, and it was · shown ·that the number of graft incompatibilities 
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significantly correlated with the subsequent clinical status of the patient. In the same 
year, skin grafts experiments were performed (Ceppelini et a/, 1969). This illustrated 
that the graft survival time decreased with increasing mismatches (identical 
siblings>baploidentical>mismatched). 
Later, in 1972, McDevitt and colleagues identified the gene(s) in mice that 
are responsible for genetically determined variation in immune reactivity to the MHC 
region (McDevitt et a/, 1972). These were the immune response (IR) genes and were 
localized in the H-2 system. T cells are known to only recognise antigen by the 
interaction of the TCR with processed antigen presented by HLA molecules. This is 
known as HLAIMHC restriction. This was first demonstrated by Zinkemagel and 
Doherty (1974) where in order to trigger an immune response, T responder cells must 
bear the same HLA molecule as the antigen presenting cell. This was demonstrated 
by showing that T cells recognising lymphocytic choriomeningitis virus antigen in 
association with H-2Kk could not recognise the same antigen associated with H-2Kd 
or H-2Db alleles. In 1976, Terhorst and colleagues ( 1976) managed to determine the 
partial protein sequence of HLA-A2. cDNA cloning and sequencing of class I genes 
were performed later in 1980 (Ploegh et a/, 1980) whereby a clone (pHLA-1) 
containing HLA-specific cDNA was constructed by reverse transcription of partially 
purified HLA mRNA. The pHLA-1 cDNA insert was found to correspond to the 
COOH-terminal forty six amino acids of an HLA-A, -B or -C antigen. Two years 
later, cDNA cloning was also performed, but this time, for the HLA-DRa chain (Lee 
et a/, 1982). In the late 1980's, X-ray crystallograpy was being used to determine 
structures of HLA molecules, which allowed a more detailed study of the 
presentation of antigens by HLA molecules eg; HLA-A2 (Bjorkman et a/, 1987). 
Due to these findings, it is now known that the primary biological role of HLA 
molecules 1s the regulation of immune responses to foreign antigens, with the 
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discrimination of selffrom non-self. These major findings up until this decade have 
allowed for a better understanding of the organisation and involvement of the HLA 
system in clinical disease, and classification of the HLA system has recently been 
described (Proceedings of the 12th International Histocompatibility Workshop, 
France, 1996). 
I. 7.3. Genetic organization and polymorphism 
The HLA region in man is encoded on the short arm of chromosome 6, and 
spans four million base pairs of DNA. The orientation of the three major gene 
clusters and their relationship with one another was first clarified by genomic cloning 
and subsequently by pulse-field gene electrophoresis, a technique which allows 
separation of large DNA fragments for construction of restriction maps (Hardy et a!, 
1986, Lawrance et a!, 1987, Dunham et a!, 1987, 1989, 1990, Spies et a!, 1989, 
Sargent et a!, 1989). More than two hundred genes have been located in the human 
HLA, many of which have immunological functions in the antigen processing and 
presentation (Figure 1.2). The HLA is divided into class I, class II and class lii 
regions (Trowsdale and Campbell, 1997). The class I region ( distal) contains genes 
encoding the classic transplantation antigens, HLA-A, -B and -C. The non-classical 
genes HLA-E, -F and -G genes are also expressed in this domain (discussed later). 
The class 11 region is at the opposite (centromeric) end and contains genes such as 
HLA-DP, -DQ and -DR. The class Ill region, lying between the other two clusters, is 
packed with genes encoding a variety of functions, including complement eg; C2, 
C4A, C4B, heat shock (HSP-70) and cytokine genes (TNF). The class I antigens, 
HLA-A, -B and -C play a cental role in T cell recognition by binding peptides for 
recognition by CD8+ T cells (discussed later). HLA class I molecules are expressed 
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on virtually all nucleated cells, with their level of expression being subject to 
regulation (Geraghty, 1993, Le Bouteiller, 1994). 
The human HLA class I region spans at least 2000 kilobases (kb) of DNA, 
and is larger than both the class 11 and class Ill regions. The nomenclature of HLA 
genes is being updated all of the time, with over two hundred and twenty five alleles 
being named since 1996 (Bodmer et at, 1998). As with class II and Ill, class I 
includes expressed genes, many of which have immunological functions in antigen 
processing and presentation (Campbell and Trowsdale, 1993). Other genes, known as 
pseudogenes, have various deleterious mutations in the DNA sequence which 
prevent transcription, or are only fragments of an entire gene. 
HLA class I genes share a very similar organization. As previously 
mentioned, HLA class I region consist of the classical transplantation antigens (class 
la) -A, -Band -C (Trowsdale and Campbell, 1997). HLA-A, -Band -C have been 
studied in detail in a heterozygous individual from which the B lymphoblastoid cell 
line (LCL) 721 is derived (Geraghty et at, 1992a, 1992b). At least twelve 
pseudogenes and gene fragments constitute the bulk of class !-related sequences, and 
three functional class I genes, HLA-E, -F and -G, commonly referred to as non-
classical or class iB genes, complete the histocompatibility complex gene family 
(Geraghty et at, 1992a). At the nomenclature meeting following the 12th International 
Workshop, one hundred and twenty four HLA-A, two hundred and fifty eight HLA-
B and seventy four HLA-C alleles were recognised (Bodmer et at, 1998). The 
extreme polymorphism of class I antigens is reflected in the existence of multiple 
loci, the large number of alleles at each locus, many of which are present at 
significant frequencies in the population, and the multiple structural differences 
among alle1es. 
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Figure 1.2. Map of the human HLA (as illustrated by Trowsdale and Campbell, 
1997). 
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HLA-DR, DQ and DP are referred to as class Il. The class 11 genes, as 
mentioned, are located at the centromeric end of the MHC, and span about one 
megabase (Stephens et a/, 1999). Over thirty genes have been mapped in the class 11 
region of the MHC (Trowsdale and Campbell, 1997). The class II region may be 
divided into genes that code for a. and p chains. Additional class Il genes, including 
DNA and DOB have also been previously identified (Kuhner and Peterson, 1992). 
Class 11 genes come in three different forms, functional genes, pseudogenes and 
genes of unknown status. Compared to class I genes, class II genes show very little 
polymorphism, with the exception of ORB gene (Blasczyk et a/, I Q98). The 
polymorphism of the ORB gene has mainly focused on the second exon, but in this 
study, the intron sequences were highly polymorphic. In contrast, HLA-DQ and -DP 
class II subregions are conserved (Andersson, 1998). Polymorphisms in the DQ 
subregion (DQA and DQB) have also now been identified (Kwok et a/, 1995, 
Hashemi-Tavoularis et at, 1998). Polymorphism allows a high degree of variation of 
antigenic recognition at the population level. However, this causes problems for 
matching patients and donors for transplantation. 
In addition, genes including TAP (transporter associated with antigen 
processing) and LMP (large multifunctional protein) are located in the class II 
region. The TAPI gene is located between the DNA and DOB genes, while TAP2 is 
located between TAPI and DOB genes. The protein products of both of these genes 
are involved in the functioning of HLA class I antigen processing (Pamer and 
Cress well, 1998). TAP functions as the protein associated with the translocation of 
peptides, ions and small molecules from the cytoplasm into the endoplasmic 
reticulum (Momburg and Hammerling, 1998). Prior to loading antigenic peptides, 
assembled HLA class I molecules associate with TAP in a complex which also 
includes the endoplasmic reticulum chaperone, calreticulin, and a recently described 
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component, tapasin (Ortmann et a!, 1997, Powis, 1997). Tapasin is a member of the 
immunoglobulin superfamily, which mediates the binding of HLA class I molecules 
to TAP, and stabilizes the HLA class I loading complex (Bangia et at, 1999). The 
Tapasin gene has been shown to be located within 500Kb of the TAP I and T AP2 
genes (Herberg et at, 1998). 
There are two LMP genes that are located in the class Il region, LMP2, which 
is immediately centromeric to TAP I, and LMP7, which is located between TAP I and 
T AP2 (Beck and Trowsdale, 1999). Both LMP2 and LMP7 genes share homology 
with proteosome, which is a proteinase complex found in the cytosol. In addition to 
functioning in the complete degradation of cell proteins, proteosomes are the source 
of most anti genic peptides present in the immune system on HLA class I molecules 
(Gaczynska et at, 1993, Goldberg et at, 1995). IFN-y has been suggested to play a 
role in the induction of both TAP and LMP gene expression (Seliger et a/, 1997). 
The class Ill region of the HLA contains genes encoding the complement 
proteins C2, C4A, C4B and Bf as well as the gene for the cytochrome P-450 enzyme 
21-hydroxylase. C2 and Bf genes are less than 2000bp apart and are situated 
approximately 30Kb telomeric of the C4A and C4B genes (Trowsdale and Camp bell, 
1992). There is extensive protein polymorphism for C4A and C4B, with Bf, C2 and 
21-hydroxylase exhibiting a degree of polymorphism (Brai et at, 1994). There are no 
genes which encode for histocompatibility products in class lii region. Genes 
encoding for TNF-a and~ and heat shock protein-70 (HSP-70) are also encoded for 
in the class Ill region. The TNF gene locus is located 250Kb centromeric to HLA-B 
and 350Kb telomeric to the C2/Bf gene complex. TNF is a pro-inflammatory 
cytokine and polymorphisms in this gene has been shown to associat~d with 
transplant rejection (Turner ei a/, 1997). HSP-70 is a gene that encodes for a protein 
that is involved in signalling the immune system of the presence of immunologically 
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dangerous situations against which an immune reaction shound be raised. It has been 
shown to be induced during tumour cell killing and the induction of Th I type 
cytokines (Todryk et a/, 1999). 
HLA genes are inherited as eo-dominant alleles. Recombination between the 
loci does occur and the frequency is about I% between A and B, 0.8% between B 
and DR and about 10% between DQ and DP (Carrington, 1999). The abnormally 
high frequency of DQ-DP recombinants is thought to be due to a recombination "hot 
spot" for the loci are known to be in close proximity in this area (Begovich et a/, 
1992). Because the six loci are relatively closely linked they are usually inherited en 
bloc by the offspring from each parent. The HLA encoded by the genes of one 
chromosome are termed an HLA haplotype and each individual therefore has two 
haplotypes. Therefore, there are four haplotypes per family. Four different 
combinations can therefore be found eg; if the paternal haplotype is GH and the 
maternal haplotype designated as IJ, then the possible combinations are GI, GJ, HI 
and HJ. 
1.7.4. Structure ofHLA molecules 
Both HLA class I and II are members of the immunoglobulin supetfamily of 
molecules, which are transmembrane glycoproteins arranged as a series of domains 
at the exterior surface of the cell. HLA class I molecules may be found on virtually 
all somatic cells, with a precise meiotic map having been determined (Bouissou et a/, 
1995). Class I molecules are heterodimeric membrane-bound glycoproteins made. up 
of a a heavy chain of 45 KDaltons (KDa), which is non-covalently associated with 
beta-2-microglobulin (f32m) (Figure 1.3) (Shields et a/, 1999). The a chain is a 
glycoprotein consisting of a polypeptide and short carbohydrate chains. This chain is 
divided into three domains, extracellular (280 amino acids), hydrophobic 
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transmembrane (23 amino acids) and hydrophilic cytoplasmic region (25-32 amino 
acids). The extracellular domain has three domains, al, a2 and a3, each of which 
consist of approximately 90 amino acids, and are encoded on exons 2, 3 and 4 
respectively (Stern and Wiley, 1994, Madden, 1995). The a2 and a3 domains have 
intra-chain disulphide bonds. j32m is a l2KDa serum protein which is encoded by a 
gene on chromosome 15. The structure is stabilised by non-covalent associations 
between the a and 13 chains forming al3 dimers (Madden, 1995). As previously 
mentioned, there is extensive polymorphism in the class I genes, mainly found in the 
a l and a2 domains. 
All of the components of the tri-molecular complex that is at the heart of T cell 
recognition had been defined in terms of primary sequence by 1985. This evidence 
was elicited by work that demonstrated peptide binding to purified HLA molecules 
by equilibrium dialysis (Babbit et a!, 1985). The HLA molecule was then discovered 
as a molecule acting as a restriction element for the peptide in question (Buus et a!, 
1987). These results established that the ligand specifically recognised by T cells is a 
binary complex ofHLA molecule and peptide. Following these experiments, the next 
major landmark was the crystallographic analysis of the structure of the human class 
I molecule, HLA-A2 (Bjorkrnan et a/, l987a, l987b ). This work then led onto the 
proposal of a hypothetical model for class 11 structure. (Figure 1.4). Other crystalline 
structures of class I molecules have also been previously determined (Krishna et a/, 
1992, Madden et a/, 1993). More recently, HLA- B27, HLA-E, H-2Kb and H-2Dd 
have been described (Rognan et a/, 1997, O'Callaghan et a/, 1998, Celia et a/, 1999, 
Achour et a/, 1999). 
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Figure 1.3. Structure of a HLA class I molecule. Panel a represents a computer 
graphic representation of human HLA-A2, which has been cleaved from the cell 
surface by the enzyme papain. Panel b shows the ribbon diagram of the structure. 
The a3 domain and P-2 microglobulin show similarities in amino acid sequence to Ig 
constant domains and have a similar folded structure (b and d) (adapted from 
Janeway and Travers, 1996). 
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The class I molecule has an antigen binding cleft which is approximately 25 
angstroms (N) by IOA0 • It is formed by a floor of eight parallel ~ pleated sheets 
flanked by side walls of a helices. Both a I and a2 domains contribute to the 
formation of the antigen binding site, and are supported by the a3 domain and ~2m 
{Young et a/, 1995). It is known that HLA class I molecules bind smaller peptides 
than class 11, with the majority of HLA class I peptides being between 8-10 amino 
acids long (Blanden, 1995, Appella et a/, 1995). As previously mentioned, both HLA 
class I and class 11 antigens bind peptides of diverse sequences with high affmity, in 
order to generate maximal immunological protection (Batalia and Co11ins, 1997). 
The class 11 antigens comprise two polypeptide chains which associate themselves in 
the endoplasmic reticulum and are then transported to the cell surface (Solheim et a/, 
1995). HLA class 11 glycoproteins are also heterodimeric and consist of a heavy 
chain (a) of35KDa and a light chain(~) of28KDa (Figure 1.4). Each glycoprotein 
chain contains two domains, al and a2 or ~I and ~2. The two chains are non-
covalently associated (Jones, 1997). It is the a I and ~I chains that fold to form the 
peptide binding cleft (Stem and Wiley, 1994). The amino acid sequence of the two 
chains indicate that they each have two membrane-external domains of 
approximately 90 aa, and a transmembrane region and cytoplasmic domain of 
approximately 40 aa. The ~ chain contains two intrachain disulphide bonds, and the 
a chain a single intrachain disulphide bond. 
Crysta11ographic studies of HLA-DRI showed that the structure of class 11 
molecules is genera11y similar to that of class I. Studies included the analysis in 
complex with peptide (Jardetzky et a/, 1996, Murthy and Stem, 1997) and without 
(Brown et a/, 1993). These analyses suggested that the antigen binding site of class 11 
molecules has a more open conformation than class I. The antigen binding groove in 
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Figure 1.4. Structure of a HLA class II molecule. Panel a shows the computer 
graphic representation of the HLA class II molecule (HLA-DRI), and panel b shows 
the equivalent ribbon diagram. The a. I and ~ 1 domains have amino acid sequence 
and structural similarites to the lg constant domains, with the two domains forming 
the peptide binding cleft (c and d) (adapted from Janeway and Travers, 1996). 
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class I molecules is able to present antigens between 10-34 residues in length 
(Appella et a/, 1995). Class 11 molecules present constitutively on the cell surfaces of 
B lymphocytes, monocytes, macrophages and dendritic cells, which all have common 
property of being antigen-presenting cells for T lymphocytes. In addition, class Il 
molecules are also found on vascular endothelium, various ductal epithelia and 
kidney glomeruli (Daar et a/, 1984). 
1.7.5. Loading and transport ofHLA molecules 
1.7.5.1. The class I pathway 
Cytoplasmic proteins are taken up by proteosomes. These organelles consist 
of seven a. and seven p subunits. The genes for two of these subunits, LMP-2 and 
LMP-7, have been implicated in the early steps of this process (Belich and 
Trowsdale, 1995, Pamer and Cresswell, 1998). When induced by IFN-y, these low 
molecular mass polypeptides replace two constitutive subunits of the 20S 
proteasome, presumably preparing the proteasome for antigen processing (Groettrup 
et a/, 1996, Griffin et a/, 1998). The IFN-y-inducible ll S regulator (P A28) also plays 
a role in the peptide production (Groettrup et at, 1995, Kuehn and Dahlmann, 1997). 
Similarly, a third subunit, MECL-1, is also inducible (Nandi et at, 1996, Groettrup et 
a/, 1997, Griffin et at, 1998). Generally, protein degradation within the cell is 
accomplished by proteosomes using the ubiquitin to target proteins towards the 
proteasome (Hochstrasser, 1995, 1996, D' Andrea and Pellman, 1998). However, it is 
unclear whether ubiquitin is required for the production of peptides in the class I 
loading pathway. Although some evidence for non proteasomal protein degradation 
exists, it has been shown by proteasomal inhibitors that inactivation attenuates the 
supply of peptides for class I molecules (Dick et a/, 1996, Craiu et a/, 1997). · 
88 
In order for these peptide fragments to reach the cell surface, they must first 
move to the endoplasmic reticulum (ER), and then cross the membrane, consisting of 
a lipid bilayer, that is confined to the ER (Figure 1.5). The transport across the 
cytosol may involve shuttling of heat shock proteins but the actual mechanism is 
unclear. To traverse the ER membrane the peptides must associate with the TAP 
proteins (Koopman et a/, 1997, Gabathuler et a/, 1998, Uebel and Tampe, 1999). 
TAP, in common with other membrane transporters, is an ATP binding cassette 
(ABC) protein. The process by which TAP transports is ATP dependent. TAP not 
only functions as a transporter for these peptides, but it also seems that it is essential 
for the eo-localisation of nascent HLA class I molecules with peptide to form the 
peptide:HLA complex. HLA molecules require peptide binding to stabilise the 
structure. Therefore, after synthesis of the class I a chain, it rapidly binds to a 
membrane bound protein, calnexin, which functions as a chaperone (Ho et a/, 1999). 
Calreticulin, BiP and tapasin, are also involved in this process (Harris et a/, 1998, 
Plemper et a/, 1997, Grandea et a/, 1997). The a chain then dissociates from calnexin 
when it binds to ~-2 microglobulin (Sugita and Brenner, 1994). As previously 
mentioned, this complex binds to T AP-1 subunit until it is stabilised by the binding 
of the peptide. Once the peptide is bound, the HLA:peptide complex dissociates from 
TAP and it is shuttled to the cell surface via the Golgi apparatus. 
1.7.5.2. The class II pathway 
Although some microorganisms replicate in the cytosol, others are 
predominantly extracellular or reside in intracellular vesicles. These pathogens are 
seperated from the cytosol by membrane and so are not accessible to the proteasome-
TAP pathway. An alternative antigen processing pathway has therefore developed 
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which involves the breakdown of proteins within these vesicles and delivery to the 
cell surface in association with class Il molecules (Figure 1.6). 
Internalised protein antigens are enclosed within acidic vesicles called 
endosomes (Pond and Watts, 1997, Brachet et a/, 1999). The low pH is essential to 
activate proteases such as the cathespins. Like HLA class I, class II molecules are 
also synthesised in the ER and yet they do not bind peptide at this site. This is 
achieved by the binding of a monomorphic protein called invariant chain. This 
protein forms a homonymous trimer which associates with nascent class 11 molecules 
(Cresswell, 1994). The interaction and trimer formation occurs at the site of the 
invariant chain transmembrane domain (Ashman and Miller, 1999). Calnexin is also 
involved as a chaperone at this stage (Arunachalam and Cresswell, 1995). Each 
subunit of the trimer associates with as a.~ class II heterodimer. Cells that lack 
invariant chain retain many class 11 molecules in the ER as misfolded proteins. The 
invariant chain trimer (Ii) also functions to target the delivery of the complex to an 
appropriate low pH endosomal compartment. Leucine based signals in the 
cytoplasmic tail of invariant chain control targeting of newly synthesised HLA class 
11 molecules to the endocytic pathway for acquisition of antigenic pep tides (Zhong et 
a/, 1997). The complex makes its way through early endosomal compartments on to 
a later, more acidic lysozome-like compartment. It is in this compartment, called 
MIIC (MHC class II compartment) that the invariant chain is cleaved so that the 
class 11 heterodimer now contains only CLIP (class ll-associated invariant chain 
peptide) in its peptide binding groove, with particular methionine residues in Ii 
(Gautam et a/, 1997). CLIP can bind all the different alleles and isotypes of class II 
(Gautam et a/, 1997). The class II molecule now has to unload the CLIP fragment 
and load a peptide from the amiy that is present in the compartment. This is 
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Figure 1.5. Loading and intracellular transport ofHLA class I molecules. 
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perfonned by DM (Pierre et a/, 1996). DM is an atypical class II molecule fonned as 
a heterodimer from the products of the non-polymorphic DMA and DMB loci within 
the MHC class II region. DM does not require peptide to stabilise its structure and it 
is not expressed on the cell surface, but operates predominantly in MIIC. DM 
catalyses the removal of any peptide from class 11 in proportion to its intrinsic rate of 
dissociation (Denzin et a/, 1996, Stebbins et a/, 1996). This is accomplished by 
stabilising a transition rate that leads to full dissociation. Thus DM ensures that only 
stably-associated peptides remain bound to class II. Once the peptide is bound, the 
class II heterodimer passes on to the cell surface. 
1.7.6. HLA typing and matching 
HLA antigens are conventionally typed by serological techniques using 
lymphocytes as the target cells. Peripheral blood lymphocytes or separated T cells 
are used for class I typing and B lymphocytes for class 11 typing, as DR and DQ 
antigens are found on B cells but not on resting T cells. The antibodies to these 
antigens may be found in the sera of repeatedly transfused patients and in 
multiparous women. It was in transfused patients that Jean Dausset was able to 
obtain antibodies for the detection of the first HLA antigen (Dausset, 1958). 
Nowadays, some laboratories still use the microdroplet lymphocyte cytotoxicity 
technique developed by Terasaki and McClelland (1964). HLA DP products were 
first detected by primed lymphocyte testing (PL T) (Shaw et al, 1980). The mixed 
lymphocyte reaction (MLC) is also of importance in HLA matching (discussed later). 
Identical HLA matching is regarded as a necessity in bone marrow transplantation 
and a bonus in organ transplantation, although, it has suggested that it may be 
acceptable that compatibiliity at the HLA-D locus only may be tolerated (Dupont et· 
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93 
CLIP 
COOH 
al a2 
b2 
a/, 1980). As previous studies have shown, differences in HLA between individuals 
do elicit an immune response (Araten et a/, 1993, Gorski, 1996), therefore it is 
important to ensure as close a match as possible in order to reduce the risk of 
allograft rejection. Histocompatibility antigens are those cellular determinants 
specific for each individual of a species that are responsible for immune rejection 
when attempts are made to transfer or transpiant cellular material from one individual 
of the same species to another (Dyer and Class, 1997). It has been shown in both 
early and more recent studies that better matching does lead to a longer survival time 
for organ allografts (Morris et a/, 1968, Batchelor and Joysey, 1969, Terasaki et a/, 
1989, Tesi et a/, 1993, De-Lin et al, 1998, Ketheesan et a/, 1999, Muro et a/, 1999). 
A high success rate in transplantation, however, has been seen even with 
partial matching, and this has been suggested to be due to a gradation of strength of 
the antigens encoded by the different loci, with the DR antigens being the strongest 
transplantation antigens. The differences in HLA antigen alloreactivity has been 
previously described, for instance, matching for HLA-B has been shown to be more 
important for allograft survival than matching for HLA-A (Zhang et a/, 1990). There 
is little data to illustrate that either DQ or DP matching is crucial for transplantation. 
In one study however, DP matching, although had no deleterious influence on first 
cadaver transplants, did illustrate a statistically significant effect on re-transplants 
(Mytilineos et a/, 1997) A study of HLA-DQ matching in cadaveric. renal 
transplantation has also been performed, with the finding that HLA-DQ matching 
does not significantly affect renal allograft survival (Freedman et a/, 1997). The 
impact of HLA mismatches on the survival of cadaveric kidney transplants has been 
shown (Held et al, 1994). In this work, over thirty thousand cadaveric transplants 
were·studied over a seven year period, and it was shown that HLA matching has a 
statistically significant and clinically important impact on short and long term graft 
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survival. In another study, one hundred and eighty one patients receiving cadaveric 
renal transplants were monitored and it was shown that allografts with better HLA-
DR and HLA-B matching showed significant lower rejection rates than those less 
well matched (Beckingham et a/, 1994). It has even been shown that poor HLA-DR 
matching is associated with increased early rejection episodes, whereas HLA-8 
matching was associated with a reduced frequency of late rejection episodes with 
improved graft function at two years (McKenna et a/, 1998). HLA-DR matching has 
been shown to beneficial not only in kidney transplantation (Opelz et a/, 1998, De-
Lin et a/, 1998, Reisaeter et al; 1998), but also in heart transplantation (Sucia-Foca et 
a/, 1998, Sheldon et a/, 1999). In one study, it was even suggested that HLA-DR 
incompatibility could predict heart transplant rejection (Costanzo-Nordin et a/, 
1998). In the past decade or so, there has been developments of molecular 
methodology. Polymorphism can be detected at the DNA level and occurs primarily 
in the variable domains (a. chain in class I; ~ chain in class Il). The conventional way 
to determine HLA specificities is still based on immunological methods. 
Recently, the polymerase chain reaction (PCR) has been used to analyse and 
characterise HLA class subtypes. Sequencing of these DNA variants allows the 
synthesis of primers complementary to the polymorphic HLA genes (Wade, 1996). It 
now appears that this method is used in tissue typing laboratories in conjunction with 
the established methods to increase the precision of recipient or live donor selection 
for transplantation. DNA analysis has been shown to be more precise in defining 
HLA DR alleles than serological typing (Olerup and Zetterquist, 1992), and has also 
been shown to illustrate a significant reduction in acute rejection episodes compared 
to the broad classification yielded by serology (Reviron et a/, 1996). PCR may be 
used in conjunction with other methods such as resticti"on fragment length 
polymorphism (RFLP) analysis using sequence specific probes (SSP) (Sengar et a/, 
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1995, Moribe et a/, 1997, Nieto et a/, 1997, Woszczek et a/, 1997, Mitsunaga et a/, 
1998, Palou et a/, 1999). Molecular PCR typing allows for precise antigen 
determination. 
It is now generally accepted that a very important part of typing potential 
donors and recipients is the cross-match between recipient sera and donor 
lymphocytes (Ting, 1989). Since hyperacute rejection of an allograft in the presence 
of pre-existing donor specific cytotoxic antibodies (Terasaki and McClelland, 1964 ), 
a positive cross-match has been a contraindication in transplantation. However, there 
are exceptions to this hypothesis. For instance, the antibody causing a positive 
crossmatch may be an autoantibody which can be directed against either the donor 8 
cells or donor 8 and T cells, which may be from some remote time in the past while a 
current serum is negative (historically positive, . currently negative). The 
immunoglobulin (Ig) class of the antibody in the peak reactive serum may be an 
important predictor of graft outcome. IgG antibodies have been shown to associated 
with graft failure whereas success has been achieved in the presence of IgM 
antibodies (Chapman et a/, 1986, Leavey et a/, 1997, McCalmon et a/, 1997). 
Antibodies are nearly always IgM whereas HLA antibodies are usually IgG, although 
IgM HLA antibodies may occur in patients on immunosuppression. Therefore, it may 
be concluded that transplantation against some positive crossmatches can be 
successfully performed, but the conditions under which the chances of success are 
optimal have still to be worked out fully. 
Flow cytometry crossmatching before transplantation has been suggested to 
be more advantageous than serological crossmatching as it has been shown that flow 
cytometry is more sensitive in the detection of pre-formed antibodies (Sutton et a/, 
1995, Kimball et a/, 1998, Przbylowski et a/, 1999), and allows the simultaneous 
detection of complement-activating and nonactivating alloantibodies, the class of 
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donor specific antibodies (lgG and/or IgM) and the donor target cells (T and/or B 
lymphocyte). One study indicated that flow cytometry crossmatching combines 
sensitivity with specificity in evaluating the patients response to the graft, with the 
suggestion that this method may even be used as a prediction marker for rejection 
(Piazza et a!, 1998). 
1.8. The minor histocompatibility complex 
1.8.1. Introduction 
In human transplantation, donors and recipients are routinely screened for 
identification of the major histocompatibility genes, and although they may be fully 
matched at this genetic level (eg; identical siblings), rejection and GVHD may still 
occur. This is now thought to be due to other histocompatiblity antigens other than 
those coded for by the MHC (HLA). These products have been termed minor 
histocompatibility antigens (Goulmy, 1988). These antigens can be peptides derived 
from cellular proteins that are presented on the cell surface by HLA class I 
molecules, which are similar to viral antigens. These histocompatiblity antigens tend 
to elicit slower graft rejection responses compared to major antigens. 
1.8.2. History 
Minor antigens were described along with major antigens in 1940 where 
Snell defined thirteen genetic loci that were responsible for tumour graft rejection in 
inbred congenital mice (Snell, 1948). The H-2 locus was later named the major 
histocompatibility complex and was responsible for the most vigorous graft rejection. 
The other loci, termed minor, also mediated tumour graft rejection but to a lesser 
extent. Later, one minor H antigen identified independently of the use of congenic 
mouse strains was the male-specific antigen H-Y. This was discovered in 
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experiments in which Eichwald and Silmser ( 1955) exchanged skin grafts between 
male and female mice of various inbred mouse strains. They found that in some (but 
not all) strains, females would reject syngeneic male grafts. Following this work, 
Snell ( 1956) interpreted these findings as evidence for a minor H antigen, encoded by 
a gene on the Y chromosome, hence the name H-Y. The ability of females of some 
but not all mouse strains to reject syngeneic male skin was subsequently found to be 
due not to allelism or failure to express H-Y, but to polymorphism of immune 
response (IR) genes (Bailey, 1971, Gasser and Silvers, 1972, Simpson, 1982) 
including both HLA and non-HLA IR genes (Simpson, 1984). 
In vitro cell mediated cytotoxic responses to the male specific antigen H-Y 
and were found to be H-Y restricted (Gordon et a/, 1975). This meant that cytotoxic 
T lymphocytes (CTLs) recognise foreign antigens, such as H-Y only when they are 
presented to the CTLs on cells which share the same homology of the H-2 region as 
expressed on the effector CTLs. Similarly, the recognition of other minor antigens by 
CTLs is also major HLA-restricted (Bevan, 1975). In 1979, CTLs of host origin were 
also shown to recognise minor histocompatibility alloantigens on tolerated H-2 
allogeneic cells in H-2 tolerant mice (Forman and Streilein, 1979). Further murine 
studies also illustrated the development of GVHD in mice due to minor 
histocompatibility antigens (Komgold and Sprent, 1983, Hamilton and Parkman, 
1983, Holda et a/, 1985). In these studies, H-2 compatible strains of mice were used. 
Lethally irradiated recipients were transplanted with donor bone marrow cells. All 
experiments showed that induction of both acute and chronic GVHD was possible 
due to minor HA disparities. 
The evidence that humans, like mice, express minor H antigens comes from 
the clinical studies involving transplantation of various organs and tissues. Ceppelini 
( 1969) illustrated that even in HLA-identical siblings, grafts were rejected, although 
98 
at a slower pace than when HLA mismatches were present. Cytotoxicity in human 
transplantation was illustrated by Goulmy et a/ (1983), where severe GVHD 
occurred in a male patient suffering from acute myeloid leukamia who had received 
HLA-matched bone marrow from his sister. Strong cytotoxicity of the post-transplant 
donor lymphocytes against the patients pre-transplant lymphocytes were found, 
demonstrating that there was a possible role of minor HLA-mismatching, and that 
minor antigens were detected by HLA-restricted CTLs during GVHD. The same 
group produced more data further illustrating the impact of mismatching for minor 
HLA in bone marrow transplantation, correlating it with incidence of GVHD 
(Goulmy et a/, 1985). However, conflicting evidence suggested that not all minor 
alloantigens were responsible for the elicitation of GVHD (Elkins et a/, 1987). In 
1988, Marrack and Kappler found evidence in mice that there is preferential usage of 
T cell al3 receptor variable gene families by T cells reacting with minor antigens 
(Marrack and Kappler, 1988). The year before, an in vitro cellular cytotoxicity assay 
using haemopoietic progenitor cells as targets was developed by Voogt et a/ ( 1987). 
Using this assay, it was demonstrated that there was differential expression of the 
minor antigens on human progenitor cells (Voogt et a/, l988a, l988b). It was found 
that the male-specific antigen H-Y and HA-I, HA-2, HA-4 and HA-5 were expressed 
on progenitor cells, while HA-3 is not. Studies following this revealed that H-Y and 
HA-3 are detectable on keratinocytes, while HA-I, HA-2, HA-4 and HA-5 are not 
(van Els et a/, 1989). The findings from these early studies have led to a better 
understanding of the immunological mechanisms involving minor antigens in 
processes such as GVHD (Simpson et a/, 1999). 
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1.8.3. T cell responses to minor antigens: MHC restriction 
Graft rejection is mediated principally by T cells and not by antibodies, as 
was originally shown in cell transfer experiments by Mitchinson (1954) and by 
Billingham et a/ ( 1954). Analysis of class I and class 11 molecules has been possible 
because antibodies are made against them. Antibodies are not made to minor 
antigens, yet in vivo T cell responses (graft rejection) to individual minor H antigens 
has allowed the chromosomal mapping of the genes encoding them in mice, in which 
breeding experiments establish mouse strains differing from the parental strain at 
single minor H loci (Bailey, 1975). These loci are scattered throughout the genome, 
and a minimum of forty have been identified. The same is likely to be true for 
humans, but because it is not possible to study individual minor H responses in vivo, 
in vitro T cell responses are the principal means for study. T cells are HLA restricted 
ie; they recognise the minor H antigen in the context of self HLA molecules, and are 
either class I (HLA-A, B orCin humans, H-2K, D or L in mouse) or class 11 (HLA-
D in humans, H-2IA or lE in mouse). The majority ofT-cell defined minor antigens 
are determined by autosomal genes inherited in a Mendelian fashion and that they 
show either high or low phenotype frequencies (Goulmy et a/, 1996). From genetic 
analysis of HLA-A2 restricted minor antigens, HA-I, HA-2, HA-4 and HA-5, it was 
shown that these four antigens can each be considered the product of a gene with one 
allele expressing the detected specificity, illustrating that the loci are independent of 
each other and independent of HLA (Schreuder et a/, 1993). Several studies have 
attempted to establish the role ofT cell responses to minor antigens (Tsoi et a/, 1980, 
Van Els et a/ 1990a, l990b, Nevala and Wettstein, 1996, Warren et a/, 1998). It was 
established in all of the studies that T cells play a predominant role in the recognition 
of minor antigens, although other risk factors may be involved. 
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HLA restricted recognition of minor antigens strongly suggests that there is a 
physical association between major HLA and minor antigens. It is now postulated 
that these antigens are peptide fragments of processed cellular molecules, which have 
become lodged in the antigen binding groove of the restricting HLA molecule, The 
various polymorphic amino acid substitutions seen in the different alleles of class I 
molecules lie within the proposed antigen-binding groove (Bjorkman et a/, 1987). 
HLA class 11 molecules may also be modelled on that of class I (Brown et a/, 1993), 
and therefore present antigen fragments in a similar fashion. This would explain how 
both class I and class 11 restricted T cells can recognise minor antigens (Roopenian et 
a/, 1993). It would also explain minor antigens are recognised by T cells and not by 
antibodies (Simpson and Roopenian, 1997). 
1.8.4. Minor histocompatibility antigen responses in transplantation 
As previously suggested, minor H antigens may be responsible for the 
continual elicitation of GVHD in HLA-matched recipient-donor pairs, and may even 
be considered to be a major risk factor for GVHD (Den Haan et a/, 1995, Goulmy et 
a/, 1996, Martin et a/, 1998). It has been suggested that some minor antigens are 
expressed on the kidney and that they can trigger graft rejection (Perreault et a/, 
1990, Beck et a/, 1993). Allograft infiltrating CTLs have been recognised to be 
present, and these are suggested to recognise minor antigens (Deckers et a/, 1997, 
Poindexter et a/, 1997). In bone marrow transplantation, an earlier study was able to 
detect HLA restricted anti-minor antigens from skin lesions from HLA-identical 
siblings (Reinsmoen et a/, 1984). More recent studies have illustrated that minor 
antigen mismatches have contributed to the development of GVHD in HLA-identical 
pairs after bone marrow transplantation (Marijt et a/, 1993, Goulrny et a/, 1996, 
Martin et al, 1998). The role of minor antigens in rejection and GVHD appears to be 
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ari important one, and further research may finally obtain a fuller picture as to their 
complete role in transplantation. 
1.9. The immune system in rejection and GVHD 
1.9.1. Introduction 
Without special treatment to suppress its activity (immunosuppression), the 
immune system responds aggressively towards a transplant, as it does towards 
infections. This response, which is known as rejection, will destroy the transplant. 
Rejection occurs because inherited genes make each one of us an individual, and also 
makes the cells within the body different. The immune system perceives these 
different cells in a transplant as foreign, and therefore mounts an attack upon them. 
The immunological aspects of each stage of rejection will be discussed. 
In vitro and in vivo studies have suggested lymphocytes to be an integral part 
of transplantation immunity (Wilson and Billingham, 1968). The response ofT cells 
to antigen involves the participation of a number of distinct receptor-ligand 
engagements. Antigen presentation and recognition plays a major role in many 
diseases and conditions, including allograft rejection both in renal (Krensky et a/, 
1990) and bone marrow transplantation (Witherspoon and Storb, 1993) and other 
disease states such as atopy (Kapsenberg et a/, 1998). Antigen receptors on 
lymphocytes play a central role in immune regulation by transmitting signals that 
positively or negatively regulate lymphocyte survival, migration, growth and 
differentiation (Healy and Goodnow, 1998). Work is constantly being undertaken to 
attempt to reach a better understanding of the cellular events that mediate incidences 
such as allograft rejection. 
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1.9.2. Overview of alloreactivity 
Responses between genetically dissimilar humans, termed alloresponsiveness 
are directed against a cluster of antigens known as the Human Leucocyte Antigens or 
HLA (Arnos and Sanfillipo, 1984). The HLA genes are differentially expressed on 
most mammalian tissues, and so these are important targets of immunoreactivity. 
This was first described by Snell and colleagues in mice (Snell, 1948) who went on 
to determine that histocompatibility genes are the genes which determine 
susceptibility and resistance to tissue transplants (Snell, 1964). The HLA molecules 
are the molecules involved in the presentation of antigens to T cells which mediate 
the immune responses of rejection. The critical role ofT cells in allograft rejection 
was first established by the failure of athymic nude rodents to effect rejection (Corley 
and Kindred, 1977), and to react to foreign antigens (Hen dry, 1979). Other early 
experiments also showed that a transplant from an allogeneic source could be 
transferred to nude mice, and the transplant tolerated (Rygaard, 1974). Experiments 
like these demonstrated that T cells were indeed involved in the rejection process. 
In the rejection response, T cells are activated by HLA molecules presenting foreign 
antigens on the grafted organ (Figure 1.7). This activation leads to a cascade of 
immunological mechanisms. In short, helper/inducer T cells recognise foreign HLA 
class II antigens via the TCR and are activated to proliferate, differentiate, and 
secrete a panel of growth factors. These induce further expression of HLA class II, 
stimulate B cells to produce antibody against determinants on the transplant and help 
T cells develop effector functions such as cytotoxicity. Cytotoxic T cells, specific for 
foreign HLA class I antigens, damage the graft. CD4 and CD8 act as accessory 
molecules to increase the stability of the interaction (Kelso et al, 1991 ), and act as 
modulators of TCR recognition· of antigen (Zamoyska, 1998). The CD4 molecule is a 
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Figure 1.7. Interaction between host T cell and graft cell. The graft cell contains the 
lll.A molecule presenting the for~n antigen. The TCR recQgnises the antigen, which in 
turn, activates the T cell. 
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ligand for the HLA class II molecules, which are distributed on lymphoid tissues 
(Hauss et a!, 1995). Expression of class II is generally limited to "professional" 
antigen presenting cells such as as dendritic cells, circulating 8 lymphocytes, 
monocytes and vascular endothelial cells (Thomas and Lipsky, 1994, Meyers, 1995) 
The CD8 molecule is a ligand for HLA class I, which is expressed on most cell 
surfaces. The HLA antigens in the allograft activate the T lymphocytes to proliferate, 
differentiate and secrete a variety of cell mediators, known as cytokines (see cytokine 
section). Both the HLA molecule and an allogeneic (foreign) peptide are required for 
T cells to recognise graft "foreigness" (Hall, 1991 ). Accessory molecules are 
required for the activation event to occur (Figure 1.8). Other molecules such as 
ICAM-1 are also present. Without the involvement of these accessory molecules, 
unresponsiveness or "anergy" may occur (Lombardi et a!, 1994). This interaction 
involves the approximation of the antigenic receptor of specific T cells to an 
antigenic peptide bound in the groove of the HLA molecule. The induction of 
expression of surface receptors for IL-2 on most cells, including activated CD4+ and 
CD8+ T cells, 8 cells and macrophages is of particular importance in the rejection 
process (Hutchinson, 1996). 
The rejection process may be divided into two stages (Lechler and Wood, 
1993, Krensky and Clayberger, 1994). Firstly, the allogeneic cell (APC) activates the 
recipients immune system, through the activation of CD4+ and CD8+ T cells through 
the HLA complex (Figure 1.8). This is termed the "afferent stage". In turn, other 
cells are then activated, inducing proliferation and subsequent cytokine release 
("efferent stage"). This induces cell migration into the graft. Other cells including 8 
cells are also activated, thereby inducing antibody synthesis. Antigen-induced 
interactions between macrophages, CD4+ and CD8+ lymphocytes and their humoral 
products are termed as critical for the completion of the allograft response 
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(Hutchinson, 1996). This whole cascade of activation, proliferation and synthesis of 
mediators such as antibodies and cytokines is responsible for the rejection and 
inevitable destruction of the graft. 
1.9.3. Indirect and direct allorecognition 
Lechler and Batchelor ( 1982) performed experiments in which long surviving 
HLA mismatched renal allografts from rats were re-transplanted into recipients 
syngeneic with the first recipients. There was a dramatic reduction in the 
iriununogenicity of the grafts because of the loss of passenger dendritic cells derived 
from the original donor. However, some of the kidneys were still rejected if 
immunosuppression was not given. Based on these experiments, the group proposed 
that there were two routes of allorecognition, the "indirect" and "direct" pathway 
(Figure 1.9). 
In the direct pathway, T cells recognise intact allo-HLA on the surface of the 
donor cells The antigenic peptides presented are derived from endogenous proteins, 
which bind into the groove of the donor HLA (antigen presenting cell) and are then 
recognised by recipient T cells (Benichou, 1999). The T cell response that results in 
early, acute cellular rejection is caused mainly by direct allorecognition (Homick and 
Lechler, 1997). Direct pathway T cells may make up as many as 5-10% of the total 
pool of peripheral T cells. The strength of alloreactivity is directly related to the 
number of activated allogeneic cells. This binary complex hypothesis was first 
described by Matzinger and Bevan ( 1977). If the ligand for alloreactive T cells is 
allo-HLA complexed with a specific peptide, this could account for the observed 
high frequency of alloreactive cells. HLA molecules on the foreign cells surface are 
·occupied by a wide variety of peptides, thus leading to a wide range of allo-HLA-
peptide complexes, and therefore stimulating a large number ofT cells (Pattison and 
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Krensky, 1997). The other hypothesis, known as the high ligand density hypothesis 
provides an alternative explanation for the high precursor frequency of alloreactive T 
cells. In this instance, the TCR ligand, which is the allo-HLA molecule itself, is 
present at a far higher density than would normally be achieved. Therefore, T cells 
with a lower specific affinity for the ligand than would be required for an antigen-
specific response can be recruited for an alloresponse. This proposal may explain the 
gradation of strength of the HLA antigens (ie: HLA-DR, -A, and -B) as each of these 
antigens differ in the number of alloreactive cells that they can stimulate. 
In the "indirect" pathway, T cells recognize processed alloantigen in the 
context of self-antigen presenting cells (Bradley, 1996). Donor alloantigens (either 
allo-major HLA, minor histocompatibility antigens, or tissue-specific antigens) are 
shed from the graft, taken up by recipient APCs and presented to CD4+ T cells 
(Suciu-Focia et a/, 1996). These activated T helper cells secrete cytokines and 
provide the necessary signals for the growth and maturation of effector cytotoxic T 
lymphocytes (CTLs) and B cells (Vella et at, 1999). Indirect presentation may be 
important in amplifying and maintaining the rejection response. The consequences of 
T cell activation by these two routes are different (Homick and Lechler, 1997). 
Rejection may be divided into three stages, hyperacute, acute and chronic. 
The immunology of each stage will be discussed below. 
1.9.4. Hyperacute rejection 
This is the initial stage of allograft rejection. Hyperacute rejection may be 
seen within minutes to hours after surgery. The presumptive mechanism in 
hyperacute rejection is humoral pre-sensitisation, since there is a high correlation 
between the presence of pre-formed cytotoxic antibodies with the blood group or 
HLA antigens of the donor (Scomik et a/, 1992, Toma, 1994, Ghasemian et a/, 
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1998). Pre-formed antibodies bind to antigens on vascular endothelium, which in 
turn, activates complement, thrombosis and activates neutrophil activity. Although 
with the recognition that positive cross-matches for IgG antibodies and not IgM 
antibodies are a contraindication to transplantation, this classical type of rejection is 
now uncommon (Leavey et a/, 1997, McCalmon et a/, 1997). HLA class I antibodies 
are also known to be contraindicative for hyperacute rejection, but not HLA class 11. 
ln addition, blood group ABO incompatibility is an absolute contraindication to 
organ transplantation as this increases the incidence of hyperacute rejection (Chui et 
a/, 1997). However, experiments performed using A1 kidneys have been shown to 
succesfully cross the ABO barrier, with the implementation of plasmapheresis to 
remove anti-AB antibodies pre-transplant, reducing the risk of hyperacute rejection 
(Nelson et a/, 1998, Tanabe et a/, 1998, Alkhunaizi et a/, 1999). 
1.9.5. Acute rejection 
Acute rejection may develop between one week and three/six months post-
transplant. The afferent limb of the immune response involves the release of 
antigenic material into the draining lymphatics, where it activates an immune 
response in the draining lymph nodes (central stage). Secondly, cellular and humoral 
effector mechanisms are generated which leave the lymph node, enter the blood, and 
are delivered to the graft, causing its destruction (efferent stage). Within a few hours 
of engraftment, neutrophils may enter the interstitium after interactions with selectins 
upregulated on vessel walls (Azuma et a/, 1996). Macrophage infiltration has been 
shown to be present in renal allograft biopsies (Svalander et a!, 1993). There is also 
evidence to show that cells such as monocytes infiltrate the allograft as early as forty 
eight hours after transplantation (Hughes et a/, 1994). 
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Acute rejection is primarily a T cell mediated host event, with both CD4+ and 
CD8+ T cells present (Dallman, 1997). Direct allorecognition is mainly associated 
with acute rejection (Shoskes and Wood, 1994, Hutchinson, 1996). From this stage, 
CD4+ T cells are activated by recognition of HLA class II antigens, which leads to 
the activation of NK cells, B cells and CD8+ cytotoxic T cells. Numbers of acute 
rejection episodes have been shown to be among the best predictors of allograft 
survival (Tesi et a/, 1993), and it is well known now that HLA mismatching between 
individuals elicits immune responses (Gorski, 1996), therefore, as previously 
mentioned, it is important to ensure as close a match as possible in order to reduce 
the risk of acute allograft rejection. 
1.9.6. Chronic rejection 
This stage presents as insidious deterioration in renal function at any time 
from six months to many years post-transplant. The pathogenesis of chronic rejection 
is a complex network of immunological, metabolic and haemodynamic events 
leading to a cascade of cellular and molect~lar events (Koskinen et a/, 1996). The 
immune and non-immune inflammation induces persistent low grade damage to the 
vascular endothelium, which in turn, leads to the induction of inflammatory 
mediators, such as IL-l, IL-6 and TNF-a (macrophages), IgM and IgG production (B 
cells) and TGF-~ (T cells) (Hayry et a/, 1993). This results in smooth muscle cell 
replication in the vascular wall, the migration of smooth muscle cells from the media 
into the intima, and generation of arteriosclerotic lesions throughout the entire length 
of the vessel wall (Lemstrom et a/, 1995). The changes seen in chronic rejection may 
be immune-mediated, or may be the result of previous damage sustained during acute 
rejection. 
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1.9.7. GVHD 
This includes acute GVHD, which occurs within the first one hundred days 
post-transplant, and chronic GVHD, which occurs following an acute episode or de 
novo. The mechanism ofGVHD, in particular acute, begins with the pre-conditioning 
regimen (radiation, chemotherapy), which leads to injury of host tissues (Hill et a/, 
1997). This gives rise to the induction of cytokines such as TNF -a and IL-l (Krenger 
et a/, 1997, Hill et a/, 1999), together with an increase in major and minor 
histocompatibility expression. The donor bone marrow is then infused, and this leads 
to the activation of Th I cells (induction of IL-2 and IFN-y) (Ochs et a/, 1996). CTL 
and NK cells become activated, together with the subsequent release of nitric oxide 
(NO) and TNF-a and IL-l (Vora et a/, 1997). Lipopolysaccharide (LPS) leaks 
through the mucosa, damaged in the beginning, and stimulates further cytokine 
secretion, thus leading to target organ damage (Cooke et a/, 1998). This cascade of 
events may be prevented if donor T cells are activated after they produce a Th2 type 
cytokine profile after transplantation. 
1.9.8. Immunological tolerance 
Graft specific immunosuppression has obvious prophylactic and therapeutic 
advantages over non-specific immunosuppression (see immunosuppressive therapy 
section). Experimental animal models have previously demonstrated that specific 
immunological tolerance of organ allografts may be achieved, and the hope is that 
similar states can be induced for clinical purposes (Calne et a/, 1994, Dong et at, 
1999, Noris et a!, 1999). The methods for inducing tolerance is short term, but the 
tolerance achieved is long term. The term ''T cell tolerance" was initially used to 
define antigen-directed unresponsiveness states resulting from deletion, anergy, 
ignornace or specific suppression (Lechler and Bluestone, 1997, Weigle and 
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Romball, 1997). It is immunologically specific, and can be transferred by T cells 
from tolerant donors to syngeneic naive animals. Tolerance may be explained by the 
proposal that the tolerance inducing protocols generate a predominantly Th2 type of 
response, and that the suppressive T cells are specific for alloantigen, but secrete IL-
4, IL-l 0 etc (Plain et a/, 1999). This immune deviation towards a Th2 type response 
may lead to the induction of "infectious tolerance" (Cobbold and Waldmann, 1998, 
Reemtsen et a!, 1999) and may be described as a form of immunoregulation, in the 
periphery, and is dependent on CD4+ T cells that suppress primary and secondary 
immune responses, such that these also become both tolerant and infectious (Cobbold 
and Waldmann, 1998). Another concept is that alloreactive T cells can be triggered 
by antigen either into an activated state where they can mediate allograft rejection, or 
into an anergic state. In this latter state, they may compete with, and inhibit the 
alloantigen activated T cells (Gillanders et a/, 1997, Chen et a/, 1998). 
There is also an observed reduction in immunogenecity of HLA incompatible 
allografts with the passage of time after transplantation. This may be explained by 
the hypothesis that the original (allogeneic) population of passenger leucocytes 
present in the graft is replaced by leucocytes of the recipient (Perico and Remuzzi, 
1997). Dendritic cells are widely accepted as the most potent APCs and have been 
suggested to play a role in tolerance induction (Steptoe and Thomson, 1996, 
Thomson and Lu, 1999). With dendritic cells being within the passenger leucocyte 
population, and being highly immunogenic, when they are replaced by recipient-
genotype dendritic cells, the allograft becomes much less immunogenic. 
1.9.9. CD4 and CD8 T cells 
The relative roles that CD4+ and CD8+ T cells have in -the mediation of 
allograft rejection is determined in part by the dependence of CD8+ cells on CD4+ 
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cells (Schulick et a/, 1993). In humans, the ability of CD8+ cells to respond to 
alloantigen without CD4+ help is very limited (Bachetoni et a/, 1993 ). If this is the 
case, then the rejection response is totally dependent upon class 11 MHC in the graft-
activating host CD4+ cells, suggesting that the CD4+ T cell dependent pathway may 
be dominant (Hall, 1991 ). It also appears that CD4+ T cells provide the majority of 
help not only to CD8+ cells, but also to B cells for alloantibody production. 
Experiments have been performed in humans indicating that T cell subsets may even 
be helpful as a marker of rejection (Olausson et a/, 1992) and even for predicting 
long term loss of allografts (Schulick et a/, 1993). Experiments to investigate T cell 
subsets in acute renal allograft rejection also suggested that there is a shift from naive 
to memory T cell phenotype in both CD4+ and CD8+ subsets in patients with 
confirmed acute graft rejection, and that the study ofT lymphocyte subsets may be 
useful in the monitoring of recipients with acute decline in renal function (Beik et a/, 
1998). The hypothesis that CD4/HLA class 11 complex is involved in the rejection 
process has been shown in rodents (Ito et a/, 1997). This study illustrated that a bi-
directional blockade of CD4/HLA class 11 complex using monoclonal antibodies in 
heart transplant recipients prolonged graft survival compared to untreated animals. 
The antibody combination was also proved to be more effective than using anti-CD4 
or anti-HLA antibodies alone, illustrating that the complex is fundamental in 
rejection. 
CD4+ T helper cells may be divided into two subpopulations, Th I and Th2. 
Th I and Th2 cells are known to secrete different panels of soluble mediators or 
cytokines (Street and Mossman, 1991 ). Th I cells produce pro-inflammatory 
cytokines such as interferon (IFN)-y, interleukin {IL)-2 and tumour necrosis factor 
-(TNF)- a. There has been suggestive evidence to indicate that there is a role for pro-
inflammatory cytokines in the activation of antigen-speci fie CD4+ T cells (Pape and 
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Jenkins, 1998). Th2 cells, on the other hand, produce anti-inflammatory cytokines 
including IL-4, IL-5 and IL-10 (Nickerson et a/, 1994). CD8+ T cells may also be 
divided into two subsets determined by their cytokine secretion (Mossman et a/, 
1997, Van Emmerik, 1997). Type l cytotoxic cells are associated with the production 
of IFN-y. Type 2 cells may suppress the killing of infected cells, and produce IL-4, 
IL-5 and IL-10 (Salgame et a/, 1991). 
1.10. Cytokines 
1.1 0.1. Introduction 
T cells are important immunoregulatory cells involved in the activation of B 
cells, macrophages and other T cells, of which many of the functions are mediated by 
soluble mediators or cytokines (Cohen et a/, 1994). Cytokines are soluble proteins or 
glycoproteins produced by lymphocytes, and in many cases other cell types, which 
act as chemical communicators between cells, but generally not as effector molecules 
in their own right (Corrigan, 1994). Most are secreted, but some can be expressed on 
the cell membrane, and others held in reservoirs in the extracellular matrix. 
Cytokines bind to specific receptors on the surface of target cells, which are coupled 
to intracellular signal transduction and second messenger pathways. 
Over the last three decades, cytokines have been given various names. 
"Lymphokines" were originally defined as cell free soluble factors generated by 
sensitised T cells in response to specific antigen (Dumonde et a/, 1969). The terms 
"cytokine" and "interleukin" served to broaden this definition to include factors 
originating from many different cell types (Aarden et a/, 1979). Cytokines were 
defined initially on the basis of their activities, but the cloning of the genes for these 
products has greatly facilitated their classification, and cyto1cine expression both in 
vitro and in vivo may now be studied at the gene, mRNA or protein level. 
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Cytokines interact in a self regulating network and any disruption of this 
network may have dramatic effects on the outcome of the immune response 
(Dallman, 1993). Cytokines are major components of both cellular and humoral 
immune responses and of their effector mechanisms. As previously described, 
cytokines may be used as target sources of immunosuppressive therapy and play a 
central role in recipient defence against infectious episodes and tumours (Soulillou, 
1993, Leimenstoll et a/, 1993). 
The physiological role of cytokines is governed by redundance (ie; several 
factors control cells in any one lineage) and pleiotropic effects (ie; most factors can 
influence more than one cell lineage) (Digiovine and Duff, 1990). Cytokines may act 
in a synergistic fashion eg; IL-4 and IL-5 for immunoglobulin switching or as 
antagonists eg; IL-4 and IFN-y on Igy2a production. Cytokines are now known to be 
involved in the majority of immune responses, being implicated in both acute 
(Schmouder and Kunkel, 1995) and chronic rejection (Stein-Oakley et a/, 1995). 
1.10.2. Cvtokine production and regulation 
A widely accepted working model for T cell regulation of the immune 
response has developed from the interpretation of many experimental and clinical 
observations in transplantation, infection, autoimmunity and other immunological 
conditions. The model suggests that signals received from the antigen presenting cell 
and bystander cells during T cell activation direct the development of the T cell 
cytokine response towards the production of either type I or type 2 cytokines 
(discussed later). The longer the immunogen persists, the more polarized the T cell 
cytokine response becomes. The preferential production of type I or type 2 cytokines 
in turn regulates the development and activation of effector cells of the inflammatory 
and immune systems, and therefore determines the outcome of the response 
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(Fitzpatrick and Kelso, 1998). This model is supported at the T cell population level 
by the demonstration that cytokine profiles are polarized in immune responses to 
certain infectious agents, allergens and other persistent immunogens in both mouse 
and man, and that these polarized profiles play a key role in antigen clearance and 
pathogenesis (Mossman and Sad, 1996). 
Most cytokines are not constitutively expressed but are rapidly synthesised in 
response to stimulation. The extent of stimulation may elicit qualitatively different 
patterns of cytokine gene expression {lmada et al, 1995). For most cytokines, the 
nature and extent of the transcription factors which regulate expression of their genes 
are not yet fully characterised. The specific consensus nucleotide recognition 
sequences for known transcription factors can be identified in genomic DNA. The 
precise biochemistry of the regulatory processes imposed even by the known 
transcription factors, is extremely complex. For example, the induction of IL-2 gene 
transcription requires both constitutive (NF-ATl and NFIL-2a) (Banerji et al, 1991, 
Chow et al, 1999) and inducible factors (AP-1 and NFKB) (Mortellaro et al, 1999), 
although other work has shown apoptosis-inhibiting factors such as AP-1 and NFKB 
not to be required for IL-2-mediated cell cycle progression (Iacobelli et al, 1999). 
Several mediators also act to limit cytokine gene expression. The classical inhibitors 
are the glucocorticoids, known to be used as anti-inflammatory drugs. The 
glucocorticoid receptor complex binds to elements in the promoter regions of the 
cytokine genes, therefore modulating cytokine gene transcription. 
Control of cytokine function may also be achieved by regulating the 
processing of precursors. Many cytokines are produced as integral membrane 
proteins which require processing enzymes for proteolytic cleavage for the release of 
the active cytokine molecule. Experiments are being done to identify these enzymes 
{Thomberry et al, 1992, Thomberry and Molineaux, 1995). Finally, modulating the 
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numbers of cytokine receptors on the cell surface may also act as a form of 
regulation. The modulation may be performed by internalization or shedding of the 
receptors. Modulation of the affinity of the receptor or its function may also be 
brought about by receptor phosphorylation, or through competition for shared 
receptor chains or signal transduction molecules (Uilrich and Schlessinger, 1990, 
Glenney, 1992). 
1.10.3. The Thl/Th2 paradigm 
CD4+ T helper cells may be divided into two subpopulations, T helper 
(Th I) and T helper 2 (Th2) cells. This was first proposed by Mossman and eo-
workers (1989), where murine CD4+ helper T cell clones were divided based on 
differences in their pattern of cytokine production. This work gave rise to the 
"Th l/Th2 paradigm". These two polarized forms of the specific cellular immune 
responses provide a useful model for explaining not only the different types of 
protection, but also the pathogenic mechanisms of several immunopathological 
disorders. Thl dominated responses are potentially effective in eradicating infectious 
agents. In contrast, Th2 responses are apparently insufficient to protect against the 
majority of infectious agents, but can provide some protection against parasites (Del 
Prete, 1998). 
Central to this paradigm is the role of certain cytokines which can act as 
cross-regulators of Th 11Th2 function. Th I cells are associated with the secretion of 
cytokines including IFN-y, IL-2 and TNF-a, while Th2 cells are associated with 
cytokines such as IL-4 and IL-10 (Romagnani, 1991, Del Prete et a/, 1994, Rincon 
and Flavell, 1997). Initial stimulation oflL-2 evokes IL-2, IL-4 and IFN-y production 
from non-Thl1Th2 cells (ie; ThO). If the primary stimulation is accompanied by 
exogenous IL-4, CD4+ T cells commit to a Th2 type profile (Abehsira-Amar et a/, 
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1992). If levels of Th I type cytokine predominates ie; IL-12, then the CD4+ T cell 
commits to Th I lineage (Palm et a/, 1996). IFN-r has also been suggested to play an 
important role in generation and commitment ofThl type cells (Miner and Croft, 
1998). This can be seen in Figure 1.1 0. As previously mentioned, there are several 
factors which have been proposed to push a T cell response predominantly towards 
Th I and Th2, including dose of antigen, site of exposure and ongoing immune 
reponses in the host (Openshaw et a/, 1995). CD8+ cytotoxic T cells may also be 
divided into two subpopulations Tcl and Tc2, and secrete the same patterns of 
cytokines as CD4+ T helper cells do (Cerwenka et a/, 1998), with the same cytokines 
helping to commit to either a Tc I or Tc2 lineage (Gish et a/, 1995). 
IFN-y, a Th I product, can inhibit the expression of the Th2 program, while a 
cytokine such as IL-4, namely a Th2 product can act to block the Th I program 
(Parronchi et a/, 1992). The Th2-derived cytokine, IL-l 0, has also been implicated in 
the crossregulation and inhibition ofThl cytokine production (Fiorentino et a/, 1991, 
Mossman and Moore, 1991 ). This has been illustrated in murine studies, but 
evidence now suggests that IL-10 is a Thl and Th2 derived cytokine, and in humans, 
this cytokine can down-regulate the function of both subpopulations (Del Prete et a/, 
1993) (Figure 1.11 ). Th 1 and Th2 cytokines also have different functional properties. 
Thl type cytokines are proposed to be pro-inflammatory, and therefore are involved 
in cell mediated inflammatory responses. Th2 cytokines, however, are anti-
inflammatory, and therefore involved in humoral immunity and may encourage 
antibody production (Mossman and Coffman, 1989). It has been shown that Th I 
clones induce delayed type hypersensitivity (DTH) reactions, with IFN-y commonly 
expressed at sites of DTH reactions (Ode-Hakim et a/, 1991 ). Th2 cytokines can also 
enhance eosinophil proliferation and function, and are mainly found in association 
with strong antibody and allergic responses (Mossman and Sad, 1996). 
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It has therefore become clear that early events in an immune response 
stimulate the production of cytokines that direct the subsequent development of T 
helper subsets producing discrete patterns of cytokines. These findings are currently 
under extensive investigation in the context of targeting these immune events for 
therapeutic intervention, with the hope of clinically managing the immune response 
in various diseases (O'Garra and Murphy, 1994). 
1.10.4. Thl. Th2 cytokines and disease 
1.10.4.1. Transplantation rejection: pro-Thl 
The Th l/Th2 paradigm has been extensively associated with the rejection 
process in transplantation and GVHD (Smith et a/, 1991, Jadus and Wepsic, 1992, 
Nickerson et a/, 1994, 1997, Dallman, 1995, Moller, 1995, Krenger et a/, 1997, 
Ferrara and Krenger, 1998). The introduction of allogeneic tissue stimulates a wide 
range of immunological responses in the recipient. In solid organ transplantation, the 
phenomenon is primarily cell-mediated, and cytokines have been suggested to play 
an integral role in the regulation and co-ordination of acute allograft rejection 
(Gaston, 1994). As T cells are activated, there is enhanced production of IL-2, 
formation of high affinity receptors, and ultimately proliferation of an antigen 
specific T cell response. 
During rejection, cytokines can facilitate tissue damage by immunological 
mechanisms, with the ultimate result of the response being rapid allograft 
destruction. The rejection response leads to an array of inflammatory responses. The 
rejection response may even be described as a "cytokine storm" where a whole array 
of cytokines are produced (Ferrara et a/, 1993, Merville et a/, l993a, l993b), with 
the activation of specific and non-specific effector mechanisms berng dependent. on 
the production of these cytokines (Bachetoni et a/, 1993). Thl cytokines, as 
121 
Cell mediated 
Immunity 
IFN-y 
....... ,...... 
~ ..... 
IL-4/IL-10 
Humoral immunity 
Figure 1.11. Regulation ofThl and Th2 responses. 
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mentioned previously are pro-inflammatory and have been widely associated with 
the association of rejection episodes in transplantation eg; kidney (D'Elios et a/, 
1997), small bowel (Galvao et a/, 1996), liver (Gaweco et a/, 1995) and heart (Van 
Besouw et a/, 1997). Studies using the famous skin explant model for predicting 
GVHD and investigating the aetiology of the disease have demonstrated the role of 
Th I cytokines as important mediators of cellular damage in the GVH reaction 
(Dickinson et a/, 1991, 1994a, 1994b ). Th 1 cytokines such as IL-6 and TNF -a have 
been shown to be significantly elevated in acute rejection biopsies (Cho et a/, 1998). 
Another study also illustrated the elevated expression of Th 1 cytokines, IL-6 and 
TNF-a in biopsies taken from patients undergoing acute renal allograft rejection, 
identifying that these cytokines do play a role in rejection (Vandenbroecke et a/, 
1991 ). IL-6 has also been associated with chronic rejection in kidney allograft 
recipients (Kaminska et a/, 1996). However, there have been conflicting results, 
suggesting that the Th 1 cytokine proteins are present but are not significantly 
elevated in both heart (Azzawi et al, 1996, Grant et a!, 1996). and kidney transplants 
(Callait-Zucman et a/, 1991), suggesting that Th1 cytokines do not act alone in the 
process of rejection. 
Cytokines such as IL-2 and IFN-y have also been suggested to be associated 
with the development of cellular rejection and that these inflammatory cytokine 
networks are active throughout the development of rejection (Stein-Oakley et a/, 
1995). Enhanced production ofiFN-y has been found in T cell clones from rejected 
kidney grafts (Benvenuto et a!, 1991). In this study, CD4+ and CD8+ T cell clones 
were generated. It was found that IFN-y was up-regulated in the clones made from 
rejected allografts compared to clones synthesized from normal peripheral blood. IL-
2 and IFN-y levels have also been shown to correlate with grades of cellular 
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rejection (Norohna et a/, 1993). Manipulation of Th I cytokine production such as 
IFN-y have also been shown to suppress allograft reactivity, thus inducing tolerance 
(Landolfo et a/, 1985, Dallman et a/, 1991). However, as before, it has been 
suggested that cytokines such as IL-2 and IFN-y may be necessary, but not sufficient 
for the development of cellular rejection (McClean et a!, 1997). 
1.1 0.4.2. Transplantation tolerance: pro-Th2 
Th2 cells have been suggested to produce cytokines that may be associated 
with tolerance (Lowry et a/, 1993). The induction of tolerance to alloantigen is 
accompanied in many cases by a decrease in the production of cytokines such as IL-2 
and IFN-y, with a sustained increase in Th2 cytokines IL-4 and IL-10 (Dallman et a/, 
1993). Patterns of Thl and Th2 cytokines have been studied (Lambert et a/, 1995; 
Joseph et a/, 1995). Lambert et a/ (1995) illustrated that differential Th 1ffh2 
production corresponds with different outcomes of grafts eg; IL-l 0 and IFN-y, while 
Joseph and colleagues illustrated that elevated Th2 cytokine expression was not 
found in rejecting allografts, thus confinning that Th I and Th2 cytokines have 
opposite roles in transplantation rejection. 
IL-10 and IL-4 have both been shown to have a protective role in the immune 
system (Holan et a/, 1994, Bromberg, 1995, Kusaka et a!, 1995), and are shown to be 
associated with tolerance in transplantation, for instance of the kidney (Burke et a/, 
1996, Weimer et a/, 1996) and the heart (Bushell et a/, 1994, Grant et a/, 1996, He et 
a/, 1998). Removal of Th2 cytokines, such as IL-4 have been suggested to even 
prevent the induction of transplantation tolerance (Bushell et a!, 1994). On the other 
hand, blocking of Th I cytokines and expansion of Th2 immune responses by 
possible immunomodulation could possibly encourage the tolerance response (Chen 
et a/, 1996). Preliminary data already shows that the administration of recombinant 
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Th2 cytokine (in particular IL-l 0) has a significant effect on the reduction of pro-
inflammatory mediators in both normal volunteers (Fuchs et a/, 1996) and transplant 
patients (Wissing et a/, 1997). However, some conflicting evidence has been 
published stating that Th2 cytokines may be both beneficial, deleterious (Picotti et a/, 
1997) and even irrelevant in transplantation (Carayol et a/, 1997, Piccotti et a/, 
1997). 
In addition Th2 cytokines such as IL-l 0 have also been found to be 
deleterious as they have been detected in rejecting allografts of the liver (Lang et a/, 
1995, 1996), heart (Cunningham et a/, 1994, Krieger et a/, 1996, El Game) et a/, 
1998), and kidney (Merville et a/, 1995). However, the presence of Th2 cytokines 
such as IL-10 may not necessarily mean that they are associated with transplantation 
rejection. As rejection is an inflammatory response, it is possible that anti-
inflammatory mediators will be present in the graft in order to either try to suppress 
the allogeneic response or even cross-regulate the effector functions of the Th 1 
cytokines (Tadmori et a/, 1994, Alfrey et a/, 1995). The presence of anti-
inflammatory mediators may therefore lead to a mechanism of tolerance. The likes of 
IL-l 0 may even serve a function of immune regulation at the site of inflammation, 
rather than in the immune suppression of the rejection response (Azzawi et a/, 1995). 
With all of this conflicting evidence, the Thlrrh2 paradigm may not be as clearly 
divided into pro- and anti-rejection cytokines. Thl and Th2 cytokines may both be 
present in the rejecting allograft, but it may be the ratio of Th I :Th2 cytokines that 
may determine a pro- or anti-rejection response (Katsikis et a/, 1994). 
1.10.5. Th 1 and Th2 cytokines in other clinical manifestations 
The Thlrrh2 paradigm may be linked to many clinical situations. Pregnancy, 
for instance has been shown to be associated with a skewing towards a Th2 type 
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response (Bjorksten, 1999). A shift towards the Th1 type response has been 
associated with unsuccessful preganacy and recurrent abortions (Raghupathy, 1997, 
Piccini et a/, 1998). Other conditions such as Bechets disease (Raziuddin et a/, 1998) 
and in particular, allergy (Kapsenberg et a/, 1998) have also been associated with 
divergent cytokine profiles. 
There is increasing evidence that T ·cell reactivity to the environment in the 
development of allergy may occur during early childhood. Initial T cell priming may 
even occur in utero (Holt et a/, 1997, Prescott et a/, 1997). Clinical manifestations 
such as allergy and atopy have been associated with a pro-Th2 response (Nakazawa 
et a/, 1997, Bjorksten, 1999) with evidence suggesting that Th2 polarization may 
occur during chilhood (Piccini et a/, 1996, Yabuhara et a/, 1997). An increase in Th2 
cytokines such as IL-4, IL-6 and IL-13 have been shown, with a dominant increase in 
IL-10 (Esnault et a/, 1996, Prescott et a/, 1998). There has also been evidence that an 
increase in IL-4 may be accompanied with a decrease in cytokines like IFN-y 
(Warner et a/, 1993, Prescott et a/, 1999). The upregulation of cytokines like 1L-4 in 
atopy is due to the fact that IL-4 acts as an isotype switch cytokine which activates 
the lgE pathway in B cells (crucial for mast cell activation and histamine release), 
while IFN-y inhibits this transformation (Jujo et a/, 1992). 
The increase in allergies has been almost blamed on the lack of dirt and 
disease since the elevated use of anti-bacterial products and vaccination in childhood. 
The first suggestions of this hypothesis was in 1989, where David Strachan, an 
epidemiologist in London, noticed that children from extensive families were less 
likely to develop eczema, asthma or hay fever. It was suggested that older siblings 
bring their younger family members into contact with more infections than in smaller 
families, thereby exposing their immune systems to antigens (reviewed by Hamilton, 
1998). Imrnunologically, this has been explained by the Th 1ffh2 responses. Th1 
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cells are predominantly activated by ThO cells being exposed to external antigens 
such as bacteria and viruses. If exposure to antigens is minimal, Th2 cells 
predominate. Therefore, individuals exposed to fewer antigens are more likely to 
have a Th2 dominated immune response (Rook and Stanford, 1998). 
At present, there is much work being carried out in order to find ways to 
compensate for the lack ofTh1 immunity. Vaccination has been suggested, with the 
intent to replace infections which stimulate the Th 1 response in order to re-address 
the cytokine balance. Previous work by Erb et a/ ( 1998) reported that inhaling 
mycobacteria can stave off allergy attacks in mice. Allergic mice were injected with 
egg white which was intended to boost their Th2 responses. When the vaccine was 
injected before the second dose of egg white, there was no allergic response. In a 
second study, Rook and Stanford (1998) showed the same effect when dead M. 
vaccae was injected into mice. Trials of this vaccine are currently underway on 
allergic patients. Extensive research is constantly being carried out in order to find 
ways to modify the immune response in conditions such as allergy (Alien and 
Maizels, 1997). 
1.11. Functional tests 
1.11.1. Mixed lymphocyte culture (MLC) 
It has been known that while normal individuals do not react against their 
own tissue, a vigorous response can be mounted against foreign tissue leading to 
graft rejection or GVHD. It is now known that the cellular basis for alloreactivity is 
the recognition by alloreactive lymphocytes of alloantigens encoded for by the HLA 
and · when allogeneic lymphocytes are cultured together, proliferation occurs 
(Dozmorov et al, 1995). · 
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When a mixture of two populations of mononuclear cells are cultured 
together, this is termed a mixed lymphocyte culture (MLC) or mixed lymphocyte 
reaction (MLR) (Bain et a/, 1964, Bach and Hirschhom, 1964). If the two 
populations of cells arise from HLA-identical individuals or single individual, the 
cells will eventually die. However, if the individuals are mismatched, the cells will 
undergo DNA synthesis, blast transformation and proliferation. This would be 
termed a two way MLC, but the standard method to use would be a one way MLC, 
where one population (stimulator) is treated either by irradiation or mitomycin C in 
order to render them unresponsive (see materials and methods). In such a culture, the 
one way MLR may be set up in either the host-versus-graft (HVG) or graft-versus-
host (GVH) direction. In this assay, the cells are cultured together and then tritiated 
eH) thymidine is added to the cultures (thymidine incorporates into the DNA of 
dividing cells only, and therefore will radiolabel the responding cell population). The 
cells are the harvested and the amount of thymidine uptake is measured by a 
scintillation counter. The response is compared to both a positive (response to HLA-
mismatched cells) and a negative control (response to autologous cells). If there is a. 
significant increase above the negative control, then the reaction is considered to be 
positive. 
During the MLR, two distinct lymphocyte populations are stimulated, 
proliferating and cytotoxic populations, both of which are stimulated by different 
HLA differences (Bach et a/, 1973). In an MLR, the responding cells are mainly 
alloreactive CD4+ T helper cells responding to HLA class 11 differences on foreign 
cells. There is also a weak response by CD8+ T cells against HLA class I differences. 
The stimulatory cells are antigen presenting monocytes or 8 cells which have HLA 
class 11 antigens on their surface. HLA-DR mismatches predominate in the MLC (AI-
Daccak et a/, 1990), with HLA-DR and DQ mismatches defined by (RFLP) analysis 
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correlating with a positive MLC reaction (Clay et a/, 1989). It has also been shown in 
macaques, who share close DNA homologies with humans, that multiple DR 
mismatches show a trend towards a higher MLC proliferative response (Lobashevsky 
et a/, 1998). However, positive reactions can occur in HLA-DR and DQ matched 
pairs suggesting that other antigens may be involved, such as HLA-A and B 
(Termijtelen and Van Rood, 1981a) and/or HLA-DP (Clay et a/, 1989). The role of 
HLA-DP remains controversial in that studies have demonstrated an influence 
(Termijtelen and Van Rood, 1981b) and no influence on the MLR (Pawelec et a/, 
1982). Other studies have also shown that certain DP mismatches may induce a 
response in the MLC, although the response is not as strong as HLA-DQ or DR 
mismatches (Cesbron et a/, 1990, Olerup et a/, 1990, Moreau et a/, 1993). 
The MLC is a semiquantitative HLA matching test which confirms HLA 
class 11 identity between donor and recipient. Although it has played a role in 
selection of unrelated donors for bone marrow transplantation (BMT), the assay is 
now thought of as being relatively imprecise and has been shown not to predict 
GVHD and/or clinical outcome after BMT in identical sibling (Lim et al, 1988, 
DeGast et a/, 1992), related haploidentical (Mickelson et a/, 1993a) and unrelated 
donors (Hows et a/, 1986, Mickelson et a/, 1993 b, 1996). In the case of renal 
transplantation, there has been evidence for (Harmon et al, 1982, Langhoff et a/, 
1985, Ghobrial et al, 1994, Agrawal et a/, 1998, Mizutani et a/, 1998, Salomao et a/, 
1998) and against (Cullen et a/, 1977, Burke et a/, 1993, Steinmann et a/, 1994) the 
MLC predicting rejection and/or clinical outcome. The reasons for this assay 
possibly not predicting clinical outcome may be that it predominantly detects CD4+ 
HLA class 11 and not CD8+ class I reactive lymphocytes, which are an important 
effector cell population, and that the assay is only semiquantitative. The MLC 
therefore, remains an uncertain method for the prediction of transplant outcome. 
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1.11.2. Cytotoxic T lymphocyte precursor (CTL-p) analysis 
A cytotoxic T lymphocyte precursor (CTL-p) is a naive cell, that has the 
potential to develop and differentiate into a mature CTL. This occurs after 
encountering a specific foreign antigen. The CTL-p assay is used in order to 
determine the frequency of alloreactive CTL-p's in a population of mononuclear 
cells by the method of limiting dilution. Limiting dilution analysis (LOA) for CTL-p 
frequency has been previously described (Lefkovits and Waldmann, l984a, l984b, 
Sharrock et a/, 1990, Kaminski et a/, 1991 ). Limiting numbers of responder cells 
(usually 5 x 104 - 0.125 x 104) are cultured with a constant number of irradiated 
stimulator cells (5 x 104). Recombinant IL-2 is added to the culture and on the day of 
harvest, 51 chromium e1Cr) labelled stimulator target cells (PHA blasts) are added to 
the cultures. The supematants are then harvested and 51 Cr release is measured. 
Positive wells are scored if the 51 Cr release is greater than the mean plus three 
standard deviations of the control (irradiated stimulator cells only). It is estimated 
that at high concentrations, there will be more CTL-p's (> l/well) than at low 
concentrations (<1/well). Using the Poisson distribution model, it is possible to 
estimate the frequency of alloreactive CTL-p in peripheral blood. 
The CTL-p response is attributed to predominantly CD8+ CTLs recognising 
HLA class I differences of foreign cells. As in the MLC, CTL-p frequencies have 
also been shown to correlate with the degree of HLA matching (Kaminski et a/, 
1988) and severity of acute GVHD in unrelated bone marrow transplantation 
(Kaminski et a/, 1989). In the case of organ transplantation, no correlation has been 
between CTL-p frequencies and rejection after renal (Steinmann et a/, 1994, Bouma 
et a/, 1995, Mestre et a/, 1996), heart (Reader et a/, 1990) or liver transplantation 
(Eberspacher et a/, 1994). There is conflicting evidence, however, which suggests 
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that CTL-p frequencies do correlate with graft outcome in heart transplantation (Hu 
et a/, 1994). 
It therefore appears that the CTL-p assay is of use for measuring GVHD in 
unrelated bone marrow transplantation. This does not appear to be the case for organ 
transplantation, and it seems that it has proved difficult to correlate pre-transplant 
CTL-p reactivity with organ graft rejection. ·However, it has been demonstrated using 
the CTL-p assay that a selective reduction of donor-specific CTL-p's were found in 
patients with a well functioning renal allograft (Herzog et a/, 1987), therefore this 
assay may be of value in post-transplant monitoring. 
1. 11 .3. Helper T lymphocvte precursor (HTL-p) analysis 
HTL-p analysis is based on the measurement of IL-2 secretion by helper T 
lymphocytes. HTL-p frequencies, like CTL-p, are quantitated by limiting dilution 
analysis. The assay is set up in a similar way to that of the CTL-p assay. Graded 
numbers of untreated responder cells are added to microtitre plates. A constant 
number of treated stimulator cells are then added to the responder cells and cultured 
as an MLC. Following incubation, a fixed concentration of an IL-2-dependent cell 
line eg; CTLL-2 is added to each well. After further incubation, tritiated thymidine 
eH) is added to the culture and incubated. The cells are then harvested, and 3H 
incorporation by the IL-2-dependent cell line is measured. HTL-p frequencies are 
calculated from the proportion of wells which are negative for IL-2 production at 
each responder cell dilution. 
Studies of HTL-p analysis have been done in order to study human peripheral 
blood mononuclear cells for alloresponsiveness (Theobald et a/, 1989, 1990, 
Reisaeter et a/, 1996). Because anti-recipient HTL's have been implicated in the 
control and amplification of alloreactive immune responses that initiate GVHD, 
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HTL-p analysis has been shown to be useful for the selection of HLA-identical 
donors in bone marrow transplantation (Schwarer et a/, 1993). Combined CTL-p and 
HTL-p limiting dilution assays have also been shown to be useful in predicting 
GVHD in unrelated donor bone marrow transplantation (Wang et a/, 1996), but not 
in HLA-identical sibling bone marrow transplantation (Dickinson et a/, 1998). The 
HTL-p assay has also been shown to be of use in determining frequencies of IL-4 
secreting HTL-p's (Imami et a/, 1997), thus illustrating that IL-4 producing HTL-p 
frequencies are associated with reduced risk of GVHD in bone marrow 
transplantation. 
However, the HTL-p assay has not been of much use, in organ transplantation 
compared to bone marrow transplantation. No correlations have been found between 
HTL-p frequencies and rejection after renal transplantation (Bouma et a/, 1995, Beik 
et a/, 1997), although a positive correlation has been found between T cell 
sensitisation and HTL-p frequencies in chronic renal failure patients (Deacock and 
Lechler, 1992). This assay, like CTL-p has a use for prediction of GVHD in bone 
marrow transplantation, but its' use for prediction in organ transplantation is still 
unclear. 
1.11.4. Cytokines as functional tests 
Cytokine profiling may be performed in vitro in several ways: 
a) Precursor frequencies of cytokine-secreting helper T cells using HTL-p analysis 
(see HTL-p section) 
b) Quantification of numbers of cells expressing intracytoplasmic cytokines by flow 
cytometry 
c) Cytokine mRNA detection by PCR or in situ hybridisation 
d) Cytokine protein secretion by ELISA 
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Limiting dilution analysis of cytokine secreting Iymphocytes has 
demonstrated large inter-individual variations in the frequencies of both alloreactive 
IL-2 and IL-4 secreting HTL-p's (see HTL-p section). Large inter-individual 
variations in both the amount of cytokine secretion by ELISA (IL-2, IL-4 and IFN-y) 
and the numbers of cytokine secreting lymphocytes by flow cytometry (IL-2 and 
IFN-y) have been demonstrated in mitogen stimulated cultures (Kaminski et a/, 1995, 
Ferry et a/, 1997). It should be mentioned that different stimuli may have different 
effects on the cytokine profile (lmada et a/, 1995). 
The MLC has been widely used for the measurement of cytokines including 
IFN-y (Manger et a/, 1981), IL-2 (Ilonen and Kartunen, 1984), IL-2 and IL-3 
(Bishara et a/, 1991, 1993), TNF-a and IL-6 (Toungouz et a/, 1993) and IL-10 
(Toungouz et a/, 1996). There is also now evidence to suggest that some cytokine 
gene polymorphisms may determine the amount of protein secreted (Daser et a/, 
1996, Turner et a/, 1997). There has been extensive work studying the clinical 
relevance of cytokine secretion in the MLC. Measurement of cytokine secretion in 
the MLC has been shown to detect HLA-DRB1 and DQB1 mismatches (Danzer et 
a/, 1994a) and variations in HLA-DR4 polymorphisms (Toungouz et a/, 1994). 
Quantitation of IL-2 and IFN-y protein secretion and/or detection of IL-2, IL-5 and 
IFN-y gene expression in the MLC has been shown to predict acute GVHD after 
identical sibling or mismatched BMT (Tanaka et a/, 1994, 1995a, 1995b ). In vitro 
skin explant studies have demonstrated the role of IFN-y and TNF-a as important 
mediators of the cellular damage observed in the skin (Dickinson et a/, 1991, 1994a, 
1994b ). High levels of both of these cytokines in MLC supematants have also been 
shown to correlate with the severity of acute GVHD after HLA-identical sibling 
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BMT (Dickinson et a/, 1994b), with this data suggesting the recognition of minor 
histocompatibility antigens. 
In renal transplantation, cytokines have also been examined. Flow cytometric 
analysis has shown a positive correlation with increased IL-2 receptor expression and 
the onset of renal allograft rejection and rejection episodes (Reed et al, 1989, 
Langley et a/, 1993). Cytokine secretion studies have shown IFN-y and IL-6 as useful 
markers in the prediction of allograft rejection, while another study demonstrated a 
correlation between high levels of IFN-y protein and a high risk of acute rejection 
(Kaminski et a/, 1995). Low levels ofiL-1 0 has been found to correlate with low risk 
of rejection (Weimer et a/, 1996), however, in contrast, high IL-10 (and TNF-a) 
cytokine genotypes have been associated with renal allograft rejection (Sankaran et 
a/, 1999). In addition, high levels of IL-l 0 mRNA transcripts have been detected in 
rejecting renal allografts (Strehlau et a/, 1997): DNA studies have demonstrated that 
polymorphisms of particular cytokine genes (TNF-a and IL-l 0) are associated with 
high/low secretor status as illustrated in both heart (Turner et al, 1995, 1997), and 
bone marrow transplantation (Middleton et a/, 1998), and even in conditions such as 
meningococcal disease (Westendorp et al, 1997). The influence of cytokine 
genotypes on allograft rejection is currently being extensively studied (Hutchinson et 
a/, 1998a, !998b ). 
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1.12. Aims and objectives 
In view of all of these findings, the general aim of this study was to develop a 
simple and reliable in vitro functional assay for the prediction of both acute and 
chronic rejection and thus improve the clinical outcome of allogeneic renal 
transplantation. The major aims and objectives include: 
i) To develop in vitro assays for quantifying cytokine protein secretion and numbers 
of cytokine secreting lymphocytes (IL-2, IL-4, IL-6, IL-l 0 and IFN-y). 
ii) To compare the quantity of protein secretion with numbers of cytokine secreting 
cells in normal individuals. 
iii) To compare IFN-y protein secretion with numbers of IFN-y secreting cells and 
IFN-G polymorphisms in normal individuals. 
iv) To compare cytokine protein secretion and numbers of cytokine secreting cells in 
the MLC with acute rejection after allogeneic renal transplantation. 
v) To compare cytokine protein secretion in the MLC with acute GVHD after HLA-
identical sibling BMT. 
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CHAPTER2 
MATERIALS AND METHODS 
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2.1. Study population 
2.1.1. Renal transplant recipients 
One hundred patients with end stage renal failure were included in the study. 
Fifty seven ofthe patients attended clinics at Derriford Hospital in Plymouth, with 
forty three of the patients attending clinics at Aberdeen Royal Infirmary, Scotland. 
All of the patients selected received an allogeneic renal transplant. Due to the 
inconclusive results gained from the Aberdeen patients, clinical details were only 
gathered for the fifty seven Plymouth transplant patients (appendix 2). Of these 
patients, thirty two were male (age range: 24-76) and twenty five were female (age 
range: 29-71 ). All renal transplant recipients were HLA typed by serology (appendix 
3). 
2.1.2. Bone marrow transplant recipients 
Eight patients undergoing bone marrow transplantation for chronic 
granulocytic leukaemia (CGL) (n=4), acute lymphoblastic leukaemia (ALL) (n=2) 
and acute myeloblastic leukaemia (AML) (n=2) were also studied. Bone marrow 
transplant recipients were HLA typed by serology (appendix 4). 
2.1.3. Transplant donors 
The donors chosen for renal transplantation were both unrelated cadaverics 
(n=S6) and live-related (n=l). The bone marrow transplant donors were HLA-
identical siblings. Renal transplant and bone marrow transplant donor HLA typing 
are shown in appendices 3 and 4. Renal transplant donors were selected on the basis 
of beneficial matching where possible and a negative serum cross-match. 
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2.1.4. Normal volunteers 
This group consisted of normal healthy volunteers randomly chosen from 
Derriford Hospital and from around the Plymouth area. 
2.2. Donor-recipient matching 
2.2.1. HLA serotvoing 
The determination of an individuals' HLA type was determined by the 
standard micro-lymphocytotoxicity test, based upon the original method by Terasaki 
and McClelland ( 1964). Donor lymphocytes were isolated from peripheral blood for 
class I (HLA-AIB) and class II (HLA-DR) matching. The lymphocytes were 
incubated with HLA typing sera in Terasaki microtitre plates for thirty minutes at 
room temperature. Rabbit complement was then added to each well and incubated for 
sixty minutes at room temperature. Quench working solution (acridine 
orange/ethidium bromide) is then added to each well and incubated for a further 
fifteen minutes in the dark at room temperature. This dye is added in order to assess 
the degree of cell lysis. The wells are then read using a fluorescent microscope and 
the results are recorded as a percentage of dead (red fluorescence; positive reaction) 
to live cells (green fluorescence; negative reaction). From these results, the HLA 
type of the cells may be determined. 
2.2.2 Cross-matching (Micro-lymphocytotoxicity) 
This method was employed to establish if there were any pre-existing 
antibodies in the patient with specificity for the donor HLA antigens. Donor 
lymphocytes were isolated from the lymph nodes (for class I) and spleen (class Il) 
matching. The lymphocytes from the lymph node (mainly T cells) and spleen (mainly 
8 cells) were seperately incubated with the most reactive serum from the patient in 
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Terasaki microtitre plates for sixty minutes at room temperature. Rabbit complement 
was added as above and incubated for ninty minutes at room temperature. Quench 
working solution was added and incubated as in section 2.2.1. Red fluorescence 
indicates a positive cross-match, while green fluorescence indicates a negative cross-
match. 
2.3. Immunosuppressive therapy 
2.3.1. Renal transplant recipients 
No immunosuppressive therapy was administered to any of the patients pre-
operatively. 500mg methylprednisolone was given during the transplant operation. 
Postoperatively, IOmg!kg cyclosporin (as Neoral) was orally given in divided doses 
(ie: 5mg!kg twice daily). In addition, lmg!kg azathioprine was administered together 
with !Omg prednisolone orally daily. Subsequent follow-up studies were undertaken. 
Cyclosporin doses were adjusted according to the blood trough level to achieve a 
range between 1 00-150ug/l after one year (Table 2.1 ). Prednisolone was given at 
IOmg daily for first three months, then reduced by 2.5mg every following three 
months. Steroids were withdrawn completely at one year in most patients. 
Acute rejection episodes were determined by commonly accepted clinical and 
laboratory criteria, and confirmed by needle biopsy. For suspected acute rejection, an 
initial course of 500mg methylprednisolone was administered on three consecutive 
days. Second rejection episodes were treated with a further course of 
methylprednisolone and conversion of cyclosporin to tacrolimus, whilst third 
episodes were treated with OKT3 antibodies. 
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Time Interval Concentration (nmoVI) at 12 hours 
0-14 days 300 
2-6 weeks 250 
7-12weeks 200 
3-6 months 175 
6-12 months 150 
after 12 months 125 
-----------------------------------------------------------------------------------------------------
Table 2.1. Target cyclosporin blood concentrations from 0-1 year. 
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2.3.2. Pre-conditioning regimen for stem cell and bone marrow patients 
Conditioning therapy consisted of 1200cGy total body irradiation, plus 60mg 
of cyclophosphamide per kg of body weight per day for two days (60mg!kg/day 
etoposide for ALL patients). This was followed by 5mg!kg cyclosporin A for one 
day. Additional GVHD prophylaxis consisted of 5mg!kg cyclosporin (days -1 to +4) 
and 8mg/m2 methotrexate (days +I, + 3, +6 and + 11 ). Infection prophylaxis included 
ciprofloxacin (500mg), itraconazole (400mg) and nebulised pentamidine (300mg) 
from day +28 monthly. 
2.4. Materials 
2.4.1. Reagents 
Acetic acid and sulphuric acid were purchased from Analar Chemicals. 
Disodium ethylene diamine tetra-acetic acid, formamide, hydrochloric acid, 
magnesium chloride, sodium chloride, sodium dodecyl sulphate (SDS), sucrose, tris-
hydroxy-methyl-methylamine and urea were purchased from BDH Laboratory 
Supplies-Merck Limited UK. Sodium hydroxide and nucleon silica were purchased 
from Scotlab UK. Chloroform and ethanol was purchased from Rathbums Limited 
UK. Dimethyl sulphoxide (DMSO), hydrogen peroxide, paraformaldehyde, 
phosphate buffered saline tablets, saponin, sodium acetate sodium bicarbonate, 
sodium carbonate, sodium perchlorate, 3,5,3',5'tetramethyl benzidine, triton X-100 
and tween 20 (poly-oxethylenesorbitanmonolaurate) were all purchased from Sigma 
Chemicals UK. 
2.4.2. Culture reagents and specialised materials 
The following reagents were used for cell culture: Fetal calf serum (FCS), 
ionomycin, L-glutamine, mitomycin C, monensin, phorbol myristate acetate (PMA) 
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and phytohaemaglutinnin (PHA) were purchased from Sigma Chemicals, UK, 
recombinant human IgG (Lome Laboratories, UK), OKT3 (anti-CD3) Novartis), 
bovine serum albumin (BSA) (Lome Laboratories UK), 32P dA TP (Amersham Life 
Sciences, UK), ficoll-hypaque ("Lymphoprep") (Robbins Scientific), human AB 
serum (Blood Transfusion Service, Bristol, UK), penicillin/streptomycin (ICN 
Pharmaceuticals Ltd), RPMI 1640 medium (Gibco Ltd, Scotland), dNTP's and T4 
polynucleotide kinase (Pharmacia, UK) and thermostable DNA polymerase (HT Life 
Technology, UK). Nucleon DNA extraction kit was purchased from Scotlab UK. 
IFN-y primers were purchased from MWG-Biotech Ltd. 
Cryovials and sodium heparin vacutainers were purchased from Greiner 
Labortechnik. Eppendorf tubes were purchased from Elkay Products. Twenty four 
well plates (CoS tar UK Ltd) were used for the incubation of cell cultures. Conjugated 
monoclonal antibodies used for flow cytometry were purchased from 
Pharmingen/Becton Dickinson except for rat anti-human IL- 10 and isotype control 
(Serotec) {Table 2.2). ELl SA kits for IL-4, IL-6, IL- 10 and IFN-y (Eurogenetics Ltd) 
and IL-2 (R and D Systems Europe Ltd). CD4 and CD8 pre-coated magnetic beads 
(Dynal UK Ltd). 
2.5. Stock solutions 
2.5.1. Flow cytometry 
i) PBS 
Dissolve one tablet in 200mls distilled water. 
ii) Staining Buffer 
PBS (pH 7.4) + 1% heat inactivated (56°C, 30 minutes) FCS. 
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Antibody Concentration of Antibody 
CD45 FITC/CD 14 PE "Leucogate" 20ul/106 cells 
Mouse anti-human CD3 (IgGl; FITC) lOul/106 cells 
Mouse anti-human CD 16 FITC/CD56PE 20ul/ 1 06 cells 
(NK cell marker; IgG 1) 
Mouse IgGl FITC isotype control 20ulll 06 cells 
immunoglobulin 
Mouse anti-human CD3 ( IgG 1, PECy5) 5ul/l 06 cells 
Mouse anti human CD4 (IgG 1, PE-Cy5) 5ulll0() cells 
Mouse anti-human CD8 (lgG 1 PECy5) Sul/106 cells 
Mouse anti-human CD3FITC/CD25PE 20ulll 0() cells 
dual stain 
Mouse IgGl PECy5 isotype control 5ul/l 0() cells 
immunoglobulin 
Mouse anti human IFN-y (IgG 1; PE) 20ul/106 cells 
Mouse anti-human IL-2 (lgG 1; PE) 20ul/1 0() cells 
Mouse anti-human IL-4 (IgG 1, P 20ul/106 cells 
Mouse IgGl PE isotype control 20ul/106 cells 
immunoglobulin 
Rat anti-human IL-l 0 (IgG2a; PE) lOull 1 06 cells 
Rat IgG2a PE isotype control lOul/106 cells 
immunoglobulin 
Table 2.2. Flow cytometry antibodies and concentrations. 
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iii) 0.5%14% Fixation Buffer 
PBS + 0.5%/4% parafonnaldehyde. Wann in 50°C waterbath until dissolved. 
iv) Permeabilisatio11 Buffer 
PBS + I 0% heat inactivated human AB serum + 0.1% saponin. 
2.5.2. ELISA (for IL-4, IL-6, IL-10 and IFN-y) 
i) Coating Buffer (O.JM carbonate/bicarbonate buffer) 
Solution A: 1.24g Na2C03.H20 in IOOmls distilled water (Baxter UK). 
Solution B 1.68g NaHC03 in 200 mls distilled water. 
Take 70mls of solution A and add solution B until pH is 9.6. 
ii) PBS Wash Buffer 
PBS (pH 7.4) + 0.005% TWEEN 20). 
iii) Substrate Buffer 
0.11 M acetate buffer: 15g sodium acetate/800mls water, pH 5.5 with glacial 
acetic acid. 
iv) 3,5,3',5' Tetramethyl benzidine 
6mg/ml TMB in DMSO. 
v) Hydrogen Peroxide Solution 
3% H20 2 in distilled water. 
vi) Substrate Solution 
Per ELISA plate: 12mls substrate buffer; 200ul TMB solution; 12ul H202 
solution. 
vii) Stop Solution 
1.8M sulphuric acid in distilled water. 
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Component IL-2 IL-4 IL-6 IL-10 IFNJ'( 
Coating antibody Pre-coated anti-II..-4, anti-IL-6 anti IL-10 anti-IFN-y 
11100 11100 11100 11100 
Sample/standard Dilution Buffer DB DB DB DB 
diluent (DB) provided 
Initial standard 1:2 1:50 1:9 1:16 1:25 
dilution 
Initial standard 2000pg/ml 100pg/ml 450pg/ml 300pg/ml 500pg/ml 
concentration 
Sample dilution Neat Neat 1:20 1:2 1:5 and 1:10 
Biotin antibody Pre-prepared 1:100 1:100 1:100 1:100 
dilution 
Detection limit 7pg/ml 0.4pg/ml 2pg/ml 3pg/ml 2pg/ml 
Table 2.3. ELISA components and concentrations. 
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2.5.3. Dynabead wash buffer 
PBS (pH 7.4) + 2% heat inactivated FCS. 
2.6. Preparation of medium 
2.6.1. Wash medium 
Wash medium was prepared using RPMI 1640 supplemented with IOOIU/ml 
penicillin, I OOug/ml streptomycin, 2mM glutamine and 0.2% sodium bicarbonate. 
2.6.2. Culture medium 
Culture medium was prepared usmg RPMI 1640 supplemented with 
IOOIU/ml penicillin, IOOug/ml streptomycin, 2mM L-glutamine, 0.2% sodium 
bicarbonate and 10% pooled heat inactivated human AB serum. 
2.6.3. Cryopreservation medium 
Freezing medium used for the cryopreservation of isolated mononuclear cells 
was prepared using 80% FCS and 20% DMSO. 
2.7. Preparation and storage of peripheral blood mononuclear ceUs (PBMCs) 
2.7.1. Whole blood 
20-40mls of peripheral blood was collected into sodium heparin vacutainers 
from normal volunteers and renal transplant recipients (immediately pre-transplant, 
three months and twelve months post-transplant). Blood samples were also taken 
from bone marrow donor and recipients. The blood was diluted I: I in RPMI 1640 
cell culture wash medium and mixed. I Omls of the diluted blood was carefully 
layered onto an equal volume of lyrnphoprep and centrifuged (Heraeus Labofuge · 
400; 2000rpm, twenty minutes at room temperature). This method is known as 
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density gradient centrifugation. The mononuclear cell interface was then transferred 
into a sterile collection tube and washed once in RPMI 1640 wash medium to 
I successfully pellet the cells ( 1500-1800 rpm, ten minutes). The supernatant was 
discarded, and the cells were washed a further two times in order to remove any 
remaining Ficoll/Hypaque (1200rpm, ten minutes). After washing, the cells were 
resuspended in 1 ml of cell culture medium and counted using a haemocytometer. The 
cell density was adjusted to 1 x 106 cells/m! for culturing or 5 x I 06 cells/m! for 
cryopreservation. These cells were used as the responder cell population in the MLC. 
2.7.2. Donor spleen 
Spleen from the cadaveric donor was collected from the operating theatre and 
immediately refrigerated on arrival. The spleen was then transferred to a sterile 
larninar for mononuclear cell isolation. The spleen was processed by gently teasing 
the tissue apart and resuspending the liquified tissue in cell culture wash medium. 
The suspension was then filtered through a sterile 0.22um filter (Sartorius 
Minisart®) to remove any debris. The filtered suspension was then layered onto an 
equal volume of Ficoli-Hypaque and centrifuged as above. The cells were then 
prepared using the whole blood method and used as stimulator cells in the MLC. 
2.7.3. Cryopreservation of samples 
I ml of isolated cells were pi petted into 2ml cryovials at a final concentration 
of at least 5 x 106 cells/mllvial and kept on ice for fifteen minutes. Cells were then 
diluted 1:1 with freezing medium (final concentration: 50% cell suspension, 40% 
FCS, 10% DMSO) and stored at -70°C overnight. The cells were transferred to liquid 
nitrogen within twenty four hours. 
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2.8. Depletion of CD4+ and CD8+ T cells 
2.8.1. Washing of dynabeads 
The dynabeads in the vial were resuspended and the required volume 
transferred to a test tube. The tube was placed on the magnet for one minute and the 
fluid pipetted off. The vial was removed from the magnet and l-2mls of PBS/FCS 
wash buffer was added. The protocol was repeated and the dynabeads were 
resuspended in a volume of PBS/FCS wash buffer equal to that originally in the vial. 
2.8.2. Depletion 
PBMCs were isolated as described in Section 2.7.1. The cells were then 
centrifuged and resuspended in PBS/FCS wash buffer at a concentration of 10-20 x 
106 cells/m!. Dynabeads (72ul ofCD4; 14lul CD8 per I x 107 PBMCs) were added, 
the suspension was mixed thouroghly and incubated for thirty to forty five minutes 
on rotator at 2-8°C. Smls of PBS/FCS wash buffer was added and the tube was 
placed in the magnet for three minutes to collect the rosetted cells and the unbound 
dynabeads. The depleted supematant was transferred to a second tube and the 
protocol was repeated for a complete depletion. The purity of the T cell subset 
populations were analysed by flow cytometry and was >98% pure (<2% debris, +/_ 
0.5). 
2.9. Cell culture 
2.9.1. In vitro stimulation of PBMCs using phorbol mvristate acetate (PMA) 
PBMCs were pipetted into a twenty four well plate at a final concentration of 
I x 106 cells/mllwell. PMA was added to corresponding wells at a final concentration 
of 20ng/ml, together with 3ug/ml monensin and I uM/ml ionomycin as described by 
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Jung et a/ ( 1993). Negative cell culture wells contained 3ug/ml monensin alone. The 
cultures were then incubated for six hours at 37°C in 5% C02 (Prussin and Metcalfe, 
1995). Following incubation, the cells were harvested and stained for flow cytometric 
analysis. 
2.9.2. In vitro stimulation ofPBMCs using ohytohaemagglutinnin (PHA) 
PBMCs were plated at a concentration of I x 106 cells/mUwell into a plastic 
twenty four well plate. PHA was added to the respective wells at a final 
concentration of 1 ug/ml. Negative wells contained mononuclear cells alone. The 
cells were then incubated for forty eight hours at 37°C in 5% C02 (previously 
optimised). The cultures were then harvested into sterile collection tubes and 
centrifuged at 1200rpm for ten minutes. The supernatants were dispensed into sterile 
cryovials and stored at -20°C for ELISA analysis. 
2.9.3. In vitro stimulation using OKT3 (anti-CD3 monoclonal antibody) 
Culture plate wells were coated with OKT3 (final concentration: 5ug/well) 
and incubated for two hours at room temperature. The wells were then washed three 
times with PBS and air dried. PBMCs were then added to the respective wells and 
incubated for forty eight hours at 37°C in 5% C02 (Kaminski et a/, 1995). Negative 
wells contained mononuclear cells alone. The cultures were then harvested and 
centrifuged at 1200rpm for ten minutes. The cell free supernatants were pipetted into 
sterile cryovials and stored at -20°C for ELISA analysis. 
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2.9.4. Mixed lymphocyte culture 
PBMC isolation was performed as previously described (Section 2. 7 .I). Cell 
concentrations were adjusted to I x 106 cells/m!. Donor stimulator cells were then 
irradiated at 30 Gy and plated out in twenty four well culture plates with the 
untreated responder lymphocytes. The plates were incubated for the calculated 
optimal time for each cytokine at 37°C in 5%C02. Following incubation, cell free 
supematants were harvested and stored at -20°C until required for cytokine analysis. 
2.10. Cellular analysis of samples 
2.1 0.1. Quantification of CD3/CD25 {IL-2 receptor) expression by two colour flow 
cytometrv 
The MLC cultures were harvested and washed twice {l200rpm, ten minutes) 
in l-2mls of PBS/0.2% BSA. 20ul of recombinant human IgG (final concentration: 
Sug/106 cells) was added to each tube and incubated at room temperature for ten 
minutes. The cells were then washed in PBS/BSA (1200rpm, ten minutes). 
Conjugated monoclonal antibodies were then added to relevant tubes {Table 2.4) and 
incubated for fifteen minutes at room temperature in the dark. The cells were then 
washed twice in PBS/BSA and resuspended in lml PBS for analysis using Coulter 
Epics Elite flow cytometer. 
NB: Cells may be resuspended in 0.5% fixation buffer and analysed within twenty 
four hours. 
2.1 0.2. Quantification of intracytoplasmic cytokine expression by two/three colour 
flow cytometry 
PMA stimulated (and unstimulated) cells were harvested and washed twice in 
staining buffer {l200rpm, ten minutes). The cells were then aspirated and 
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resuspended in I OOul of 4% fixation buffer as described by Sander et a! ( 1991 ), and 
incubated for fifteen minutes at room temperature. Cells were then stained with 
relevant cell surface antigen monoclonal antibodies (Table 2.4) and incubated for 
fifteen minutes at room temperature (in the dark). The stained lymphocytes were then 
washed twice in permeabilisation buffer. The cell pellet was resuspended in I OOul of 
permeabilisation buffer and incubated for one hour at room temperature (the saponin 
allows the cell membranes to become permeabilised while the AB serum acts as a 
blocking agent). Relevant conjugated anti-cytokine monoclonal antibodies (Table 
2.4) were added and incubated for fifteen minutes at room temperature (in the dark). 
The samples were then washed twice in staining buffer and resuspended in I m! PBS 
for flow cytometric analysis. 
2.10.3. Quantification of cvtokine protein by ELISA 
2.1 0.3.1. Eurogenetics® method {IL-4,1L-6, IL-10 and IFN-y) 
Concentrations may be found in Table 2.3: 
1. Coating antibody was diluted and IOOul added to each microtitre plate well. 
The plate was incubated overnight at room temperature. 
/ 
2. The plate was washed five times in PBS alone. 
3. Blocking buffer was diluted and 200ul added to each well. The plate was 
incubated for one hour at room temperature. 
4. The plate was washed five times in PBS/TWEEN 20. 
5. Leaving the substrate blank wells empty, I OOul of prepared standard and 
sample dilutions were added to the appropriate wells and incubated as in step 
3. 
6. Step 4 repeated. 
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Intracytoplasmic (I C) Responder Cells Alone MLC Culture I PMA 
and MLC (Two Colour) (MLC)/Unstimulated (IC) Stimulated (IC) 
Leucogate Leucogate 
*FITC + PE antibody *FITC/PE antibody 
controls control 
FITC + PE antibodies **FITC antibody + PE 
control 
**PE antibody + FITC 
control 
FITC + PE antibodies 
Three Colour Unstimulated PMA Stimulated 
Leucogate Leucogate 
*FITC + PE + PECyS *FITC + PE + PECyS 
controls controls 
FITC + PE + PECyS **FITC antibody + PE 
antibodies and PECyS controls 
**PE antibody + FITC 
and PECy5 controls 
**PECyS antibody + 
FITC and PE controls 
FITC + PE + PECyS 
antibodies 
-
Table 2.4. Staining protocols for two and three colour flow cytometry experiments 
(*negative control;** compensation analysis). 
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7. Leaving the substrate blank wells empty, lOOul of diluted biotinylated 
antibody was added to all wells and incubated as in step 3. 
8. Step 4 repeated. 
9. lOOul of substrate solution was added to all wells and incubated in the dark 
for thirty minutes at room temperature. 
10. IOOul of stop solution was added to all wells. The plate was read at 450nm 
using a Dias Microplate Reader. 
2.1 0.3 .2. R and D Systems® method CIL-2) 
1. IOOul of assay diluent RDlA was added to each well. 
2. lOOul of standard and sample was added to appropriate wells and incubated 
for two hours at room temperature. 
3. The plate was washed three times in prepared wash buffer. 
4. 200ul of conjugate was added to each well and incubated for two hours at 
room temperature. 
5. Step 3 repeated. 
6. 200ul of substrate solution was added to each well and incubated for twenty 
minutes at room temperature. 
7. SOul of stop solution was added to each well. The plate was read at 450nm 
(wavelength correction 570nm). 
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2.11. DNA analysis 
These methods were performed by Mr Mohammed Jahromi for the IFN-y 
gene polymorphism study: 
2.11.1. Preparation of DNA 
DNA was extracted using the Nucleon kit. 4mls of Nucleon A ( lOmM Tris-
HCI, 320mM sucrose, 1% Triton X-1 00, 5mM MgCh, pH 8.0 using concentrated 
NaOH) was added to 1ml of blood (taken into 5% EDTA). The sample was shaken 
for four minutes at room temperature and then centrifuged ( 1300rpm, five minutes). 
The supernatant was discarded and 2mls of Nucleon B (400mM Tris-HCI, pH 8.0 
using concentrated NaOH, 60mM EDT A, 150mM NaCI, 1% SDS) was added to the 
tube to disrupt nuclear membranes. The pellet was then resuspended and incubated at 
37°C for ten to fifteen minutes. The suspension was then pipetted into a 15ml 
polypropylene tube, and 500ul of sodium perchlorate (5M) was added and the tube 
was inverted ten to fifteen times. 2ml of ice cold chloroform was then added and the 
tube again inverted ten to fifteen times. After centrifugation ( 1300rpm, three 
minutes), 200ul of Nucleon silica was added to the mixture and centrifuged at 
1300rpm for three minutes at room temperature. The upper aqueous phase containing 
the DNA was then transferred to a clean plastic tube. The aqueous phase was again 
centrifuged to remove any remaining silica and the supernatant decanted into a fresh 
tube. Two volumes of ice cold 100% ethanol was then added in order to precipitate 
the DNA. The DNA was then extracted using a hooker pasteur pipette into an 
eppendorf tube containing 70% ethanol. The DNA was then air dried and finally 
resuspended into an eppendorftube containing 500ul sterile water. Absorbency of the 
DNA was measured between 260nm and 280nm, using a Cecil 5500 
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Spectrophotometer (Cecil UK) and the concentration calculated (formula: ug/ul = 
OD260 x 50 x dilution factor/1000). DNA samples were then stored at -70°C. 
2.11.2. Analysis of IFN-y microsatellite polymorphism 
2.11.2.1. Polymerase chain reaction (PCR) 
A I 00-300ng aliquot of extracted DNA was used in the amplification 
reaction. A pair of amplimers flanking a 123 base pair region of the IFN-y gene 
containing a (CA)12 dinucleotide repeat were used for the amplification of the 
microsatellite. The forward amplimer was labelled with e2P] dA TP by T4 
polynucleotide kinase. 2pmol of the unlabelled amplimer together with genomic 
DNA was mixed with lpmol of labelled amplimer, O.Snmol/1 dNTPs, 2mmol/l 
Magnesium (Mg+) and 0.2 units of thermostable DNA polymerase in I x super 
buffer. The reaction was made up to a final volume of 20ul with double distilled 
water and PCR was performed using a Techne Thermal Cycler (Fischer, UK). 
Forward 
5' TCA CAA TTG ATT TTA TTC TTA C 3' 
Reverse 
5' TGC CTT CCT GTA GGG TAT TAT T 3' 
The PCR reaction conditions were as follows: 
95°C denaturation step (60 seconds), 48°C annealing step (30 seconds) and a 72°C 
elongation step (40 seconds), followed by a 72°C extension step (5 minutes). 
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2.11.2.2. Gel electrophoresis and autoradiography 
An aliquot of the PCR products was electrophoresed through a 6% 
formamide/urea gel in 0.5% Tris/borate electrophoresis (TBE) buffer (!Ox solution: 
0.89mM Tris base, 0.89M Boric acid, 2mM EDT A (pH8.0)) for three hours at 90 
watts. The gel was then subsequently dried, and autoradiography was performed 
using Kodak X-Omat film with intensifying screens at -85°C for twenty four hours. 
2.12. Analysis of data 
Protein secretion and expression over time in normal volunteers was analysed 
using Analysis of variance. Univariate analysis of cytokine comparison data was 
performed using Pearsons correlation and Spearmans rank analysis (for non-normal 
data). IFN-G polymorphism was performed using Logistic regression analysis. For 
the analysis of the rejection data, cytokine levels were divided into groups using the 
median value as a cut-off. Patients were divided into two groups, those who did not 
undergo rejection, and those with at least one acute rejection episode. A preliminary 
analysis using Chi squared (:x.2) tests was undertaken to find associations between 
rejection and the following parameters: cytokine levels, patient and donor sex and 
age, HLA sensitisation, patient and donor CMV status, and HLA and HLA-DR 
mismatching.Variables significant at the p=<0.2 level were entered into "backward 
stepping" multivariate Logistic regression analysis. All quoted p values are two-
sided. In addition, relationships between cytokine protein secretion and HLAIHLA-
DR mismatching were analysed using the Kruskal-Wallis test. Significant differences 
in median cytokine protein secretion between rejectors and non-rejectors were also 
calculated using the Mann-Whitney U test. 
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CHAPTER3 
OPTIMISATION AND ANALYSIS OF CYTOKINE PROTEIN, 
FREQUENCY AND GENE POL YMORPIDSMS IN NORMAL 
INDIVIDUALS 
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3.1. Optimisation of cultures 
3.1.1. Introduction 
It has been known for some time that the MLC can be used as a tool for 
studying cytokine production (Ilonen and Kartunen, 1984, Danzer et al 1994a, 
1994b, Takahara et al. 1993). Such studies have demonstrated that several cytokines 
may be produced in an MLC response (Bishara et a/, 1991, Toungouz et a/, 1993, 
1994, 1996). The standard procedure for an MLC is to set up a one way culture, 
where the donor cells are nulled by treatment and cultured together with untreated 
responder cells. Although previous studies have illustrated that cytokine secretion 
occurs within the MLC, it was considered important to optimise the reaction 
response in terms of incubation times and methods of inactivating the stimulator 
cells. This included examining peak levels of cytokine protein secretion, sensitivity 
of the MLC and optimal treatments for the production of a one way response. The 
project also included measurement of cytokines in PMA and PHA stimulated 
cultures. It was therefore also imperative that cytokine secretion profiles were 
optimised for mitogen stimulation. 
3 .1.2. Kinetics of cytokine protein secretion 
The MLC cultures were set up using irradiated stimulator lymphocytes and 
untreated responder cells (Materials and Methods, Section 2.9.4), The cultures were 
incubated from day zero up to day eight. Cell free supernatants were harvested every 
twenty four hours and analysed for cytokine protein (IL-2, IL-4, IL-l 0 and IFN-y) by 
sandwich ELISA. IL-6 was also optimised in the latter part of the project. It was 
found that there was a variation in optimal secretion times between the cytokines. 
Although protein levels varied between individuals on repeating the experiments 
(n=3), the optimal secretion times remained constant for each cytokine. Baseline 
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levels (ie: responder cells alone) remained below detectable limits. For all five 
cytokines, there appeared to be an increase in protein production up to day three. 
After day three, IL-2 (Figure 3.la) and IL-10 (Figure 3.lb) protein levels decreased. 
However, for both IL-4 (Figure 3.2a) and IFN-y (Figure 3.2b), peak secretion 
occurred on day four of the culture. IL-6 was found to be optimally secreted on day 
five of culture (Figure 3.3). For IL-2, IL-4, IL-10 and IFN-y, the optimal cytokine 
times obtained from these experiments were then used in further studies. However, 
for IL-6, as the patient MLC cultures had already been harvested on days three and 
four for ELISA analysis, IL-6 levels had to be measured on day four. 
3.1.3. Comparison of cell free and cell based ELISAs 
These experiments were carried out in order to determine whether there were 
any significant differences between the measurement of cytokine secretion in culture 
supematant by standard ELISA and direct cytokine secretion from cells by capture 
ELISA (capture ELISA involved the addition of MLC cells direct onto the ELISA 
plate). Taking the optimal cytokine secretion data into account, MLCs were only 
incubated for up to six days in these experiments. As before, these experiments were 
repeated for reproducibility (n=3). The cytokines appeared to peak at the same times 
as before, but it can be seen for IL-4, as an example (Figure 3.4), that there was no 
significant difference between the cell free and cell based method. This was also the 
case for IL-2, IL-10 and IFN-y (data not shown). Future ELISA experiments were 
therefore carried out using cell free supematants. As IL-6 was optimised at a later 
date, this experiment was not performed for this cytokine. 
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Figure 3.1. Cytokine secretion profile for IL-2 (a) and IL-10 (b) in one way MLC 
(data shown from single experiment). 
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Figure 3.2. Cytokine secretion profile for IL-4 (a) and IFN-gamma (b) in one way 
MLC (data shown from single experiment). 
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Figures 3.3 and 3.4. Cytokine secretion profile for IL-6 in one way MLC (upper 
figure) and IL-4 protein secretion in cell free and cell based ELlS As (broken line-cell 
free; solid line-cell based) (lower figure). Data shown from single experiment. 
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3 .1.4. Treatment of stimulator cells 
It was important to establish the most suitable method of treatment for the 
stimulator cells in the MLC. Two treatments were compared, gamma irradiation 
(caesium source) and chemical treatment by mitomycin C. Not only did the most 
suitable method have to chosen, but also the optimal dose or concentration in order to 
ensure that the stimulator cells were unresponsive. 
Both populations of cells (stimulator (S) and responder (R) cells) were 
initially treated with various concentrations of mitomycin C (5-50ug/ml). The 
positive control included untreated cells (R+S). Cell free supernatants were harvested 
at optimal time points as previously established for each cytokine and analysed by 
ELISA. Again, these experiments were not performed for IL-6. With the other four 
cytokines, no pattern of decrease in cytokine protein response with increasing 
concentration was found (Figure 3.5 illustrates pattern for IL-l 0). Therefore, as a 
dose could not be determined by this method, irradiation treatment was considered. 
Both populations of cells (ie: stimulator and responder cells) were treated 
with gamma irradiation at several doses (5-50 Gy). Controls again included untreated 
cells (R+S). Cell free supernatants were again harvested at optimal time points. It 
was established that between 20-30 Gy was the suitable dose range for all four 
cytokines (Figure 3.6 illustrates dose response for IFN-y). Therefore, mitomycin C 
treatment was considered unreliable at any of the concentrations used, and that 
irradiation was the method of choice. 
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Figures 3.5 and 3.6. Effect of mitomycin C treatment on IL-10 secretion (upper 
figure) and effect of irradiation treatment on IFN-gamrna secretion (lower figure). 
Data shown from single experiment. 
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3.1.5. Cytokine and CD3/CD25 {IL-2 receptor) expression in MLC 
Once the conditions had been optimised for the MLC, the next step was to 
quantify peak cytokine (IL-2, IL-4, IL-IO and IFN-y) expression in T cells (not 
performed for IL-6}. The peak IL-2 receptor (CD25) expression was also measured in 
order to study levels of activation in T cells. Flow cytometric analysis was performed 
at two, four, six, ten and twenty four hours for the first day, and then every twenty 
four hours up to five days. At every time point, it was found that, due to the nature of 
the culture, it was impossible to gate a clear lymphocyte region, and therefore neither 
the cytokine or CD25 expression could be analysed (data not shown). It was 
therefore decided that only cytokine protein would be measured by ELISA. 
3.1.6. PHA and OKT3 stimulated cultures 
PHA and OKT3 cultures were included in the study of cytokine protein 
secretion by normal volunteers for ELISA analysis (all cytokine protein data may be 
found in appendix l}. Optimisation experiments concluded that peak secretion for all 
four cytokines (IL-2, IL-4, IL-IO and IFN-y) was around forty eight hours. This time 
point was therefore used in all PHA and OKT3-stimulated cultures. 
3 .I. 7. PMA stimulated cultures 
PMA cultures were also included in the study of cytokine expression by 
normal volunteers for flow cytometric analysis (all cytokine expression data may be 
found in appendix l). The optimal time point used in these experiments was six 
hours for IL-2 and IFN-y, as previously described by Prussin and Metcalfe ( 1995). 
Experiments were also carried out to determine peak cytokine expression. for IL-4 
and IL-IO. PMA stimulated cultures were set up and cells were harvested at various 
time points within a twenty four hour period (four, six, ten and twenty four hours). 
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Both cytokines were found to be below detectable limits at all four time points (data 
not shown). Therefore, only IL-2 and IFN-y were investigated in further experiments. 
3.2. Cytokine expression in normal volunteers 
3.2.1. Introduction 
It has been shown that many different cytokines may be secreted during an 
immune response. However, little is known about the variance of cytokine secretion 
and frequencies of cytokine expression between individuals and what factors may 
have an influence on these levels. As previously mentioned, inter-individual 
variations in both cytokine secretion and numbers of cytokine secreting cells have 
been demonstrated suggesting that there may be differences between random 
individuals and that there may be factors that affect these differences (Kaminski et a/, 
1995; Ferry et a/, 1997). 
In this part of the study, flow cytometry and ELISA were used as the methods 
of choice to establish the level of variation in both numbers of cytokine secreting 
cells and levels of secreted cytokine protein in mitogen stimulated cultures 
respectively in normal volunteers. 
3.2.2. Cytokine expression in CD3+ T cells 
The aim of this part of the study was to analyse the frequencies of cytokine 
expression using two colour flow cytometric analysis in normal volunteers. 
Lymphocytes were stimulated with PMA and ionomycin and incubated for six hours 
as previously optimised (Prussin and Metcalfe, 1995). Cultures were the harvested 
and stained for T cell expression of both IL-2 and IFN-y. As previously mentioned, 
-
kinetic-studies were performed for both IL-4 and IL-10; but expression appeared to 
be below detectable limits on the flow cytometer. 
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A group of twenty nonnal healthy volunteers were randomly chosen. Figure 
3.7 illustrates the frequency distribution of both IFN-y and IL-2 in CD3+ T cells. It 
can be seen that there is a wide distribution of expression with both cytokines, 
illustrating a clear inter-individual variation between the individuals within the group 
(IFN-y range: 0.8-48.7%; IL-2 range: 0.8-37.3%). Twelve (60%) of the individuals 
expressed less than 10% CD3/IFN-y, forming a cluster of "low expressors". Only 
three individuals (15%) expressed less than 10% CD3/IL-2. Only the distribution 
pattern yielded by IL-2 confonned to a nonnal distribution. 
As previously mentioned, there were clear high and low cytokine expressors 
within the group studied. Figures 3.8 and 3.9 illustrate flow cytometric data of both a 
low and high expressor for IL-2 and IFN-y respectively. A distinct difference in 
cytokine expression may be observed between the individuals. An increase in both 
IL-2 and IFN-y expression with PMA stimulation was clearly identified in each 
individual when compared to unstimulated cells. 
3.2.3. Cvtokine expression in T cell subsets and natural killer (NK) cells 
Two colour flow cytometry was also used to measure IL-2 and IFN-y 
expression in CD4+ and CD8+ T cell subsets. Four individuals were randomly 
chosen to detennine the predominance of expression. PBMCs were stimulated with 
PMA and ionomycin as before (Section 2.9.1). Figures 3.10 and 3.11 illustrates the 
percentage of expression in one of the individuals for IL-2 and IFN-y in CD4+ and 
CD8+ T cells respectively, analysed by flow cytometry. In this individual, it can be 
seen that IL-2 is predominantly expressed by CD4+ T cells, as was the case for the 
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Inter-individual variations were observed for both cytokines 
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Figure 3.8. IL-2 expression in normal volunteers. Figure 3 .8a represents low 
cytokine expression in unstimulated and stimulated cells. Figure 3.8b illustrates the 
relative high expression of IL-2 in unstimulated and stimulated cells. FITC= 
fluorescein isothiocyanate, PE=phycoerythrin. Quadrant 1 =IL-2+; quadrant 2= 
double positive (CD3+/IL-2+ ); quadrant 3=negative (CD3-/IL-2-); quadrant 
4=CD3+. 
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Figure 3.9. IFN-gamma ·expression in normal volunteers. Figure 3.9a illustrates low 
cytokine expression in unstimulated and stimulated cells. Figure 3.9b represents 
relative high expression of IFNy in unstimulated and stimulated cells. Quadrant 
l =IFN+; quandrant 2=CD3+/IFN+; quandrant 3=CD3-/IFN-; quandrant 4=CD3+. 
170 
other individuals analysed (Figure 3.10). IFN-y, however appeared to yield a 
different profile, with this cytokine being predominantly expressed by CD8+ T cells 
(Figure 3.11 ). 
It was also of interest to analyse whether natural killer (NK) cells contributed 
to cytokine expression in nonnal individuals. A negligible contribution was observed 
to both IL-2 and IFN-y expression by NK cells (0.1-0.2%, data not shown). 
3.2.4. Co-exoression of cytokines in T cell subsets 
eo-expression of IL-2 and IFN-y in both CD4+ and CD8+ T cells in the same 
individuals was then studied. Attempts were originally made using three colour flow 
cytometry on PMA stimulated PBMCs. Results, however showed that CD4 
expression was down-regulated by PMA and therefore another method had to be 
found in order to carry out these experiments (data not shown). It was therefore 
decided that both CD4+ and CD8+ T cell subsets would be isolated by precoated 
magnetic bead selection. Purity was detennined by flow cytometry and each T cell 
subset then stimulated with PMA. Two colour flow cytometry was then used to 
detennine IL-2/IFN-y expression in each subset. 
Figure 3.12 illustrates the expression ofiL-2 and IFN-y in (a) CD4+ and (b) 
CD8+ T cells. It can be seen that eo-expression is relatively low (<2%) in each 
subset, compared to single cytokine expression (Figures 3 .I 0 and 3 .I I). There was 
also no statistical significance between the level of eo-expression in CD4+ and CD8+ 
T cells (p = 0 3). 
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Figure 3.10. IL-2 expression in CD4+ (a) and COS+ (b) T cells. IL-2 expression was 
shown to be predominantly expressed in CD4+ T cells. 
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Figure 3.11. IFN-gamma expression in CD4+ (a) and CD8+ (b) T cells. Lower levels 
of expression were observed with IFN-y compared with IL-2. Predominant 
expression was seen in CD8+ T cells. 
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Figure 3.12. eo-expression of IL-2 and IFN-gamma in CD4+ (a) and CD8+ (b) 
isolated T cells. Low levels of eo-expression in both CD4+ and CD8+ T cells were 
observed. 
174 
3.2.5. Variation of cytokine expression over time 
In order to establish whether cytokine expression varies with time in the same 
individuals, five volunteers were assayed on six separate occasions over a twelve 
month period. This group included individuals with both high and low numbers of 
cytokine expressing cells. 
Analysis of variance did not demonstrate a diurnal effect (p=0.893). Of the 
five individuals, two were found to be consistent over time for both IFN-y (CV: 0.05 
and 0.01) and IL-2 (CV: 0.15 and 0.25), whilst there was a modest degree of 
variation in the remaining three individuals for IFN-y (CV: -1, -0.25, -0.5) and IL-2 
( 1.5, 2.0 and 4.1 ). 
3.3. Cytokine secretion in normal volunteers 
3.3.1. Cytokine secretion by CD3+ T cells using PHA stimulation 
PHA stimulated cultures were set up using the same group of twenty normal 
healthy volunteers and supernatants harvested for analysis of cytokine (IL-2, IL-4, 
IL-l 0 and IFN-y) protein by ELlS A. Time points for peak cytokine secretion had 
been previously optimised. Low, medium and high secretion was based on calculated 
ranges for each individual cytokine. 
Inter-individual variation of secretion was observed for IFN-y (Std Dev: 
3426.28). As seen in Figure 3.13a, a large cluster of individuals (n=l2) were classed 
as "low secretors" (<2000pg/ml). Two individuals appeared to be "intermediate 
secretors" (2-8000pg/ml), while six remaining subjects were classed as "high 
secretors" (these individuals secreted at least 8000pg/ml, exact data not shown). In 
contrast, IL-4 yielded a different pattern (Std Dev: 16.0 17). The majority (n= 17) of 
the individuals secreted low-medium amounts of IL-4 (<30pg/ml), again yielding a 
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large cluster at the lower end of the scale. Only three individuals secreted high levels 
of this cytokine (>30pg/ml; Figure 3.13b). 
In the case of IL-2, (Std Dev: 430.691 ), a cluster of "low-medium secretors" 
was again evident (n= 18; <I OOOpg/ml). Only two individuals within the group 
secreted high levels (> 1 OOOpg/ml; Figure 3.14a), and may be classed as outliers. 
Finally, for IL-l 0, there appeared to be a more widespread distribution of secretion 
(Std Dev: 205.37). Just under half (n=8) of the group secreted higher (>200pg/ml) 
amounts ofiL-10 cytokine (Figure 3.14b). 
3.3.2. Variation of cytokine secretion over time 
In order to establish whether cytokine secretion varies with time in the same 
individual, four volunteers were assayed every two months over a twelve month 
period, as with cytokine expression. This experiment was only performed with PHA 
stimulated data as OKT3 experiments were performed at a much later stage of the 
project. These particular individuals were chosen as they represented a group of high 
and low secretors for IL~2, IL-4, IL-10 and IFN-y. Analysis of variance was again 
performed. 
Analysis of cytokine secretion demonstrated no diurnal effect as with 
cytokine expression (p=0.545). For low secretion of the cytokines, three of the 
cytokines (IFN-y, IL-4 and IL-l 0) were relatively consistent over time (CV: 0.2, 0.15 
and 0.3 respectively). IL-2 appeared to exhibit a modest degree of variation (CV: 
0. 7). For high secretion, two of the cytokines were consistent over time (CV for IFN-
y: 0.25; IL-10: 0.1.6), with IL-2 and IL-4 varying slightly (CV: 0.62 and 0.55 
respectively). 
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Figure 3.J3. Variation in IFN-gamma (a) and IL-4 (b) secretion with PHA 
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Figure 3.14. Variation in IL-2 (a) and IL-10 (b) secretion with PHA stimulation. 
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3.3.3 Cytokine secretion by CD3+ T cells using OKT3 stimulation 
OKT3 was coated onto culture plates for two hours (room temperature) 
followed by incubation with PBMCs isolated from sixteen of the group subjects (four 
of the subjects were unavailable for analysis). Cell free supernatants were then 
harvested and assayed by ELISA. Optimal time points for each cytokine had been 
previously determined (Kaminski et a!, 1995). 
Inter-individual variations were also seen for IFN-y with OKT3 stimulation 
(Figure 3.15a). Although, nearly all of the individuals could be classed as "low-
medium secretors" (n=l5), secretion levels for ten of those individuals secreted more 
than 2000pg/ml. Only one individual secreted a very high amount of IFN-y 
(16330pg/ml), and may be classed as an outlier. OKT3 stimulation also yielded inter-
individual variation for IL-4 secretion (Figure 3.15b). However, although there 
appeared to be a more widespread distribution with this mitogen, levels of cytokine 
secretion were generally lower than those reached with PHA stimulation. With 
OKT3, all (n=l6) of the group yielded between 12pg/ml and 22pg/ml ofiL-4. There 
were no clear outliers with this cytokine. 
The pattern yielded by OKT3 again differed for IL-2 secretion (Figure 3.16a). 
Levels achieved were extremely low with this mitogen, with the highest amount only 
being l 03pg/ml. The majority of the group (n= 15) again formed a cluster of low-
medium secretors (4-23pg/ml), with only the one individual secreting the highest 
amount (103pg/ml; outlier). However, a very large inter-individual variation was 
observed with IL-10 secretion (Figure 3.16b). As with PHA, a wide distribution 
could be seen, and therefore high or low secretion could not be determined. Only one 
individual secreted less than 200pg/ml, with ten individuals secreting between 2-
800pg/ml. The remaining four subjects managed to secrete more than 800pg/ml. 
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3.4. Relationship between Thl and Th2 cytokines 
3.4.1. Introduction 
In view of the inter-individual variations which were found in both the 
numbers of cytokine secreting cells and protein secretion, it was important to 
determine whether there was a relationship between frequency and protein. It has 
also been suggested that within the Th lffh2 paradigm, inter-regulation may occur, 
and therefore a possible inverse correlation could be expected. Therefore the 
relationship between the Th I {IL-2 and IFN-y) and Th2 cytokines (IL-4 and IL-10) 
protein levels was examined. 
3.4.2. Cvtokine expression and PHA-stimulated protein 
In order to determine whether a correlation existed between IL-2 protein and 
frequency of IL-2 secreting cells, the data was analysed by Pearsons correlation 
analysis. A significant relationship was found between the amount of IL-2 protein 
secreted and numbers of IL-2 expressing cells (p=0.02; r=0.5). A sigmoidal 
relationship was also present between the two variables (figure not shown), log y 
transformation was performed (Figure 3.17). This generated a highly significant and 
linear relationship between the two parameters (p=0.0007; r=0.7). There also 
appeared to be two outliers (marked *), and therefore analysis was again performed 
without these subjects to see if they made a difference to the significance of the 
relationship. Analysis revealed there to be no strong influence by the two subjects, 
therefore these data points were not omitted (data not shown). Statistical analysis 
used for IL-2 could not be used for IFN-y as the data did not conform to a normal 
distribution. The data for IFN-y was therefore analysed using Spearmans rank 
analysis. The data was also plotted out of interest to see if there was any kind of 
relationship between IFN-y protein and frequency. For any of the data analysed by 
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Spearmans rank analysis, the plots were not representative of the statistical analysis 
as the data is ranked. Figure 3.18 illustrates this plot. Interestingly, although there 
appears to be no relationship between these two variables (p=0.762; r-0.07), it can 
be seen from the plot that there is a bi-modal distribution formed by this data. The 
majority of the individuals (n= 12) were both low secretors and expressors, with the 
second group (n=6) secreting high levels of protein but expressing low numbers of 
cytokine-positive cells. 
3.4.3. Cytokine expression and OKT3-stimulated protein 
This data was also analysed by Spearmans rank analysis due a to a non-
normal distribution. The data was again plotted. Figures 3.19 and 3.20 illustrate the 
relationships between protein and frequency for IL-2 and IFN-y respectively. It can 
be seen in Figure 3.19 that the majority of the individuals are low secretors (hence 
the non-normal distribution). Analysis revealed there to be no relationship between 
IL-2 protein and frequency (p=0.29; r=-0.54). Only one individual secreted a higher 
amount of IL-2 (>I OOpg/ml). IFN-y appeared to give a similar pattern, with thirteen 
of the individuals forming a cluster of both low secretors and expressors (Figure 
3.20). The overall pattern was similar to that of the relationship between IFN-y 
expression and PHA stimulated protein. there was also no relationship found between 
IFN-y protein and frequency (p=O. 7; r=O.I ). 
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3.4.4. Thl versus Th2 protein (PHA) 
3.4.4.1. IFN-y versus IL-4 
All analysis of this data was performed usmg Spearmans rank analysis. 
Figure 3.21 illustrates the observed relationship between IFN-y and IL-4 protein. 
Analysis revealed there to be no relationship (p=0.563; r=O.l3). From the plot, a 
large cluster of individuals (n= 11) appeared to be low secretors for both cytokines. A 
second cluster is also evident, whereby a group of individuals secreted high levels of 
IFN-y and low levels of IL-4 (n=6). The remaining three subjects secreted lower 
levels ofiFN-y with increasing levels ofiL-4. 
3.4.4.2. IL-2 versus IL-4 
The second Thl cytokine IL-2 was then analysed against IL-4 to see whether 
there was a relationship between these two cytokines. No relationship was found 
(p=0.275; r-0.25). Plotting the data revealed there to be a random relationship 
between these two proteins (Figure 3.22). 
3.4.4.3.IFN"y versus IL-10 
The second Th2 cytokine, IL-10, was then plotted against IFN-y. Analysis 
revealed there to be a strong relationship between the two cytokines (p=O.OOl; 
r-0.9155). This was reflected in the diagrammatic plot (Figure 3.23), which would 
suggest that there was a positive correlation between the two cytokines. 
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3.4.4.4. IL-2 versus IL-10 
Finally, IL-2 was plotted against IL-10, but this time, Pearsons correlation 
analysis could be performed as they both conformed to a normal distribution. Figure 
3.24 illustrates the relationship between these two cytokines. A sigmoidal 
relationship was initially observed, therefore log y transformation was performed. 
This yielded a linear but non-significant relationship between this Thl and Th2 
protein (p=0.07; r=0.408). 
3.4.5. Thl versus Th2 protein (OKT3) 
3.4.5.1. IFN-y versus IL-4 
The relationship between Th I and Th2 proteins with OKT3 stimulation also 
required analysis. As only one set of data {IL-l 0) conformed to a normal distribution, 
Spearmans rank analysis was performed. However, it was also still of interest to 
observe the visual relationship between the proteins. The relationship between IFN-y 
and IL-4 may be seen in Figure 3.25. It is obvious from this plot that there is no real 
relationship between these two cytokines, which was reflected by the analysis 
(p=0.34, r=O.l2). Interestingly there appears to be a cluster of low-medium IL-4 
secretors, which are also low secretors for IFN-y (n=l4). 
3.4.5.2. IL-2 versus IL-4 
The relationship between IL-2 and IL-4 was then plotted and analysed. This 
plot may be seen in Figure 3.26. Again, there appeared to be no obvious relationship 
between these two proteins. Analysis revealed there to be no relationship (p=0.096; 
r=0.42). However, the observed relationship did appear similar to that of IFN-y and 
IL-4, with the majority of the individuals (n=l4) forming a cluster in the lower half 
of the plot. 
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3.4.5.3. IFN-y versus IL-10 
The second Th2 cytokine, IL-10, was then plotted against IFN-y. This can be 
seen in Figure 3.27. The observed relationship between these cytokine proteins is 
again random, with the analysis showing no relationship at all (p=0.31; r=-0.27). For 
the majority of the individuals (n= 15), there was a normal distribution of IL-l 0 
secretion, with IFN-y secretion levels remaining low-medium. Only one individual 
secreted high levels ofiFN-y protein. 
3.4.5.4. IL-2 versus IL-10 
Finally, IL-2 protein data was plotted against IL-10 (Figure 3.28). As the 
group consisted of mainly low IL-2 secretors (n= 15), there was no obvious 
relationship between these two cytokines. Analysis also illustrated no relationship 
(p=0.57; r=-0.16). Only one individual was seen to secrete medium-high levels ofiL-
2 protein. 
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3.5. Relationship between IFN-y gene polymorphisms (IFN-G), IFN-y protein 
secretion and expression 
3.5.1. Introduction 
DNA studies have demonstrated that polymorphisms of particular cytokine 
genes (TNF-a and IL-10) are associated with high/low secretor status (Turner et al, 
1995, 1997). Due to the interesting bi-modal nature of the IFN-y protein data, 
analysis was also performed to determine the role of IFN-G gene polymorph isms on 
IFN"y expression and protein secretion. 
3.5.2. IFN-G gene polymorohisms. protein secretion (PHA) and frequency 
Analysis was performed using logistic regression analysis to determine the 
role of IFN-G gene polymorphisms on expression and secretion of this cytokine. 
Although relationships have been found for other cytokines, in this case, there was 
no statistically significant relationship between these three parameters (p value 
range: 0.252-0.588). A summary of the data is shown in Table 3.1. 
3.5.3. IFN-G gene polymorohisms, protein secretion (0KT3) and frequency 
Analysis was again performed using logistic regression analysis to determine 
whether stimulation with OKT3 made any difference to the relationship between 
IFN-y protein, frequency and/or gene polymorphisms. The analysis was performed 
on sixteen individuals that were available. Again, there was no significant 
relationship between any of these parameters, as was seen with PHA-stimulated IFN-
'Y protein (p value range: 0.083-0.328). A summary of the data is also shown in Table 
3.1. 
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Patient 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
Protein 
(PHA) 
pglml 
267 
646 
501 
8000 
640 
534 
998 
400 
1040 
2798 
863 
308 
2159 
243 
53 
8000 
8000 
8000 
8000 
8000 
Protein 
(OKT3) 
pglml 
2786 
1046 
2236 
4250 
1188 
ND 
ND 
1470 
4441 
3757 
3718 
6341 
5048 
3355 
226 
16330 
ND 
1290 
ND 
3491 
Expression Allele 1 
(%) 
19 123 
14 123 
10 127 
8 123 
2 129 
11 123 
2 133 
4 121 
3 127 
17 127 
41 123 
49 127 
4 125 
123 
6 123 
5 123 
25 127 
5 123 
3 123 
5 123 
Allele 2 
127 
119 
127 
127 
133 
123 
127 
127 
127 
127 
123 
129 
130 
129 
133 
133 
127 
127 
123 
123 
Table 3.1. Summary of IFN-y protein (OKT3 and PHA-stimulated), expression and 
IFN-G gene polymorphism data. 
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3.6. Summary 
The experiments designed for the optimisation of the MLC were performed 
using blood from normal healthy volunteers. The initial experiments involved the 
incubation of "donor" and "recipient" lymphocytes together for up to eight days and 
the cytokine (IL-2, IL-4, IL-10, IFN-y and IL-6) responses measured to establish 
peak cytokine secretion. The results showed there to be peak IL-l 0 and IL-2 protein 
secretion on day three, with peak IFN-y and IL-4 secretion on day four. Peak 
secretion for IL-6 was found on day five, although for practical reasons, day four was 
used to collect supematants. Further experiments showed there to be no significant 
difference in cytokine secretion between cell free and cell based culture samples. 
Titration experiments for the treatment of the stimulator cell population in the MLC 
found a 20-30 Gy dose to be sufficient to abrogate cytokine secretion and therefore 
have a real one way MLC. Neither cytokine or cell surface marker expression was 
able to be measured by flow cytometry, therefore only measurement of protein 
secretion was used. 
In the case of PHA and OKT3 stimulated PBMCs from normal volunteers, 
inter-individual variations were found in both cytokine expression (IL-2 and IFN-y) 
and protein secretion (IL-2, IL-4, IL- 10 and IFN-y). For PHA stimulation, a 
significant relationship was found between IL-2 protein secretion and frequency. A 
strong yet non-significant relationship was found between IL-2 and IL-l 0 (p=0.07), 
with a significant relationship being found between IL-10 and IFN-y. No relationship 
was found between IFN-y gene polymorphisms, protein secretion and/or frequency. 
For OKT3 stimulated protein, there was no relationships between IL-2 
protein and frequency or IFN-y protein and frequency. As IL-10 protein was the only 
data to conform to a normal distribution, Spearmans rank analysis was performed. 
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No relationships were found between any of the cytokines. In addition, no 
relationship was found between IFN-y gene polymorphisms, frequency and/or 
protein. 
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CHAPTER4 
PREDICTION OF RENAL ALLOGRAFT REJECTION 
BY CYTOKINE SECRETION IN MIXED L YMPHOCYTE 
REACTION 
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4.1. Introduction 
The mixed lymphocyte reaction (MLR) has played a historical role in organ 
transplantation. In renal transplantation, there is evidence for (Harmon et a!, 1982, 
Langhoff et a!, 1985) and against (Cullen et a!, 1977, Burke et a!, 1993, Steinmann et 
a!, 1994) the MLR predicting rejection and clinical outcome. However, the 
concensus is that it is not of clinical value. Kaminski et a! ( 1995) demonstrated a 
correlation between high levels of IFN-y in mitogen stimulated culture and rejection 
in renal transplantation. In view of these findings, cytokine protein secretion was 
measured in MLR to determine whether such an assay is predictive for acute 
rejection after allogeneic renal transplantation. 
4.2. Study group 
This consisted of fifty six consecutive patients who received a cadaveric renal 
transplant from an unrelated donor, and one patient receiving a renal transplant from 
a live related donor (see materials and methods chapter for detail). 
4.3. HLA and HLA-DR matching 
The group consisted of one "fully HLA matched" patient (000), three patients 
with one mismatch, eleven patients with two mismatches, twenty one patients with 
three mismatches, thirteen patients with four mismatches, seven patients with five 
mismatches, and one "fully mismatched" patient (appendix 2). In addition, within the 
study group, there were fifteen patients with zero antigen HLA-DR mismatch, thirty 
two with one antigen DR mismatches and ten with full HLA-DR mismatching 
(appendix 3). 
198 
4.4. Cytokine secretion in MLR and HLA mismatching 
Univariate analysis was performed using the Kruskal-Wallis test. This 
analysis was chosen as the cytokine protein data was of a non-normal distribution. 
Original analysis was performed with cytokine protein and HLA mismatching (0-6), 
but when plotted there were single individuals who had either 0 or 1 HLA antigen 
mismatch. Analysis showed there to be no significant relationship between increase 
in HLA mismatching and levels of cytokine protein in the MLR (p values for IFN-
y=0.47; IL-10=0.544; IL-6=0.723; IL-4=0.24; IL2=0.4). In order to attempt to even 
the data, the patients were placed into two groups, 0-3 HLA mismatches (group 1) 
and 4-6 HLA mismatches (group 2). This gave rise to a 50:50 split. When analysis 
was performed on the grouped data, there still appeared to be no correlation between 
cytokine protein and HLA mismatching (p values for MLC: IFN-y=0.224; IL-l 0 
MLC=0.24; IL-6 MLC= 0.77; IL-4 MLC= 0.61; IL-2 MLC= 0.64; p values for 
spontaneous: IFN=0.05; IL-l 0=0.88; IL-6=0.655; IL-4=0.3; IL-2=0.54). 
Analysis was then performed to observe if there was any relationship between 
HLA-DR mismatching and cytokine protein. As the data was evenly distributed 
when looking at 0, 1 and 2 HLA-DR mismatches, the data was not grouped as it was 
for full HLA mismatching analysis. Analysis revealed there to be a significant 
correlation between an increase in HLA-DR mismatches and both MLR IL-10 (p= 
0.03) and MLR IFN-y (p= 0.019). This data may be seen in Figures 4.la and 4.lb 
respectively. There was no correlation found between increase in HLA-DR 
mismatching and MLR IL-2 (p value= 0.07), MLR IL-4 (p= 0.07) or MLR IL-6 
(p=0.65). Analysis was performed with spontaneous protein secretion data, and no 
correlations were found with any of the cytokines and HLA-DR mismatching (p 
values for IFN-y=0.4; IL-l 0=0.42; IL-6=0.65; IL-4=0.8; IL-2=0.12). 
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a) 
b) 
Figure 4.1. Relationship between 1-ll..A-DR mismatching and ll.,-10 (a) and IFN-
gamma (b) protein secretion (Box and Whisker plot). 
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4.5. Inter-individual variations in cytokine protein in the MLR 
Pre-transplant one way MLRs were set up between patient and donor and 
cytokine protein secretion (IL-2, IL-4, IL-6, IL-10 and IFN-y) measured by ELISA. 
The data was analysed to d,etermine whether there were differences in cytokine 
protein secretion between individuals and whether these differences predicted 
rejection. The clinical outcome was twenty seven rejectors and twenty six non-
rejectors. Two patients were unevaluable for surgical reasons and two patients died. 
Significant differences were calculated using the Mann-Whitney U test. Figure 4.2 
illustrates inter-individual variations in IL-2 (a) and IL-4 (b) protein secretion 
(protein secretion ranges: IL-2 - 0-1329pg/ml; IL-4 - 2-24pg/ml). It can be seen that 
there was no significant difference in median IL-2 levels between rejectors and non-
rejectors (spontaneous p= 0.4, MLR p=0.09). There was a significant difference 
between rejectors and non-rejectors in median IL-4 secretion in spontaneous 
(p=0.03) and a strong, yet non-significant difference in MLR cultures (p=0.06). 
Figure 4.3a shows the inter-individual variations in rejectors and non-
t:ejectors for IL-l 0 protein secretion (range - 0-298pg/ml). Although there was no 
significant difference between spontaneous secretion in rejectors and non-rejectors 
(p=0.68), there was in the MLR cultures (p=O.O 18), thus illustrating that there is a 
association between increase in risk of rejection and increase in MLR-stimulated IL-
10 secretion (discussed later). Figure 4.3b illustrates IFN-y secretion (range - 0-
9718pg/ml). As for all of the other cytokines, there are inter-individual variations in 
both patient groups, and there is also a significant increase in MLR-stimulated IFN-y 
secretion in rejectors compared to non-rejectors (p=O.O 126). There was no significant 
difference in spontaneous secretion (p=0.468). As for IL-l 0, this would suggest that 
there was also a correlation between increase in risk of rejection and MLR- -
stimulated IFN-y 
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Figure 4.2. Inter-individuill variations in IL-2 (a) and IL-4 (b) protein secretion in 
rejector (R) and non-rejector (NR) groups. Spon=spontaneous; MLR=mixed 
lymphocyte culture. 
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Figure 4.3. Inter-individual variations in IL-10 (a) and IFN-gamma (b) protein 
secretion in rejector (R) and non-rejector (NR) groups. Spon=spo~taneous; 
MLR=rnixed lymphocyte culture. 
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and increase in IFN-y secretion (discussed later). Finally, IL-6 protein secretion was 
analysed (Figure 4.4; protein range -7-13598pg/ml). From the analysis, there was no 
significant difference in either spontaneous or MLR-stimulated IL-6 protein secretion 
between non-rejectors and rejectors (spontaneous p=O. 717, MLR p=0.235). 
4.6. Thl versus Th2 cytokines 
As with the normal study group, analysis was performed to determine if there 
were any correlations between the cytokine proteins, both with spontaneous and 
MLR secretion. As all of the data did not conform to a normal distribution, standard 
regression analysis could not be performed. Therefore, the data was ranked and 
Spearmans rank correlation analysis was performed. Using this analysis, there were 
several correlations found. Observed data was not plotted for this part of the thesis as 
there were so many correlations found. Spontaneous IFN-y secretion appeared to 
correlate with several other cytokine protein measurements including MLR-
stimulated IFN-y (correlation coefficient (CC)=0.272, p=O.O I), spontaneous IL-10 
(CC=0.45, p=O.OOl), MLR-stimulated IL-10 (CC=0.34, p=O.Ol) and spontaneous IL-
2 (CC=0.47, p=O.OOI), although the correlation coefficients were not that strong. 
MLR-stimulated IFN-y was also found to significantly correlate, although not that 
strongly with spontaneous IL-10 (CC=0.34, p=0.009). The strongest significant 
correlations were found between MLR-stimulated IFN-y and MLR-stimulated IL-10 
(CC=0.75, p=O.OOOI), and MLR-stimulated IFN-y and MLR-stimulated IL-4 
(CC=0.82, p=O.OOOI). 
Spontaneous IL-10, when analysed was found to weakly correlate with both 
MLR-stimulated IL-10 (CC=0.34, p=0.006) and MLR-stimulated IL-4 (CC=0.57, 
p=0.004). Finally, there appeared to stronger significant correlations between MLR-
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stimulated IL-4 and spontaneous IL-4 (CC=0.64, p=0.002) and MLR-stimulated IL-2 
(CC=0.7, p=O.OOI). As all of the correlation coefficients were positive, it could be 
concluded that there were no inverse correlations between any of the spontaneous or 
MLR-stimulated cytokines analysed. 
4. 7. Role of clinical factors and rejection 
4.7.1. Total HLA and HLA-DR mismatching and rejection 
Univariate analysis (r} test) was performed to analyse whether there was 
relationship between both HLA or HLA-DR mismatching with incidence of acute 
rejection. HLA mismatching was represented as 0 (full house match) to 6 (full house 
mismatch). HLA-DR mismatching was represented as 0-2. As expected, when 
analysis was performed, both increases in HLA and HLA-DR mismatching 
correlated with increased incidence of acute rejection (p values-0.03 and 0.014 
respectively). 
4. 7 .2. Patient sex and age 
It was also of interest to analyse the relationship between patient age and sex 
with incidence of acute rejection. Univariate analysis (x_2 test) was again performed. 
Analysis revealed there to be no correlation between either patient sex or age and 
rejection (p= 0.87 and 0.97 respectively). The data therefore confirmed that patient 
age or sex as independent variables had no effect on risk of rejection. 
4.7.3. Donor sex and age 
The same analysis was performed to establish whether the age and/or sex of 
the donor had any bearing on the risk of rejection post-transplant. Results revealed 
there to be a non-significant relationship between rejection and donor age (p=0.36). 
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Figure 4.4. Inter-individual variations in IL-6 protein secretion in rejector (R) and 
non-rejector (NR) groups. Spon=spontaneous; MLR =mixed lymphocyte culture. 
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However, donor sex was found to be related to incidence of rejection, and therefore a 
factor associated with increased risk (p=0.009). 
4.7.4. Cytomegalovirus (CMV) status 
x2 analysis was performed to analyse whether patient or donor CMV status 
(ie: positive or negative) had any influence on the risk of rejection. Analysis revealed 
there to be no significant correlation between either patient (p=0.49) or donor 
(p=0.29) CMV status and incidence of rejection. 
4.8. Effect of cytokine protein secretion on incidence of rejection 
In order to determine whether cytokine protein secretion was independently 
related to incidence of acute rejection, univariate analysis was again performed using 
the x2 test, where rejection was compared with both baseline (or background) levels 
of cytokine and cytokine protein secreted in the MLR. Median cut-off points were 
calculated for each cytokine to determine high and low secretion groups. 
Interestingly, when the baseline data was compared to rejection, it was found that 
there were no significant correlations except for IL-4 background and rejection 
(p=0.005). The secreted levels for IL-4 background however, only ranged from 0-2 
(low) and 3-7 (high). 
When the MLC cytokine protein data was compared with incidence of 
rejection, more patterns were found. There appeared to be no relationship between 
rejection and IL-2 (p=0.21 ), IL-4 (p=0.22) or IL-6 (p=0.07). However, there was a 
different result for both IFN-y and IL-10. With both of these cytokines, there was a 
strong correlation with rejection, suggesting that the higher the secretion of either 
IFN-y (p=0.003) or IL-l 0 (p=0.009), the more likely the patient was to reject. 
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4.9. Multivariate analysis 
Previous univariate analysis had shown that not only were increases in 
spontaneous IL-4 secretion, MLR-stimulated IL-10 and IFN-y protein secretion, 
HLA and HLA-DR mismatching and donor sex associated with incidence of 
rejection, but also that increases in both MLR-stimulated IL-l 0 and IFN-y protein 
secretion were also associated with an increase in HLA-DR mismatching. On the 
strength of these findings, multivariate Logistic analysis was perfonned. Multivariate 
analysis produced a model that included three variables, but analysis of interactions 
allowed a combination of HLA mismatching and IL-l 0 levels to produce a model 
with two variables acting as independent predictors of graft rejection (Table 4.1 ). 
The relative risk of rejection was higher with female donors compared to 
male donors (p=0.006; relative risk(RR)=8.02). Compared with patients with 
mismatches at only 1-3 HLA antigens and an IL- 10 level of> I Opg/ml, patients with 
4-6 mismatches and an IL- 10 level of <I Opg/ml or 1-3 mismatches and an IL-l 0 
level of >!Opg/ml had an increased risk of rejection (p=0.027, RR=6.04). Patients 
with 4-6 mismatches and an IL-l 0 level of> I Opg/ml had a greatly increased risk of 
rejection (p=0.003; RR=25.5), indicating that the highest risk factors for rejection 
were high HLA mismatching and high IL-l 0 secretion. 
4.10. Effect of clinical and immunological factors on graft survival 
It was initially also of interest to analyse the effects of both clinical factors 
(ie: HLA mismatching, donor sex and age etc) and immunological factors 
(ie:cytokine profiles) on renal allograft survival. Unfortunately, this could not be 
perfonned due to the small number of patients who exhibited graft failure (n=6), 
therefore this has not been included in the study. 
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Variable N Relative Risk p value 
Donor sex 25 1.00 
Male 
Female 28 8.02 0.006 
HLA mismatch and 
IL-l 0 level 
1-3 and low 19 1.00 
1-3 and low or 
1-3 and high 23 6.04 0.027 
4-6 and high 11 25.5 0.003 
Table 4.1. Model from a logistic analysis describing renal rejection following 
transplantation in 53 patients. 1-3 and 4-6 refer to the number of HLA mismatches, 
low and high refer to IL-10 secretion at the <10 and >lOpg!ml levels in mixed 
lymphocyte reaction. 
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4.11. Comparison of pre- and post-transplant cytokine proftles 
For some of the patients, follow-up clinical samples were able to be collected. 
These samples were taken at three and twelve months post-transplant. Forty four 
samples (twenty one rejectors, twenty three non-rejectors) were taken at three months 
post-transplant and seventeen samples (nine rejectors, eight non-rejectors) were 
taken at twelve months post-transplant. As with the fifty seven pre-transplant 
samples, one-way MLRs were set up between patient and donor and cytokine protein 
measured by ELISA (IL-2, IL-4, IL-10 and IFN-y). Limited time did not permit the 
measurement of IL-6. Data was then plotted to analyse the pattern of cytokine 
secretion. 
Figures 4.5 and 4.6 illustrate the patterns of cytokine secretion for IL-2 and 
IL-4 in both rejector (a) and non-rejector (b) groups respectively. Figures 4.7 and 4.8 
illustrate the patterns of cytokine secretion for IL-10 and IFN-y in rejector (a) and 
non-rejector (b) groups respectively. It can be seen for all cytokines and in both 
patient groups that there is an overall negative trend in cytokine secretion. Although 
some of the patients did show an increase in some cytokines but not others, there 
were two patients that increased in all four cytokines measured (pre-transplant and 
three month post-transplant measurements only). The first patient (patient 51, non 
rejector) significantly increased in IFN-y (0-1 001 pg/ml), IL-l 0 (0-8pg.ml), IL-2 (33-
257pg/ml) and IL-4 (3-20pg/ml). The second patient (patient 57, rejector) also 
significantly increased in IFN-y (574-1600pg/ml), IL-10 (8-24pg/ml), IL-2 (357-
988pg/ml) and IL-4 (ll-24pg/ml). It was unclear as to why these two patients did not 
respond in the same way as most of the other patients. 
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4.12. Summary 
MLRs were set up between fifty seven renal patient donor pairs and cytokine 
protein was measured by ELISA. Inter-individual variations were found in all 
cytokine profiles. Significant differences were found between rejectors and non-
rejectors in spontaneous IL-4, MLR-stimulated IL-10 and MLR-stimulated IFN-y 
protein secretion. Many significant correlations were found between the cytokines 
including MLR-stimulated IFN-y and IL-10, MLR-stimulated IFN-y and IL-4, and 
MLR-stimulated IL-4 and IL-2. A significant correlation was also found between 
HLA-DR mismatching and both MLR-stimulated IL-l 0 and IFN-y protein secretion. 
Univariate analysis was also performed to find which variables were related 
to incidence of rejection. Both HLA and HLA-DR mismatching were found to be 
associated. Female donor sex, MLR-stimulated IL-10, MLR-stimulated IFN-y and 
spontaneous IL-4 protein secretion were also associated with risk of rejection. 
Multivariate analysis revealed that female donors, HLA mismatching and IL-10 
protein secretion were the main factors associated with rejection. The highest risk of 
rejection occurred in patients who had both high HLA mismatching ( 4-6 antigen) and 
high IL-10 protein secretion (>IOpg/ml; RR=25.5). In addition, it was generally 
found that cytokine protein secretion decreased following transplantation. This was 
found in some patients up to twelve months post-transplant. 
215 
CHAPTERS 
RELATIONSIDP OF CYTOKINE PROFILES TO CLINICAL 
OUTCOME AFTER IDENTICAL SIBLING BMT 
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5.1. Introduction 
Bone marrow transplantation (BMT) is preferentially carried out in cases 
where an HLA-identical sibling donor is available. GVHD may still occur in these 
transplants, and this is due to differences in minor histocompatibility antigens. The 
mixed lymphocyte reaction (MLR) has been used as a semiquantitative HLA 
matching test for confirming HLA class 11 identity between donor and recipient. 
Although this assay has played an important historical role in the selection of 
unrelated donors for BMT, it is not predictive of acute GVHD after HLA-identical 
sibling BMT (Lim et a/, 1988, DeGast et a/, 1992). 
It is well known that cytokines are generated in the MLR, IL-2 and IFN-y 
protein secretion and IL-2, IFN-y and IL-5 gene expression have been detected in 
MLR between HLA-identical siblings (Tanaka et a/, 1994, l995a). However, these 
studies used a two-way MLR enhanced by Con A. Experiments using the skin 
explant assay have also demonstrated the role of the cytokines TNF-a and IFN-y as 
important mediators of the in vitro cellular damage seen in the skin (Dickinson et a/, 
1991, l994a, 1994b). 
In view of these findings, MLRs were set up between HLA-identical sibling 
donor-recipient pairs and cytokine protein secretion was measured by ELISA. These 
pre-transplant cytokine profiles (IL-2, IL-4, IL-l 0 and IFN-y) were then correlated 
with the severity of GVHD. IL-6 protein levels was not determined as there was not 
enough sample. 
5.2. Patient group 
Eight patients (four chronic granulocytic leukaemia (CGL), two acute 
lymphoblastic leukaemia (ALL), two acute myeloblastic leukaemia (AML)) who 
received an identical sibling transplant were used in this part of the study. 
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5.3. Cytokine proflles and their relevance to BMT clinical outcome 
5.3.1. IL-2 
Table 5.1 illustrates both the post-transplant clinical data and the cytokine 
profiles yielded. It can be seen that three of the patient-donor pairs secreted no IL-2 
at all (pairs one to three). These pairs were found to have yielded a low grade (ie; 0-
1) of GVHD. Four of the transplant pairs yielded between 2 and approximately 
4pg!ml ofiL-2 (pairs four, five, seven and eight). One of these pairs yielded the most 
severe grade of GVHD in the study group (grade Ill). Only one pair secreted around 
16pg!ml of IL-2 (pair six). GVHD outcome was low risk (grade I) There appeared to 
be no correlation between levels of IL-2 and relative risk of GVHD. As there was an 
overall poor MLC response between the transplant pairs for IL-2 secretion it was 
decided that statistical analysis would not be performed. 
5.3.2. IFN-y 
The MLC response for IFN-y appeared to be even weaker than for IL-2. Only 
one BMT pair secreted any IFN-y at all (pair three; 1.657pg!ml). This pair gave rise 
to grade 0 GVHD. With the results yielded for IFN-y, it was again decided that 
analysis would not be performed. 
5.3.3. IL-4 
The results yielded for IL-4 were different to those found for both the Thl 
cytokines. In all eight BMT pairs, both the controls (donor cells alone and irradiated 
recipient cells alone) and the MLC group gave rise to IL-4 levels exceeding I Opg!ml. 
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Patient- GVHD IL-2 IFN-y IL-4 IL-10 
Donor Pair Grade (pglml) (pglml) (pglml) (pglml) 
1 Rec 0 0 13.362 0 
Donor I 0 0 14.361 0 
MLC 0 0 14.365 0 
2 Rec 0 0 12.488 0 
Donor 0 0 0 13.496 0 
MLC 0 0 13.697 0 
3 Rec 0 1.011 11.335 0 
Donor 0 0 0 13.026 0 
MLC 0 1.657 14.165 0 
4Rec 0 0 12.892 0 
Donor 0 2.660 0 14.231 0 
MLC 3.343 0 14.564 0 
5Rec 0 0 12.082 0.470 
Donor Ill 0 0 12.161 1.124 
MLC 2.660 0 17.147 1.413 
6Rec 0 0 15.650 0 
Donor I 0 0 16.467 0.324 
MLC 15.968 0 16.536 4.364 
7Rec 0 0 15.172 0 
Donor 11 0 0 16.604 1.557 
MLC 2.660 0 17.486 1.846 
8Rec 0 0 14.143 0 
Donor 0 0 0 15.582 0 
MLC 4.030 0 16.536 0.470 
Table 5.1. Clinical and laboratory data for HLA-identical sibling BMT pairs (Rec 
(Recipient) and donor data represent the background control samples) . . 
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However, in all pairs, there appeared to be little difference in IL-4 secretion between 
the control samples and the MLC responses and little inter-patient variation. The 
second highest overall response was yieded by pair five (17.147), whom gave rise to 
the highest grade of GVHD (III). The lowest IL-4 response gave rise to grade 0 
GVHD (pair two; 13.697pg/ml). Again, due to the lack of significant response 
between donor and recipient, analysis was not performed. 
5.3.4. IL-10 
Finally, the culture supematants were measured for IL-10 protein. Again, 
there was an overall poor response by the BMT pairs. Four of the eight donor pairs 
yielded no IL-10 cytokine protein at all (pairs one to four), all of which were 0 or low 
grade (I) GVHD . Three of the transplant pairs secreted between 0 and 2pg/ml (pairs 
five (grade III), seven (grade II) and eight (grade 0)). One pair (pair six) yielded in 
the excess of 4pg/ml of IL-l 0 protein (grade 1). From the results shown, there 
appeared to be no advantage in analysing this data statistically. 
5.4. Summary 
The MLC was used to determine pre-transplant cytokine profiles (IL-2, IFN-
y, IL-4 and IL-10) in BMT HLA-identical sibling pairs. MLCs were set up and 
culture supematants harvested at optimised time points for the cytokines in question. 
It was then hoped that statistical analysis could be performed to determine if the 
cytokine profiles correlated with acute GVHD. 
With all four cytokines, there appeared to be a lack of response by the MLC, 
with the lowest response being seen for IFN-y cytokine protein. Although there 
appeared to be a better response for IL-4 protein, there was little difference between 
the background control and MLC samples and inter-patient variation. It was decided 
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that analysis would not be performed to ascertain the relationship between the 
cytokine profiles and GVHD outcome as there was low responses for all four 
cytokines, and it was therefore felt that application of statistical analysis would not 
be informative. 
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CHAPTER6 
DISCUSSION 
222 
6.1. Optimisation and analysis of cytokine profiles in normal individuals 
6.1.1. Introduction 
Th1ffh2 polarisation is thought to be associated with allograft rejection and 
GVHD. In view of the fact that cytokines are secreted during mixed lymphocyte 
reaction (MLR) and mitogen stimulation, the aim of this project was to develop an in 
vitro functional assay for the prediction of acute (and chronic) rejection in renal 
transplantation. In the first instance, studies were performed to optimise and analyse 
cytokine profiles in normal individuals. 
6.1.2. Optimisation of culture conditions 
6.1.2.1. Mixed lymphocyte culture 
Previous studies have shown several cytokines to be produced during an 
MLC response (Bishara et al, 1991, Toungouz et al, 1993, 1994, 1996). However, for 
the purposes of this study, it was considered important to optimise the conditions for 
the MLC in normal individuals. Firstly the kinetics of protein secretion was 
determined for cytokines IL-2, IL-4, IL-10 and IFN-y {IL-6 at a later point) by 
ELISA. It was found that there was a variation in time for optimal secretion between 
each cytokine, which confirmed the importance of these experiments. These 
incubation times were then used in future experiments. Other experiments have also 
shown a difference in time points for cytokine secretion (Kohka et a/, 1999) in which 
IFN- y, IL-6 and II-10 were included. It was observed that first detection of these 
cytokines was at twelve hours, with a marked increase thereafter. Secretion ofiL-12 
was not detected until forty eight hours. The levels of IFN-y were downregulated 
with the addition of anti-IL-18 and anti-IL-12 antibodies, suggesting that the 
secretion of IFN-y may be dependent on IL-18 in the early phase of the MLR, and 
dependent on both IL-18 and IL-12 in the late phase. This may well be the case for 
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the experiments performed in this project. Optimisation of cytokine protein and 
receptor expression in MLC was also performed in a similar manner by flow 
cytometry. This part of the project failed due to the incapability of gating a clear 
lymphocyte region within the PBMC population. As the stimulator cells were treated 
for this culture, there may have been an increased level of background debris, 
therefore making it more difficult to determine live from dead or dying lymphocytes. 
This did appear to become more apparent as the culture incubation time increased. In 
retrospect, a viability stain (eg; propidium iodide) may have been a way in which the 
dead or dying cells could have been designated from the live cells. If the cells are 
positive for propidium iodide, then the cells are dead. Knowing the approximate 
position of the lymphocytes on the screen, the live lymphocytes may then be gated 
(propidium iodide negative). However, the failure of detection of cytokine expression 
in the MLC was not a surprise as the number of alloreactive cells, and therefore 
cytokine expression were expected to be below the limit of detection of the flow 
cytometer (sensitivity= I%). 
To determine the response of only the responder (or recipient) cells in this 
culture, the stimulator (or donor) cells had to be treated in some way in order to 
render them unresponsive. This culture, as previously mentioned, is termed a one 
way MLR or one way MLC. This may be performed by chemical treatment, using 
mitomycin C, or gamma irradiation. There is a standardised technique using the 
irradiation method (Dupont et a!, 1980), although this is performed for proliferation 
measurement in the MLC. For the purposes of this study, I wanted to confirm the 
most suitable method of treatment for the measurement of cytokines in the MLR. 
Both irradiation and mitomycin C experiments were performed, using titrated doses 
in order to determine the cut-off points of cytokine secretion. In the irradiation 
experiments, there was a clear cut-off point at 20-30 Gy. However, for mitomycin C, 
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the cut-off point could not be determined as the cytokine secretion pattern was very 
sporadic. It is unclear as to the reason for this result, but from these experiments it 
was concluded that the irradiation technique was the most suitable method. 
Both gamma irradiation and mitomycin C treatment of stimulator cells have 
been used in previous experiments in order to achieve unidirectionality of response 
in the MLR (Leenaerts et a/, 1992, Malinowski et al, 1992). Both irradiation and 
mitomycin C treatment are known to block lymphocyte replication and downregulate 
HLA expression. As in the experiments performed in this project, it has been shown 
that gamma irradiation has a more profound effect on nulling stimulator cells in the 
MLR than mitomycin C (Malinowski et a/, 1992). 
6.1.2.2. Mitogen stimulated cultures 
Experiments have been performed to attempt to enumerate cytokine profiles 
at both the protein (Hutchings et al, 1989, Mossman and Fong, 1989) and expression 
level (Sander et al, 1991, Jung et al, 1993). However, different mitogens may have 
different effects on cytokine profiles. Jason and Lamed (1997) and Katial et al ( 1998) 
both demonstrated a broad spectrum of cytokine levels in normal individuals, varying 
with the mitogen used. PHA and OKT3 mitogens were used for the stimulation of 
protein secretion while PMA was used for protein expression studies. OKT3 had 
previously been optimised (Kaminski et al, 1995), therefore experiments were only 
perfomed for the other two mitogens. For the four cytokines of interest (IL-2, IL-4, 
IL-l 0 and IFN-y), forty eight hours appeared to be the optimal incubation time for 
peak protein secretion. Optimisation of cytokine expression using PMA stimulation 
had previously been performed (Prussin and Metcalfe, 1995), and therefore these 
conditions were used. These experiments were repeated and confirmed. In addition, 
Mascher et a/ ( 1999) also studied the expression of these cytokines, together with· 
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TNF-a.. This study found that peak cytokine expression for IL-2 and IFN-y was 
between six and eight hours. Although IFN-y remained stable for twenty four hours, 
IL-2 declined markedly after eight hours. Interestingly, in optimisation experiments 
performed in this project, IL-4 and IL-l 0 were found to be below detectable limits. 
This may be due to both of these cytokines being expressed and secreted at much 
lower levels than IFN-y and IL-2, or may be used up much more quickly in both an 
autocrine and paracrine fashion. Like all assays, flow cytometry has a baseline of 
positivity, and both IL-4 and.IL-10 were found to be below this baseline (1%). 
In an attempt to improve the detection of both of these cytokines, increased 
amounts of conjugated anti-cytokine antibodies were used. This only increased the 
background, and not the detection of intracellular cytokine. This also occurred when 
the length ofpermeabilisation incubation time was increased together with a decrease 
in blocking incubation time (to allow more anti-cytokine antibody to bind, and 
therefore increase the sensitivity). Therefore, amendments to the protocol did not 
seem to improve the detection of either IL-4 or IL-l 0 cytokine expression. In 
contrast, other studies have claimed that IL-4 {Andersson et a/, 1990) and IL-l 0 
together with IL-4 (Rostaing et a!, 1999b) can be detected. However, as with this 
study, the Th2 cytokines (both IL-4 and IL-10) were found to be detected at lower 
levels than cytokines such as IL-2 and IFN-y (Rostaing et a/, 1999b ). 
6.1.3. Inter-individual variation in cytokine profiles in normal individuals 
Frequencies of various cytokines have been suggested to vary (Merville et at, 
1993a). Little is known about the variance of both cytokine secretion and frequencies 
of cytokine expression between individuals and what factors may have an influence 
on these levels. Mitogen stimulation of lymphocytes has demonstrated large inter-
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individual variations in IL-2, IL-4 and IFN-y cytokine protein secretion by ELISA 
(Kaminski et a!, 1995) and numbers of IL-2 and IFN-y cytokine expressing cells by 
flow cytometry (Ferry et a!, 1997). In this project, a group of normal individuals 
were randomly chosen and PHA and OKT3-stimulated cytokine protein by ELISA 
(IL-2, IL-4, IL-l 0 and IFN-y) and PMA-stimulated cytokine expression by flow 
cytometry (IL-2 and IFN-y) measured. Large inter-individual variations were also 
found in both PHA and OKT3-stimulated protein secretion and PMA-stimulated 
expression, confirming these previous findings. Different levels of cytokine protein 
were secreted between OKT3 and PHA, confirming that different mitogens elicit 
different effects on cytokine production (Imada et al, 1994 ). Interestingly, there 
appeared to be a bi-modal distribution for PHA-stimulated IFN-y protein secretion. It 
may be concluded from these results that a low, medium and high secretor status 
does exist in cytokine profiling. Although these experiments were performed using 
mitogen stimulation, this may also be seen in the MLR (Chapter 4), and therefore 
may play an important role in the determination of whether these inter-individual 
variabilities may determine clinical outcome. Use of other mitogens in mononuclear 
cell cultures, including Concanavilin A (ConA) and lipopolysaccharide (LPS) have 
also illustrated significant inter-individual variations in cytokine production, which is 
unaffected by the type of stimulus used or by time (Yaqoob et a!, 1999). 
6.1.4. Contribution to cytokine production by CD4+ and CD8+ T cells and NK cells 
Additional experiments were also performed to determine the contribution of 
CD4+ and CD8+ T cells to cytokine expression. In conformation of previous 
findings (Prussin and Metcalfe, 1995, North et al, 1996), this study demonstrated 
predominant expression of IL-2 by CD4+ T cells illustrating that IL-2, on activation 
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of mainly T helper cells, is expressed (and secreted) as part of the cytokine cascade, 
and stimulates proliferation in an autocrine fashion, which leads to the paracrine 
activation of CD8+ T cells. IFN-y.is also believed to activate CTLs, but is also 
suggested to be associated with the recruitment of macrophages to the site of immune 
response (Nickerson et al, 1994). IFN-y expression, as with this study, has also been 
shown to be primarily expressed by CD8+ T cells (Sewell et al, 1997), although in 
this project, the increased expression was negligible. Experiments were also 
performed to study cytokine eo-expression in T cell subsets. Results showed there to 
be low eo-expression of both cytokines, sugesting that upon activation, CD4+ and 
CD8+ T cells produce a preponderance of either IL-2 or IFN-y. Therefore, although 
there is a difference in the predominant cell subtype between these two cytokines, 
they are both known to play an equally important role in the cytokine cascade and the 
pro-inflammatory immune response. This is in accordance with previous data 
(Caruso et a!, 1998), where a high percentage of cells expressing either IL-2 or IFN-y 
was observed, but not with double expression. NK cells were found to express 
extremely low levels of IL-2 and IFN-y. IFN-y has been shown to be one of the 
cytokines produced by NK cells on activation (Perussia, 1996) and cross-linking of 
molecules such as CD45 (Shen et al, 1995) and NKR-Pl (Arase et al, 1996). The use 
of PMA stimulation was therefore not sufficient to observe cytokine expression, 
although this did illustrate that NK cells did not contribute to IL-2 and IFN-y 
expression in these experiments. 
6.1.5. Relationships between Th I and Th2 cvtokine profiles 
Although it has been previously demonstrated that inter-individual 
differences do occur in both cytokine protein secretion and expression, little is 
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known about the factors responsible for the production of cytokine protein. Recently, 
there has been evidence to demonstrate that genetic polymorphisms may determine 
the amount of cytokine protein secreted (Daser et a/, 1996) and that particular 
cytokine genes are associated with high/low secretor status (Turner et a/, 1995, 
1997). Analysis was therefore performed to determine the relationship between 
cytokine protein and secretion (for IL-2 and IFN-y), between Th I and Th2 cytokine 
protein secretion, and due to the bi-modal nature of the IFN-y protein secretion 
profile, between IFN-y protein, IFN-y cytokine expression and IFN-y gene 
polymorphisms (discussed later). The analysis illustrated a positive correlation 
between IL-2 protein secretion and frequency, suggesting that the number of IL-2 
secreting cells determined the amount of IL-2 protein secreted. However, there did 
appear to be two individuals who could be classed as outliers. Although these 
individuals did not affect the analysis, it would have been of interest to observe if 
these points were included in a second population cluster. The study group was not 
extended due to limited time (see section 6.1. 7). 
Strong positive relationships were found between IFN-y!IL-2 and IL-10 PHA- . 
stimulated protein secretion. This result was surprising as an inverse correlation was 
expected between Th 1 and Th2 cytokines. OKT3 stimulation demonstrated no 
relationships between any of the cytokine profiles. The use of mitogen stimulation 
may be regarded as rather synthetic compared to activation in culture conditions such 
as the MLC. The MLC may be regarded as a more true reflection of the in vivo 
immune response than mitogen stimulation. The fact that absent or unexpected 
relationships were observed between cytokine protein secretion patterns in particular 
may be due to this. Mitogen compounds tend to push the cell to its' maximum 
. 
stimulatory capacity, and therefore, as previously stated, does not give a true 
reflection of the in vivo immune response, although does give an idea of what may 
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occur when lymphocytes are activated in different individuals. Inter-individual 
variation has been shown to exist in normal individuals, and this may have clinical 
relevance in cytokine profiling and clinical outcome in transplant patients. 
6.1.6. Relationship between IFN-G gene oolymomhisms. protein secretion and 
frequency 
It has been shown that even a single base change in the DNA sequence can 
greatly increase or decrease the binding of a particular transcription factor (Wilson et 
a/, 1992, Bailly et a/, 1993). In this instance, the frequency of polymorphic 
dinucleotide repeats (CA) of the microsatellite region in the IFN-y gene was studied. 
Unlike IL-2, no relationship was found between IFN-y protein secretion and 
expression. This would therefore suggest that the number of IFN-y expressing cells 
does not determine the amount of IFN-y secreted. It is unsure as to why there is a 
relationship between expression and protein secretion with IL-2 and not IFN-y. This 
may be due to that different IFN-y expressing cells may vary in IFN-y protein 
production, which is obviously less random than with IL-2. However, this finding 
does suggest that another factor may influence IFN-y protein production. Therefore, 
IFN-y gene polymorphisrns were studied. No relationship was found between IFN-y 
expression, protein production and gene polymorphisms. This finding was in contrast 
to Pravica et a/ (1999). In this study, the frequency of the IFN-y CA repeat 
polymorphism was investigated in normal volunteers, together with the production of 
IFN-y in the supematants of PHA stimulated PBMCs isolated from the same 
individuals. They found that there was a correlation between IFN-y genotype and in 
vitro IFN-y production. It was unclear as to why no correlation between IFN-y 
genotype and protein production was found in this study. One explanation could be 
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that either another polymorphism in the IFN-y gene or even in another gene may be 
responsible for determining IFN-y protein production. However, this would have to 
investigated. 
6.1. 7. Summary of statistical analysis 
The aim of the analysis studying the relationships between protein secretion 
and expression was to observe whether the number of cytokine expressing cells 
determined the amount of protein secreted. The reason for analysing the relationships 
between Thl and Th2 cytokine protein secretion profiles was to assess if there was 
an inverse correlation. This was expected due to the understanding that Th l and Th2 
cytokines regulate each other. It may be argued that if enough. multiple comparisons 
are analysed, then a relationship will eventually be found. However, this not the case 
for this analysis, as when relationships were found eg; IL-2 protein and frequency, 
the level of significance was strong. Cytokine protein secretion data were 
catergorised as low-medium and high. For the majority of the cytokines, the group 
was split into three subgroups to obtain arbitary ranges for low, medium and high 
secretion. However, for cytokines such as PHA-stimulated IL-2 and OKT3 
stimulated IFN-y and IL-4, this was not so simple, as there were clear outliers within 
the data distribution. Therefore, as the outliers were included in the data analysis (see 
below), the majority of the individuals were classed as low-medium secretors. 
Each of the sets of data were then tested for normality. Pearsons correlation 
analysis was performed on the data conforming to a normal distribution. Most of the 
data did not conform to a normal distribution, therefore Spearmans Rank analysis 
was used. When the spread of data was plotted, there were outliers (eg; PHA 
-
stimulated IL-2, OKT3 stimulated IFN-y and IL-2). In normal circumstances, these 
outliers would be eliminated as they may skew the analysis. However, this was not 
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done with this study group as it was thought that they may have a biological 
significance in the variation of cytokine production. For all analysis, p values were 
corrected, but this did not affect the level (or lack) of significance. If time had 
permitted, the number of normal individuals would have been increased to ascertain 
whether a more normal overall distribution of protein secretion was present within 
the group. This would have been of particular interest with PHA-stimulated IFN-y as 
a bi-modal distribution was observed. 
6.2. Cytok.ine protein secretion in the MLR - predictive value for renal allograft 
rejection 
6.2.1 Introduction 
The MLR has been shown to be relatively imprecise in the prediction of 
GVHD in bone marrow transplantation (Lim et a!, 1988, DeGast et a!, 1992, Hows et 
a!, 1986, Mickelson et a!, 1994) or rejection in renal transplantation (Cullen et a!, 
1977, Burke et al, 1993, Steinmann et a!, 1994). Although some studies have shown 
the MLR to predict rejection following renal transplantation (Harmon et a/, 1982, 
Langhoff et a/, 1985), it is now accepted that the standard MLR is of limited value. 
Based on this previous work, it was decided that that there was a need for a simple in 
vitro functional assay for determining clinical outcome in renal transplantation. I 
therefore set out to study the role of cytokine profiles and other clinical factors in the 
prediction of allograft rejection in renal transplantation. 
6.2.2. HLA and HLA-DR mismatching and cytokine profiles 
Cytokine protein data was compared with degree of HLA and HLA-DR 
mismatching using Kruskal-Wallis testing. Interestingly, there appeared to be no 
significant association between total HLA mismatching and any of the MLR 
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cytokine profiles. There was a significant correlation however between HLA-DR 
mismatching and MLR-stimulated IL-10, and between HLA-DR mismatching and 
MLR-stimulated IFN-y. No correlations were found between either total HLA or 
HLA-DR mismatching with any spontaneous cytokine secretion. This would suggest 
that alloactivation of lymphocytes in the MLR, when there is a higher degree of 
HLA-DR mismatching, induces higher secretion of both IL-10 and IFN-y, and that 
these cytokines were associated as independent variables. Previous work has shown 
that measurement of cytokine secretion Cll!l detect both mismatches (Danzer et a/, 
1994) and polymorphisms in HLA genes (Toungouz et a/, 1994). In the work by 
Danzer et al (1994), it was shown that cytokine determination in the MLR is suitable 
to detect identical alleles of both HLA-DRB I and HLA-DQB 1. It was shown that 
HLA-DP has no stimulatory effect on cytokine release and also suggested that HLA-
DR is more effective in inducing IFN-y secretion than HLA-DQ. This data would 
therefore explain as to why there is a positive correlation between HLA-DR 
mismatching and IFN-y secretion. Toungouz et al (1994) also showed that HLA-DR 
mismatches may increase cytokine production in the MLR. However, in contrast, 
they found one of these cytokines to be IL-6. Later work by the same group also 
showed that an increase in HLA-DR mismatching (increase from one to two HLA-
DR mismatches) led to an increase not only in IFN-y, but also TNF-a production in 
the MLR (Toungouz et a/, 1996). They concluded that a decrease in HLA-DR 
mismatching (ie: one mismatch) led to optimal IL-10 production, which in turn 
exerted efficient inhibition of the Th 1 cytokines produced in the MLR. 
IL-10 has been suggested to be associated with Th2 cells and therefore with 
tolerance in kidney transplantation (Romagnani, 1991 ). The finding that IL-l 0 is 
associated with HLA-DR mismatching, and that this mismatching is strongly 
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associated with rejection would suggest that IL-l 0 may be also associated with the 
rejection process. IL-l 0 has also been proposed to have the role of down-regulating 
both Thl and Th2 subpopulations (Del Prete et a/, 1993). Recent work has shown an 
association with HLA-DR mismatching and IL-10 secretion (Sankaran et a/, 1999). 
This research also found an association with allograft rejection (discussed later). The 
relationship between IFN-y, IL-10 and incidence of rejection will be discussed later. 
6.2.3. Inter-individual variations in cvtokine profiles 
It was previously established (chapter 3) that inter-individual variations were 
present when normal individuals were stimulated with mitogen. However, it was also 
of interest to observe whether variations occurred in the MLR response. Cytokine 
protein data was gathered and the patient study group was divided into rejector (R) 
and non-rejector (NR) groups. As the cytokine protein data did not conform to a 
normal distribution, the medians of each group were compared instead of the means. 
The analysis was only performed for pre-transplant data. For all five cytokines (IL-2, 
IL-4, IL-6, IL-10 and IFN-y), there did appear to be inter-individual variations in 
both rejectors and non-rejectors in the MLR response. Previous work also 
demonstrated similar variations, albeit in mitogen-stimulated cultures (Kaminski et 
a/, 1995, Cartwright et a/, 1999). However, the variations found in the MLR response 
were not as clear for spontaneous/background secretion. At present, there is no data 
to support variations in cytokine excretor levels in vivo. This would prove to be quite 
difficult to study as cytokines are suggested to have a relatively short half-life in 
vivo, and therefore would not accurately be able to be measured. Therefore, 
cytokines are only measured in vitro. Results also showed there to be no significant 
difference between rejectors and non-rejectors for IL-2, IL-4 or IL-6 secretion. 
However, a strong significant difference was seen for IL-10 and IFN-y secretion in 
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the MLR response. This is in accordance with Karninski et a/ ( 1995) where not only 
were inter-individual variations were seen in both rejectors and non-rejectors, but 
that the only significant difference that was found out of IL-2, IL-4 and IFN-y 
secretion was IFN-y. However, this study did not look at either IL-6 or IL-l 0 and the 
method of stimulation used was OKT3 mitogen. The important observation of inter-
individual variability has also been shown by Turner et a/ ( 1997). It was suggested 
that there can be a 3-20 fold difference between the highest and the lowest cytokine 
production upon in vitro stimulation. No significant differences were found for any 
of the cytokines between the two groups in spontaneous cytokine release. The data 
found in this study indicates that not only are there are variations in cytokine protein 
secretion in response to alloactivation, but also that there are smaller. yet present 
spontaneous inter-individual variations. These variations may be due to differing 
individual abilities to spontaneously secrete particular levels of cytokines, leading to 
the possibility of the involvement of cytokine gene polymorphisms. 
6.2.4. Th 1 versus Th2 cvtokines 
In the group of normal individuals (chapter 3), I wished to determine whether 
any relationships existed between Th 1 and Th2 cytokines. As cytokine secretion was 
seen spontaneously as well as in the MLC response, analysis was also performed for 
this data. As previously mentioned, as the data did not conform to a normal 
distribution, the data had to be ranked and Spearmans rank correlation analysis 
performed. Using this analysis, there appeared to be quite a few correlations. Of 
major interest was the positive correlation between IFN-y and IL-10. IFN-y secreted 
in the MLR correlated with both spontaneously secreted and MLR-stimulated IL-10. 
This was of particular interest as a correlation was found between these two 
cytokines in mitogen stimulated cultures (see chapter 3). There are other publications 
235 
which have shown synergistic production of both IL-10 and IFN-y in conditions 
other than renal allograft rejection, including heart allograft rejection (Van Hoffen et 
a/, 1996) and even malaria (Wenisch et a/, 1995), and therefore suggests that that 
stimulatory and inhibitory cytokines for macrophage activation and/or antibody 
production (ie; Thl and Th2 immunoreaction respectively). There were also very 
strong significant correlations between MLR-stimulated IFN-y and MLR-stimulated 
IL-4, and MLR-stimulated IL-2 and MLR-stimulated IL-4. There were no inverse 
relationships between any of the cytokines. 
During an MLR, it is known that the cells undergo DNA synthesis, blast 
transformation and proliferation. During this reaction, as in allograft rejection, 
cytokines are also produced. The Th1/Th2 paradigm has been implicated in playing a 
role in transplantation (Soulillou, 1993) and that Th1 and Th2 derived cytokines may 
even regulate each other (Nickerson et a/ 1994, 1997). The positive correlations 
found between both Th I and Th2 cytokines suggest that production of Th I cytokines 
such as IFN-y do not suppress Th2 cytokine production such as IL-4. As with 
mitogen stimulation (Katial et a/, 1998), it appears that alloactivation in the MLR 
leads to a global up-regulation of cytokine synthesis, and that Th 1/Th2 regulation 
may be a little more complex than originally thought. 
6.2.5. Effect ofHLA and HLA-DR mismatching on incidence of rejection 
The first part of the analysis to be performed was to establish which relevant 
factors play a role in clinical outcome involved analysing the relationship between 
HLA mismatching and risk of rejection. Univariate analysis was performed using the 
x_2 test. This analysis showed there to be not only a relationship between increase in 
total HLA mismatching and risk of renal allograft rejection but also increase in HLA-
DR mismatching and risk of rejection, both as independent variables. These findings 
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are in accordance with 8eckingham et al (1994) who also found lower rejection rates 
with better HLA matching. Reviron et a/ (1996) also found that better HLA-DR 
matching reduced the risk of acute rejection after kidney transplantation, and even 
found that generic (ie; more specific) HLA-DR matching improved the risk of 
rejection even more than broad HLA-DR antigen matching. This is supported by an 
earlier study by Al-Daccak et al (1990) who found that a higher response was seen in 
the MLR with HLA-DRJ mismatches compared to some of the other HLA-DR 
haplotypes, suggesting that allorecognition does not necessarily have to be the 
recognition of the whole HLA molecule, but possibly a processed HLA molecule 
presented as a nominal antigen. More recent studies have also illustrated the benefits 
of HLA-DR matching (Reisaeter et a/, 1998, McKenna et a/, 1998). McKenna et al 
( 1998) studied one hundred and five renal transplant patients, and it was found that 
poor HLA-DR matching was associated with an increase in both early (0-3 months 
post-transplant) and late (4-6 months post-transplant) rejection episodes. It was also 
found that poor HLA-A and 8 matching was only associated with late rejection 
episodes. However, in this study, we did not analyse HLA-A and -8 mismatching. 
Reisaeter et a[ ( 1998) looked at a larger cohort of patients ( 655), and not only found 
an increase in rejection episodes with increased HLA-DR mismatches, but also worse 
allograft survival. In heart transplantation, it has been suggested that HLA-DR 
incompatibility may even predict rejection (Costanzo-Nordin et a/, 1993). It has also 
been thought that HLA-DR matching is primarily more important than other HLA 
antigens. This is due to the hypothesis that HLA-DR may stimulate more alloreactive 
cells than mismatches at HLA-A or HLA-8, for instance, and therefore HLA-DR 
mismatches lead to higher risks of rejection. This would explain why this project and 
many other stUdies have found HLA-DR to be strongly associated with rejection. 
Therefore, it may be suggested that although overall HLA matching was found to 
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have a significant association with risk of rejection, it may have been influenced by 
the independently strong association between HLA-DR and rejection. 
Much attention has been focused on the need for HLA-DR matching in 
transplantation, in particular HLA-DRB I since the use of molecular HLA typing 
(Kobayashi et a/, 1992, Nojima et a/, 1996, Lardy et a/, 1997). The method of PCR-
RFLP analysis allows the analysis of the genotype for HLA-DRB I alleles by 
digestion using restriction endonucleases in order to determine the "splits" at the 
DRB I gene level. In each of these experiments, an increase in HLA-DRB I 
mismatches were significantly associated with higher risk of graft rejection. These 
findings thus confirm the benefits of HLA genotyping for HLA-DRB 1 in addition to 
serological typing for HLA-DR. It is thought that mismatches for HLA-DRB I play a 
role in allograft rejection due to the mismatches localised in the beta-pleated sheet of 
the DRBI molecule (Adorno et a/, 1999a, 1999b). 
6.2.6. Effect of sex and age on incidence of rejection 
Univariate analysis was again performed to assess whether either patient or 
donor sex/age were related to incidence of rejection. Both donor and patient age were 
not associated with rejection. Patient sex was also not significantly associated. 
However, donor sex appeared to be independently strongly associated with the 
incidence of rejection (p value=0.009). It is well established that transplantation of 
male tissue into female recipients may lead to graft rejection in organ transplantation 
(and GVHD in bone marrow transplantation) due to the role of the male-specific 
minor histocompatibility antigen H-Y (Scott et a/, 1997, Simpson et a/, 1997). The 
recent identification of two peptides that in association with the mouse H-2K or 
human HLA-87 MHC class I molecules, are recognised by H-Y specific T cells. The 
human peptide has been identified as a derivative from SMCY, an evolutionary 
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conserved protein encoded on the Y chromosome (Wang et a/, J 995). It was 
therefore a surprise to find that female donors led to a higher risk of rejection. This 
finding however is in accordance with Vereerstraeten et a/ (1999). This study was 
not only looking at incidence of rejection but also rate of graft failure due to rejection 
and technical failure. The poorest graft outcomes were kidneys from female donors 
to male recipients. In contrast to this finding was earlier data from Kawauchi et al 
( 1993) where male donor into female recipients increased the risk of allograft 
rejection. However, this finding was not a direct comparison as this study included 
heart transplants in children. This particular finding was surprising, but it even may 
be due to the cohort of patients chosen, although this is unlikely. The nature of why 
female donors were a higher risk than male donors remains inconclusive. 
6.2.7. CMV status and incidence of rejection 
The study of transplant patients with CMV infection and its effect on 
incidence of graft rejection has led to a mixture of findings. Here, it was of interest to 
analyse whether either the donor or recipient CMV status had any bearing on the risk 
of rejection. Results showed that neither the patient CMV or donor CMV status was 
significantly correlated to rejection. An association between either acute or chronic 
rejection and CMV infection has been reported in renal transplantation (Yeung et a/, 
1998, Kashyap et a/, 1999) but mostly in liver transplantation (Lautenschlager et al, 
1997, Rosen et a/, 1998). CMV has been shown to have been detected in renal 
allograft biopsies by PCR (Chen et at, 1992, Lee et a/, 1992, Cunningham et a/, 
1995). Cytomegaloviral inclusions have also been detected by histological methods 
(Kashyap et a/, 1999). The role of CMV infection in allograft rejection has been 
widely studied, and has been suggested to be involved in the induction of smooth 
muscle proliferation and intimal thickening (Borchers et a/, 1999) and endothelial 
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cell damage (Toyoda et a/, 1997). The finding that CMV status was not associated 
with risk of rejection in this study was surprising, although there has been previous 
suggestion that risk of rejection is associated with manifestation of CMV disease and 
not CMV infection alone (Bouedjoro et a/, 1999). 
6.2.8. Cvtokine protein and rejection 
Analysis was also performed to establish whether there were any significant 
associations between any of the cytokine proteins (both background and MLC) with 
risk of rejection. For the purpose of the analysis, median cut-off points had to be 
determined in order to produce a low and high secretor group (50:50). The results 
showed there to be a significant association between IL-4 background secretion and 
incidence of rejection (p value=0.005). This finding was surprising as Th2 cytokines 
such as IL-4 have been linked with allograft tolerance (Dallman et a/, 1993, 
Nickerson et a/, 1997). In addition, both MLR-IL- 10 and IFN-y were significantly 
correlated with rejection (p values=0.009 and 0.003 respectively). 
There has been a lot of work that suggests that during transplant rejection, an 
array of soluble mediators or cytokines are secreted in response to the recognition of 
foreign antigens on the graft by activated T cells, and depending on which cytokines 
are produced, different clinical outcomes may occur. As previously described, the 
"Thl/Th2 paradigm" is said to play a role. T helper I (Thl) cells are said to secrete 
cytokines such as IFN-y, IL-2 and IL-6, where these cytokines are suggested to be 
highly associated with transplant rejection. On the other hand, Th2 cells secrete 
cytokines including IL-4 and IL-l 0 and are proposed to be associated with tolerance 
(Mosmann and Coffman, 1989, Romagnani, 1991). These polarised Th1/Th2 
cytokines are also said to regulate each other (Nickerson et a/, 1994, Dallman, 1995), 
and that even the prevention of Thl responses is critical for tolerance (Chen et a/, 
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1996). However, more recently, it has become apparent that the Thlffh2 model, 
while providing a valuable framework for models such as transplant rejection, has 
been oversimplified (Kelso, 1995, Mosmann and Sad, 1996, Zhai et a/, 1999). As 
suggested by these three groups, this paradigm may not be sufficient to explain the 
recently demonstrated in vivo effects of cytokine manipulation on allograft rejection 
and survival. 
Our results suggest that both IFN-y and IL-l 0 are associated with incidence 
of rejection along with spontaneous IL-4 secretion. Thl cytokines such as IFN-y have 
been strongly associated with transplant rejection (Merville et a/, 1993a, 1993b, 
1995, D'Elios and Del Prete, 1998 (review), Oliveira et a/, 1998, Heeger et a/, 1999) 
and therefore this finding was expected. Merville et a/ ( 1993a) studied cytokine 
secretion (IFN-y, IL-2, IL-4, IL-6 and IL-10) in rejecting human kidney allografts. 
The results showed spontaneous secretion ofiFN-y, IL-6 and IL-10 with induction of 
IFN-y by IL-2 in rejecting allografts. IL-4 was found to be inhibitory. Although this 
study implicated both IFN-y and IL-10 in allograft rejection, the study focused on 
spontaneous secretion, of which we found IL-4 to be of importance. As previously 
mentioned, the same group, in a later study (Merville et a/, 1995) found high 
secretion of both IFN-y and IL-10 in activated cells in rejected kidney allografts, 
supporting the results found in this project. Oliveira et a/ ( 1998) analysed fifty six 
adult cadaver renal transplants by fine needle aspiration biopsy and found a high 
proportion of acute rejection patients to have a high percentage of Thl cytokine 
infiltration (IFN-y). Heeger et a/ (1999) found that pre-transplant frequencies of 
donor-specific IFN-y producing lymphocytes correlated with the risk of post-
transplant rejection episodes. The fact that IFN-y has been found to not only be 
associated with rejection in this study, but also in previous data, would allow the 
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suggestion that IFN-y may well contribute, together with other factors, to the 
occurrence, and possibly even to the progression of allograft rejection. 
Findings such as in the work of Joseph et a/ (1995) found using PCR that IL-
l 0 was expressed in rejecting allografts while IFN-y was absent. Xu et a/ ( 1995) 
demonstrated that IL-10 mRNA (together with IL-2 mRNA) significantly correlated 
with acute renal allograft rejection. These studies differ from the one here as they 
were looking at cytokine gene expression and not protein secretion. In addition, Lang 
et a/ ( 1996) measured levels oflL-2, IL-4, IL-l 0 and IFN-y in post-transplant serum 
and bile samples in liver transplant recipients. Significant elevations of both IL-4 and 
IL-l 0 were found at the site of rejection, with increased circulatory levels of IL-2, 
IL-4 and IFN-y. Weimer et a/ (1996) investigated the association of acute kidney 
graft rejection with factors including pre-transplant T helper/suppressor activity and 
in vitro cytokine profiles. The results showed that pre-transplant CD4 helper defects 
and low IL-l 0 responses predicted a low risk of graft rejection. Strehlau et a/ ( 1997) 
found that during acute renal allograft rejection, intragraft expression of cytokines, 
including IL-l 0, are significantly heightened. The finding that spontaneous IL-6 or 
MLR-stimulated IL-6 secretion did not appear to be associated with rejection was 
unusual. Kaminska et al ( 1996) studied baseline IL-6 serum and urine levels in 
rejected kidney allografts and found a significant positive association. Recent data 
presented by Marshall et al (British Transplantation Society Annual Congress, 1999) 
demonstrated a significant association between IL-6 low secretor polymorphism in 
the donor kidney and rejection. However, in the MLRs set up in this thesis project, 
IL-6 measured was that secreted by the recipient. Therefore the role of IL-6 m 
rejection is still not clearly understood, and further work needs to be carried out. 
Cytokine secretion has also been studied in heart transplantation. Grant et a/ 
( 1996) looked at serum cytokine secretion in twenty eight cardiac transplant 
....•. 
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recipients. It was found that there was no systemic relationship between cytokine 
levels and histological rejection in cardiac transplant recipients. This study again 
slightly differed to this project as the MLR was not used as a stimulation model for 
cytokine secretion. The MLR itself is currently considered as an unreliable assay for 
the prediction of rejection as there is evidence for (Langhoff et a/, 1985) and against 
(Cullen et a/, 1977, Steinmann et a/, 1994) the predictive nature of this assay. 
However, in BMT, a modification of the MLR (skin explant assay) has shown not 
only to demonstrate a direct involvement of cytokines (IFN-y and TNF-a.) in GVHD 
(Dickinson et a/, 1991) but also as a predictive method for GVHD in identical sibling 
pair BMT (Dickinson et a/, 1994b), thus suggesting that this modified cytokine-
based MLR may play a predictive role in BMT. Dickinson et a/ (1998) have more 
recently demonstrated that the skin explant assay to be more predictive for acute 
GVHD in comparison to CTL-p and HTL-p frequency analysis. Although some of 
our findings (ie; association of rejection with spontaneous IL-4 and MLR-stimulated 
IL-10 secretion) do not confirm original hypotheses about the role of Thl/Th2 
cytokines in rejection, it has still been illustrated that the pre-transplant cytokine-
based MLR may possibly predict risk of rejection, using IL-10 and IFN-y as 
predictive "markers". The association between spontaneous IL-4 secretion and 
rejection is also interesting as it may be possible that certain IL-4 gene 
polymorphisms may play a role in determining high/low IL-4 secretor status, and 
therefore risk of rejection. 
6.2.9. Multivariate analysis 
It has now been established that the cytokines IL-4 (spontaneous), IL-10 and 
IFN-y (MLR) are associated with rejection together with increase in HLA and HLA-
DR mismatching and donor sex as independent factors. In addition, it was shown that 
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both IL-10 and IFN-y secretion were associated with HLA-DR mismatching, but not 
total HLA mismatching. Based on these findings, multivariate analysis was then 
performed to determine whether any of these variables were associated in any way. It 
was found that relative risk of rejection was higher with female donors (RR=8.02; 
discussed earlier). In addition, a high HLA mismatch together with high IL-10 
secretion led to the highest risk of rejection (RR=25.46). As previously discussed, 
increase in HLA mismatching does correlate with increase risk of rejection. IL-10 
has also been associated with increased rejection episodes (also previously 
discussed). However, this finding was of interest as risk of rejection appeared to 
increase even more when both factors were involved. It may be concluded therefore 
that measurement of IL-l 0 secretion in the MLR succesfully predicted the highest 
risk of rejection compared to other cytokines. 
It has been shown that polymorphisms in the IL-l 0 gene promoter correlate 
with the amount of protein secreted (Turner et a/, 1997). In this same study, it was 
shown that low IL-10 secretor genotypes were associated with rejection after heart 
transplantation. Although the group looked at heart and not kidney transplant 
patients, the findings by Turner et a/ (1997) were in contrast to this study, as high IL-
l 0 secretion was found to be associated with increased risk of rejection. However, in 
agreement with the findings in this project is a recent publication by Sankaran et a/ 
(1999) where an association between high IL-10 (and TNF-a) producer genotype, 
HLA-DR mismatching and renal allograft rejection. In this study, rejection was also 
associated with high TNF-a genotype and HLA-DR mismatching. Genetic 
polymorphisms in the IL-10 promoter region is already being investigated with 
regards to renal transplantation (Kobayashi et a/, 1999), and therefore immediate 
analysis should be carried out to correlate the IL-10 genotypes of the renal transplant 
patients in this study with IL-10 protein secretion and risk of rejection. From this 
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further work, it will hopefully be detennined whether high IL-l 0 secretor genotypes 
are at more risk of rejection than low secretor genotypes. 
As with previous studies and this project illustrating a correlation between IL-
l 0 and rejection, this was a surprising result considering the anti-inflammatory 
functions of IL-10. As with Sankaran et a/ (1999), it was expected that high IL-10 
production would act against the production of proinflammatory Th I type cytokines, 
such as IFN-y (in this project) and TNF-a (in Sankaran et a/, 1999), and hence 
suppress acute graft rejection. However, recent reports have suggested that IL-10 
may enhance antibody responses against the graft (Merville et a/, 1995). 
Furthennore, IL-10 has been shown to be a potent stimulator, inducing 
differentiation and proliferation of 8 cells (Rousset et a/, 1992), thus activating 8 
cells to secrete immunoglobulins (Defrance et a/, 1992, 8anchereau et a/, 1993), thus 
driving the immune response towards the humoral pathway, and therefore part of the 
acute rejection response may be antibody mediated. 
6.2.10. Clinical and immunological factors on graft survival 
Analysis could not be perfonned to analyse whether any of the factors 
discussed above had any effect on graft survival as there were only a small number of 
renal transplant patients that suffered graft failure (n=6). It has been shown that 
factors such as HLA mismatches play a role in graft survival (Famey et a/, 1996, 
Freedman et a/, 1997, Fuller et a/, 1999, van der Meer et a/, 1999), therefore it would 
have been of interest to analyse whether HLA-DR was relevant to graft survival in 
this study, along with the predominant cytokines, IL-10 and IFN-y. 
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6.2.11. Pre- and post-transplant cvtokine profiles 
Finally, pre- and post-transplant cytokine profiles were compared in both 
rejectors and non-rejector groups. Unfortunately, not all of the patients had cytokine 
profiles measured at twelve months. In the four cytokines compared (IL-2, IL-4, IL-
10 and IFN-y), there appeared to be a general decrease in cytokine secretion after 
transplantation. There were no differences in cytokine profiles when comparing 
rejectors and non-rejectors. Only two patients (one rejector, one non-rejector) 
appeared to show an increase in all cytokine secretion. The fact that the majority of 
the patient group did show a decrease in cytokine production was almost certainly 
due to the effect of the immunosuppressive protocol. Immunosuppressive drugs such 
as cyclosporin A are known to suppress the activation of T cells and therefore 
cytokine secretion (Kahan, 1996, Bach and Viard, 1993, Rostaing et a/, 1999a). It 
was unsure as to why there was a subsequent decrease in cytokine production after 
three months in some patients, when dosage on immunosuppression is progressively 
reduced before this time. This may indicate induced tolerance in these patients, and 
therefore their whole cytokine profile continues to decrease. The reduction in 
cytokine production in a few of the patients may also be due to an increased number 
of alloreactive cells compared to other patients, and therefore the cytokine levels in 
these particular patients took longer to decrease, irrespective of reduction in 
immunosuppressive drugs. It remains unclear as to why two patients showed an 
increase post-transplant in all of the cytokines secreted. 
6.2.12 Summary of statistical analysis 
As stated previously, univariate analysis performed included x2 test, Kruskal-
Wallis test and Mann-Whitney U test. The x2 test was used as a preliminary analysis 
to find independent predictors of rejection eg; patient sex, HLA mismatching etc. To 
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establish whether cytokine protein levels were associated with rejection, low/high 
secretor status had to be determined. This was performed by dividing the groups so 
that a 50:50 split could be achieved. The data was handled in this way as it was 
easier for the analysis than to try and split the group into low, medium and high 
secretors as for the normal individuals (chapter 3). As before, there were outliers 
within the group, but these were again included in the analysis as they may be 
biologically significant. All of the data was again tested for normality, and it was 
found that each set of cytokine protein data did not conform to a normal distribution. 
Therefore, Kruskal-Wallis test was used when analysing the relationship between 
HLA and HLA-DR mismatching and protein secretion, and Mann-Whitney U test 
when analysing the significant difference in protein secretion between rejectors and 
non-rejectors as these analyses use the medians instead of the means (which would 
be used if the data was normally distributed). 
In addition, Th I and Th2 cytokine protein profiles were compared to analyse 
whether there were inverse relationships between the cytokines (as for the normal 
individuals) using Spearmans Rank analysis. Although some of the relationships 
appeared to be significant eg; spotaneous IFN-y and MLR-stimulated IL-10 
(CC=0.34, p=O.OI), this was not really a strong correlation compared to the 
relationship between MLR-stimulated IFN-y and MLR-stimulated IL-10 (CC=0.75, 
p=O.OOO I). Therefore, it may be suggested here that if enough multiple comparisons 
are performed, relationships may be found, even if they are weak. Finally, 
multivariate analysis was performed to establish the most significant factors 
associated with rejection. For this and the preliminary analysis, all p values were 
corrected, and again this did not affect the level (or lack of significance). 
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6.3. Thl and Th2 cytokine profiles- relationship to clinical outcome after 
identical sibling BMT 
6.3.1. Introduction 
GVHD may still occur after HLA-identical sibling BMT, and this is thought 
to be due to differences in minor histocompatibility antigens. The mixed Iymphocyte 
reaction (MLR) as measured by eH) thymidine incorporation has not been shown to 
be predictive for acute GVHD after identical sibling BMT. (Lim et a/, 1988, DeGast 
et a/, 1992). In this study, we wished to investigate whether the measurement of 
cytokines generated during the MLR were more predictive than eH) thymidine 
incorporation 
6.3.2. Cvtokine profiles and BMT clinical outcome 
MLRs were set up between eight HLA-identical donor-recipient pairs in the 
donor-versus-patient direction and Th I and Th2 cytokines (IL-2, IL-4, IL-l 0 and 
IFN-y) measured by ELISA. As there is evidence that Th I cytokines are thought to 
be implicated in acute GVHD (lmamura et a/, 1994, Tanaka et a/, 1995a, Krenger et 
a/, 1997), we wished to correlate these cytokine profiles with acute GVHD. Very low 
levels of secretion of IL-2, IL-10 and IFN-y were observed. In the case of IL-4, 
higher levels were detected but there was no inter-patient variation. No correlation 
was demonstrated between all four cytokines and acute GVHD. Donor-versus 
recipient cytokine production was essentially negative therefore, no real information 
could be evaluated from these results. 
It could be suggested that this study has not demonstrated evidence ofT cell 
responsiveness against minor histocompatibility antigens as measured by cytokine 
secretion in standard MLR, which is in accordance with previous studies using <l>JI 
thymidine incorporation (Lim et a/, 1988, DeGast et a/, 1992). It is well known that 
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cytokines are generated in the MLR. IL-2 and IFN-y protein secretion and IL-2, IFN-
y and IL-5 gene expression have been detected in MLR between HLA-identical 
siblings (Tanaka et a/, 1994, 1995a). However, these studies used a two-way MLR 
enhanced by Con A, and therefore these findings are not truly comparable to our 
results. 1n contrast to our findings, Dickinson et a[ ( 1994b) has demonstrated in the 
MLR section of the skin explant assay that high levels of Th I cytokines (in this case, 
TNF-a and IFN-y) correlate with the severity of acute GVHD after identical sibling 
BMT. This may be due to the difference in the way in which the MLR was set up in 
Dickinson et a/ (1994b) compared to this study. The MLR in Dickinson et a/ (1994b) 
was set up in 25ml culture flasks while the MLRs in this study were set up in 24 well 
culture plates. Although the culture plates in this study were tilted to enhance cell to 
cell contact, this may not have been as effective as if the cultures were set up in 
flasks for HLA-identical sibling pairs. Quantitative assays such as HTL-p frequency 
analysis (Schwarer et a/, 1993), are currently the only predictive assays for identical 
sibling BMT available, although a more recent study by Dickinson et a/ ( 1998) has 
shown that this quantitative assay (also including HTL-p and CTL-p analysis) 
illustrates no predictive value compared to the much referenced skin explant assay. 
From the results in this project, it may therefore be concluded that cytokine secretion 
during standard MLR is not a predictor for acute GVHD after identical sibling BMT. 
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6.4. Future work 
Future work that may arise from this project: 
t Both IL-10 and IFN-y were found to be strongly associated with risk of rejection. 
As cytokine secretor status has been linked to gene polymorphisms, it would be 
of interest to analyse IL-10 and IFN-y gene polymorphisms in the renal patient 
group and correlate this with the protein secretion data obtained from this project 
and rejection status. 
t As spontaneous IL-4 was also found to be associated with rejection, it would be 
of interest to look at IL-4 gene polymorphisms in this renal patient group. The 
role of IL-6 remains unclear in transplantation, and therefore IL-6 gene 
polymorphisms in this patient group may also be identified. All of this gene 
polymorphism data may then be correlated with protein secretion and rejection 
status. 
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6.5. Concluding points 
The main conclusions from this project are as follows: 
• Inter-individual variations m cytokine protein secretion and expression were 
found in mitogen stimulated and MLR cultures (protein secretion only). 
• A positive relationship was found between mitogen stimulated IL-2 protein and 
expression. 
• No relationship between IFN-y protein secretion, expression and/or gene 
polymorpbisms was observed. 
• Univariate analysis showed an association between HLA-DR mismatching and 
both IL-10 and IFN-y secretion in the MLR. 
• Univariate analysis also illustrated an association between renal allograft 
rejection and the following factors: spontaneous IL-4 protein secretion, IL-l 0 and 
IFN-y secretion in the MLR, donor sex, total HLA and HLA-DR mismatching. 
• Multivariate analysis showed an association between increased risk of rejection 
and the following factors: female donor sex, and in particular high HLA 
mismatching and high IL-l 0 protein secretion in the MLR. 
• A global decrease in cytokine protein secretion post-transplant was observed. 
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• The MLC was found to be of no predictive value for GVHD in identical sibling 
bone marrow transplantation. 
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Appendix 1 Cytokine data from normal individuals 
· PHA stimulated cvtokine protein (unstimulated in italics, stimulated in bold) 
Volunteer IL-2 IL-4 IL-10 IFN-y 
SB 0 1 I 0 
6 11 70 267 
GH 0 I 0 0 
0 15 35 645 
RS 0 I 0 0 
28 7 9 501 
NC 0 3 0 0 
1424 21 635 8000 
YW 0 I I 0 
8 37 139 640 
BY 0 2 I 0 
65 12 73 534 
SL 3 I I 0 
9 19 90 998 
SB 0 I I 0 
78 14 58 400 
SP 0 1 1 0 
12 8 87 1040 
PD 9 1 1 0 
178 69 216 2798 
PC 0 1 1 0 
51 13 85 863 
JC 2 1 1 0 
36 5 48 308 
DR 0 1 1 0 
353 20 260 2159 
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Appendix 1 continued 
Volunteer IL-2 IL-4 IL-10 IFN-y 
AK 20 1 1 0 
202 49 34 243 
NH 0 1 2 0 
30 7 24 53 
ss 0 3 1 0 
301 10 340 8000 
GJ 1 2 1 33 
97 10 460 8000 
TH 39 2 1 40 
200 7 635 8000 
CB 0 2 0 0 
1403 20 440 8000 
VM 95 2 1 0 
581 12 386 8000 
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Appendix 1 continued 
OKT3 stimulated cytokine protein (unstimulated in italics, stimulated in bold) 
Volunteer IL-2 IL-4 IL-10 IFN-y 
SB 4 14 0 0 
6 18 720 2786 
GH 4 14 0 0 
7 19 742 1046 
RS 3 15 0 3 
5 17 859 2236 
NC 5 15 0 2 
5 15 516 4250 
YW 5 13 0 6 
22 17 907 1188 
SB 4 13 0 5 
103 21 634 1470 
SP 4 13 0 6 
14 15 164 4441 
PD 7 16 1 2 
7 18 694 3757 
PC 5 15 0 5 
23 22 371 3718 
JC 10 12 0 0 
15 12 523 6341 
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Appendix 1 continued 
Volunteer IL-2 IL-4 IL-10 IFN-y 
DR 5 14 0 4 
10 16 973 5048 
AK 5 13 0 30 
6 15 975 3355 
NH 4 16 0 5 
10 22 351 226 
ss 5 12 0 20 
5 13 374 16330 
TH 8 13 0 11 
9 14 848 1290 
VM 4 15 0 7 
5 17 675 3491 
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Appendix 1 continued 
Cvtokine expression using PMA stimulation 
Volunteer IL-2 IFN-y 
SB 37 19 
GH 11 14 
RS 23 10 
NC 28 8 
YW 13 2 
BY 11 11 
SL 12 2 
SB 7 4 
SP 3 
PD 20 17 
PC 23 41 
JC 4 49 
DR 35 4 
AK 30 1 
NH 23 6 
ss 27 5 
GJ 21 25 
TH 19 5 
CB 36 3 
VM 27 5 
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Appendix 2 Clinical and laboratory details of renal transplant patients and donors 
Patient Donor Patient Patient Donor Donor 
age sex age sex 
HC AB 45 M 67 F 
MP AB 56 M 67 F 
MK GB 23 M 58 M 
KR AB 57 M 39 M 
BC AB 51 F 39 M 
JM vs 63 M 24 F 
LF MR 73 M 16 M 
MH AH 22 M 46 F 
AD LD 26 F 39 F 
SJ LF 34 F 26 M 
GE LF 49 M 26 M 
SD VH 48 F 46 F 
SG vu 49 F 46 F 
JC CT 64 M 37 F 
RE CT 59 M 37 F 
PD JJ 58 M 40 M 
AB TK 51 M 22 F 
CH JS 46 F 12 F 
JB JS 27 M 12 F 
RJ MB 62 M 57 F 
JPW SJ 44 F 26 M 
MT BG 54 F 50 M 
NH CB 29 F 39 F 
BP CB 60 F 39 F 
MB MP 38 M 47 F 
RH MP 47 M 47 F 
ES GR 34 F 41 M 
BW- DS 33 F 56 M 
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Appendix 2 continued 
Patient Donor Patient Patient Donor Donor 
age sex age sex 
EE DM 69 F 38 F 
EC PC 69 M 45 M 
GN PC 58 M 45 M 
KB EW 20 F 23 F 
TW AG 33 F 55 M 
AB AG 30 M 55 M 
JW PL 54 F 69 F 
AR PL 61 M 69 F 
LW JW 42 F 34 M 
PM KS 54 F 23 M 
NH CL 39 M 40 F 
RH DM 42 M 51 F 
JH DM 32 F 51 F 
JC SP 28 M 38 M 
JM BW 55 F 50 M 
AL BW 29 M 50 M 
SM WH 29 F 58 M 
cw WH 43 M 58 M 
DBR JT 50 M 67 F 
BS BJ 63 M 59 F 
JN BJ 38 F 59 F 
PG AP 43 M 69 F 
JT NG 24 M 23 M 
JL MB 53 M 53 F 
JA MB 54 M 53 F 
VE AJ 35 F 66 M 
CS KB 34 F 60 F 
NW JN 33 M 32 M 
WB JN 57 M 32 M 
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Appendix 2 continued 
Patient Rejection HLA anti- Previous Delayed/Immediate 
bodies(%) transplant function 
HC y 0 0 Immediate (Imm) 
MP y 0 0 I mm 
MK y 0 0 Imm 
KR N 4 0 I mm 
BC y 0 0 I mm 
JM N 0 0 I mm 
LF N 12 0 I mm 
MH N 0 0 I mm 
AD N 0 I mm 
SJ y 0 0 I mm 
GE N 0 2 I mm 
SD y 4 0 Delayed (Del) 
SG y 0 0 I mm 
JC y 0 0 I mm 
RE y 0 0 Del 
PD N 0 0 Imm 
AB y 0 0 Del 
CH N 0 0 I mm 
JB y 40 0 Del 
RJ N 0 0 Del 
JPW y 0 0 I mm 
MT N 0 0 I mm 
NH y 8 0 Del 
BP y ND 0 I mm 
MB y 0 0 I mm 
RH y 0 0 Del 
ES N 0 0 I mm 
BW N 0 I mm 
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Appendix 2 continued 
Patient Rejection HLA Previous Delayed/Immediate 
antibodies transplant function 
EE N 0 I mm 
EC N 0 0 I mm 
GN N 0 0 I mm 
KB N 0 0 I mm 
TW N 0 0 I mm 
AB NIA 0 2 Del 
JW y 0 0 Del 
AR N 0 0 I mm 
LW N 0 I mm 
PM N 0 0 Del 
NH y 8 0 I mm 
RH y 0 0 I mm 
JH y 0 0 Del 
JC N 0 0 I mm 
JM y 0 0 Del 
AL y 0 0 Del 
SM y 0 0 I mm 
cw N 0 0 Del 
DBR N 0 0 Del 
BS N 0 0 Nephrectomy 
JN NIA 0 0 I mm 
PG y ND 0 Del 
JT N 0 0 I mm 
JL y 0 0 I mm 
JA y 0 0 I mm 
VE N 12 Del 
CS y 0 0 I mm 
NW N 28 Del 
WB y 0 0 I mm 
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Appendix 2 continued 
Patient Donor Patient Donor HLA HLA-DR 
CMV CMV antigen mismatches 
HC AB Positive (P) p 5 2 
MP AB Negative (N) p 4 2 
MK GB N N 5 
KR AB p N 5 2 
BC AB p N 4 2 
JM vs p N 0 
LF MR N N 4 
MH AH N N 0 
AD LD N p 2 0 
SJ LF N N 6 2 
GE LF p N 3 
SD VH N p 4 
SG VH p p 3 
JC CT p p 2 
RE CT p p 3 0 
PD JJ p p 4 
AB TK N p 4 
CH JS N p 3 
JB JS N p 3 
RJ MB N p 3 
JPW SJ N N 4 
MT BG N p 5 2 
NH CB N p 4 
BP CB p p 3 
MB MP p N 5 2 
RH MP N N 5 2 
ES GR N N 3 0 
BW DS N N 4 
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Appendix 2 continued 
Patient Donor Patient Donor HLA HLA-DR 
CMV CMV antigen mismatches 
EE DM p p 2 0 
EC PC N p 3 
GN PC p p 2 
KB EW N p 3 0 
TW AG N N 3 0 
AB AG N p 3 0 
JW PL p p 4 
AR PL N p 3 
LW JW p p 2 1 
PM KS N p 3 
NH CL p p 3 
RH DM N p 2 
JH DM N N 2 
JC SP N p 2 
JM BW N p 2 
AL BW N p 3 0 
SM WH N p 3 
cw WH p p 2 0 
DBR JT N p 3 
BS BJ p p 0 0 
JN BJ N p 2 0 
PG AP N p 3 
JT NG N N 4 0 
JL MB N N 5 2 
JA MB N N 4 2 
VE AJ N p 0 
CS KB N N 4 
NW JN p N 3 
WB JN N N 3 
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Appendix 2 continued 
Patient Creatinine at 12 months Cold ischaemia time 
HC 131 20hrs 45mins 
MP 137 18hrs 45mins 
MK 392 22hrs 
KR 224 15hrs 45mins 
BC RIP 16hrs 
JM 121 16hrs I Omins 
LF 120 13hrs 50mins 
MH 166 2hrs 
AD 128 36hrs 
SJ 87 16hrs 46mins 
GE 138 2Ihrs 12mins 
SD RIP 17hrs 40mins 
SG 265 20hrs I Omins 
JC ~--- 168 18hrs 7 rnins 
RE Return to haemodialysis 15hrs 22mins 
PD 127 7hrs 40mins 
AB 160 Unknown 
CH 145 I Ohrs I Omins 
JB Unknown 17hrs 20mins 
RJ RIP I8hrs 35mins 
JPW 163 14hrs 40mins 
MT 114 43hrs 56mins 
NH Return to CAPD 23hrs 15mins 
BP 181 18hrs 
MB 219 16hrs 18mins 
RH Return to haemodialysis Unknown 
ES 150 19hrs llmins 
BW 117 15hrs IOmins 
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Appendix 2 continued 
Patient Creatinine at 12 months Cold ischaemia time 
EE 91 20hrs 40mins 
EC 189 21hrs 53mins 
GN 161 16hrs 5mins 
KB 136 25hrs 40mins 
TW 152 12hrs 27mins 
AB Return to haemodialysis 16hrs 58mins 
JW 180 20hrs 18mins 
AR 173 15hrs 39mins 
LW 130 25hrs 20mins 
PM 106 21hrs 4mins 
NH 143 28hrs 39mins 
RH 260 19hrs 12mins 
JH 143 16hrs 57mins 
JC 109 10hrs 9mins 
JM 121 16hrs 40mins 
AL NIA 19hrs 35mins 
SM 126 16hrs 2mins 
cw NIA 7hrs 2mins 
DBR RIP 21hrs 15mins 
BS Nephrectomy 22hrs 15mins 
JN Nephrectomy 18hrs 30mins 
PG Nephrectomy 17hrs 17mins 
JT NIA 11hrs 24mins 
JL NIA 19hrs 22mins 
JA NIA 21hrs 37mins 
VE NIA 43hrs 55mins 
CS NIA 25hrs lmin 
NW NIA 12hrs 35mins 
WB NIA 9hrs 52mins 
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Appendix 2 continued. 
Pre-transplant cvtokine profiles (background in italics, MLC in bold) 
PaUDon IL-2 IL-4 IL-6 IL-10 IFN-y 
HC/AB 0 pg/ml 9 1060 65 2129 
10 12 5856 71 3804 
MP/AB 0 10 355 149 649 
31 13 4165 184 1266 
MK/GB 10 3 310 2 30 
260 7 545 19 799 
KR/AB 4 2 1089 3 7 
842 13 1289 11 2531 
BC/AB 6 3 304 8 7 
917 11 1244 36 2728 
JMNS 1 3 136 0 4 
29 3 364 2 319 
LF/MR 4 3 1064 3 17 
555 10 8073 43 2896 
MH/AH 14 2 1315 5 39 
38 3 1788 5 96 
AD/LD 1 1 310 1 2 
127 3 951 2 313 
SJ/LF 0 10 356 0 0 
1319 20 3986 40 4311 
GEILF 0 10 637 4 0 
315 15 3936 10 1476 
SDNH 4 10 1060 172 120 
266 19 13598 298 9718 
SGNH 0 1 1078 96 110 
199 14 9386 142 7221 
JC/CT 0 9 1764 8 0 
. 
343 15 7851 13 2246 
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Appendix 2 continued. 
Pat/Don IL-2 IL-4 IL-6 IL-10 IFN-y 
RE/CT 0 10 1129 4 0 
321 14 5022 10 1540 
PD/JJ 1 2 0 0 3 
108 9 1127 6 985 
AB/TK 4 3 785 4 9 
120 5 1608 14 220 
CH/JS 2 9 1341 11 0 
37 10 6787 24 122 
JB/JS 3 10 1078 7 0 
81 11 8749 13 377 
RJ/MB 0 1 0 0 0 
1 2 16 0 0 
JPW/SJ 0 3 10 0 5 
179 5 97 0 16 
MT!BG 0 4 184 0 0 
110 7 485 6 291 
NH/CB 7 9 943 0 15 
120 12 3562 9 2612 
BP/CB 0 9 562 1 0 
174 14 1448 3 1085 
MB/MP 7 0 1 0 0 
16 1 14 0 17 
RH/MP 0 0 0 0 3 
0 2 11 0 0 
ES/GR 0 9 1396 26 1 
1 10 16790 68 92 
BW/DS 0 2 900 9 0 
12 2 950 1 11 
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Appendix 2 continued. 
Pat/Don IL-2 IL-4 IL-6 IL-10 IFN-y 
EE/DM 0 0 0 0 0 
0 2 16 0 0 
EC/PC 34 2 0 10 64 
442 15 993 16 642 
GN/PC 10 0 265 5 10 
208 5 2086 10 429 
KB/EW 1 2 502 0 0 
108 9 1127 6 985 
TW/AG 5 3 340 0 0 
7 4 750 1 7 
AB/AG 0 3 561 0 0 
1 4 30 0 0 
JW/PL 0 9 61 1 4 
232 14 663 3 1725 
ARIPL 1 3 1000 2 0 
316 11 1131 8 1447 
LW/JW 0 2 893 0 0 
0 2 7 0 0 
PM/KS 0 2 0 2 0 
455 12 3359 16 1690 
NH/CL 3 3 446 1 0 
7 4 542 4 9 
RHIDM 0 5 493 1 0 
728 24 3104 25 3606 
JH/DM 7 2 178 0 0 
593 14 754 23 1866 
JC/SP 13 0 249 0 5 
320 6 1473 12 446 
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Appendix 2 continued. 
PaUDon IL-2 IL-4 IL-6 IL-10 IFN-y 
JMJBW 4 3 146 9 I5 
400 5 6890 17 1850 
ALIBW 0 2 I266 2 0 
436 6 2504 15 642 
SM/WH 3 77 0 20 
454 8 1172 21 3504 
CW/WH 0 3 6I2 0 0 
44 8 447 4 194 
DBRIJT 3 3 52 4 4 
1017 14 966 46 4519 
BS!BJ 5 4 455 5 I7 
159 9 2472 8 505 
JNIBJ 4 4 3896 5 2 
572 14 2692 22 1330 
PG/AP I I 324 0 3 
0 2 75 0 0 
JT/NG 0 4 34 0 I 
33 3 78 0 0 
JL/MB 0 3 3I 0 0 
719 12 1839 46 1107 
JA/MB 0 3 147 0 0 
503 16 942 57 2386 
VE/AJ I 2 268 0 0 
6 3 137 0 0 
CSIKB Ill 7 9I 6 26 
130 7 367 23 53 
NW/JN 8I 7 8 7 10 
284 11 116 9 382 
WB/JN 0 7 64 0 0 
357 11 176 8 574 
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Appendix 2 continued. 
3 month post-transplant cvtokine profiles (background in italics, MLC in bold) 
Pat/Don IL-2 IL-4 IL-10 IFN-y 
HC/AB 0 3 0 0 
1 6 0 76 
MP/AB 0 3 0 0 
179 7 0 33 
MK/GB I 0 0 0 
249 4 0 1 
KR/AB 0 0 7 
34 2 0 26 
BC/AB ND ND ND ND 
ND ND ND ND 
JMNS 6 I 0 0 
298 2 0 0 
LF/MR 0 2 I7 I 
9 2 20 0 
MH/AH 0 I 0 0 
1 2 0 0 
AD lLD 0 I 0 3 
20 2 2 35 
SJ/LF 0 2 0 0 
517 10 1 2 
GEILF 0 3 0 0 
60 5 0 51 
SDNH I 2 0 0 
416 6 0 9 
SGNH 3 2 0 0 
7 3 0 2 
JC/CT 0 2 0 0 
78 3 - 0 1 
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Appendix 2 continued. 
Pat/Don IL-2 IL-4 IL-10 IFN-y 
RE/CT 0 3 0 0 
50 7 0 978 
PD/JJ 0 15 2 22 
170 17 9 837 
AB/TK 1 1 0 0 
20 2 0 0 
CH/JS 0 2 0 0 
28 4 0 21 
JB/JS ND ND ND ND 
ND ND ND ND 
RJ/MB 1 3 0 0 
1 5 0 1 
JPW/SJ 4 2 0 0 
115 3 1 1 
MT/BG 3 1 0 0 
3 2 0 12 
NH/CB ND ND ND ND 
ND ND ND ND 
BP/CB 1 15 0 1 
3 15 1 4 
MB/MP ND ND ND ND 
ND ND ND ND 
RH/MP ND ND ND ND 
ND ND ND ND 
ES/GR 0 2 0 18 
3 3 0 0 
BW/DS 0 16 2 4 
0 18 4 5 
EE/DM 2 14 0 2 
5 15 0 5 
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Appendix 2 continued. 
Pat/Don IL-2 IL-4 IL-10 IFN-y 
EC/PC 3 3 0 0 
41 6 0 0 
GN/PC ND ND ND ND 
ND ND ND ND 
KB/EW 0 3 0 0 
174 7 0 113 
TW/AG 0 3 0 2 
0 4 0 8 
AB/AG ND ND ND ND 
ND ND ND ND 
JW/PL 2 15 0 2 
10 16 8 2 
ARIPL 0 1 0 0 
0 15 0 0 
LW/JW 0 2 0 0 
1 3 0 1 
PM!KS 4 3 0 0 
31 3 0 2 
Nil/CL 1 2 0 0 
2 3 0 0 
RHIDM 1 3 0 0 
2 6 0 0 
JH/DM 1 3 0 0 
4 6 0 0 
JC/SP 2 3 0 0 
3 4 0 0 
JM/BW 2 2 0 0 
204 7 3 337 
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Appendix 2 continued. 
Pat/Don IL-2 IL-4 IL-10 IFN-y 
AL/BW 1 3 4 0 
143 5 14 142 
SMIWH 2 2 2 0 
118 6 3 389 
CW/WH 4 3 0 7 
11 4 0 14 
DBR/JT ND ND ND ND 
ND ND ND ND 
BS/BJ ND ND ND ND 
ND ND ND ND 
JN/BJ ND ND ND ND 
ND ND ND ND 
PG/AP ND ND ND ND 
ND ND ND ND 
JT/NG 0 17 0 1 
257 20 8 1002 
JL/MB 2 15 0 2 
603 18 7 602 
JAIMB 0 16 1 0 
359 25 19 359 
VE/AJ ND ND ND ND 
ND ND ND ND 
CS/KB ND ND ND ND 
ND ND ND ND 
NW/JN 234 24 29 193 
561 25 31 249 
WB/JN 0 18 1 1 
988 24 24 1600 
274 
Appendix 2 continued. 
12 months post-transplant cytokine profiles (background in italics, MLC in bold) 
Pat/Don IL-2 IL-4 IL-10 IFN-y 
HC/AB 6 4 0 0 
120 10 0 274 
MP/AB 4 4 0 0 
169 9 0 61 
MK/GB 5 3 0 6 
17 4 0 6 
KRJAB 1 3 0 0 
65 6 0 128 
BC/AB ND ND ND ND 
ND ND ND ND 
JMNS 2 3 0 0 
6 4 0 0 
LF/MR 3 3 0 0 
26 4 1 5 
MH/AH 1 3 0 0 
3 4 0 1 
AD lLD 1 2 0 0 
55 4 0 71 
SJ/LF 2 2 0 0 
118 8 2 149 
GE/LF 3 2 0 14 
24 8 2 476 
SDNH ND ND ND ND 
ND ND ND ND 
SGNH 1 3 0 0 
12 3 0 0 
JC/CT 4 4 0 2 
161 6 0 408 
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Appendix 2 continued. 
PaUDon IL-2 IL-4 IL-10 IFN-y 
RE/CT ND ND ND ND 
ND ND ND ND 
PD/JJ ND ND ND ND 
ND ND ND ND 
AB/TK 0 3 0 0 
44 3 1 16 
CH/JS ND ND ND ND 
ND ND ND ND 
JB/JS ND ND ND ND 
ND ND ND ND 
RJ/MB ND ND ND ND 
ND ND ND ND 
JPW/SJ 0 3 0 0 
35 5 0 5 
MT/BG ND ND ND ND 
ND ND ND ND 
NH/CB ND ND ND ND 
ND ND ND ND 
BP/CB 0 16 0 2 
0 15 0 14 
MB/MP ND ND ND ND 
ND ND ND ND 
RH/MP ND ND ND ND 
ND ND ND ND 
ES/GR 0 2 0 0 
0 2 0 0 
BW/DS ND ND ND ND 
ND ND ND ND 
EE/DM 0 15 0 0 
1 16 0 0 
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Appendix 2 continued. 
Pat/Don IL-2 IL-4 IL-10 IFN-y 
EC/PC ND ND ND ND 
ND ND ND ND 
GN/PC ND ND ND ND 
ND ND ND ND 
KBIEW ND ND ND ND 
ND ND ND ND 
TW/AG ND ND ND ND 
ND ND ND ND 
AB/AG ND ND ND ND 
ND ND ND ND 
JW/PL ND ND ND ND 
ND ND ND ND 
AR/PL ND ND ND ND 
ND ND ND ND 
LW/JW ND ND ND ND 
ND ND ND ND 
PMIKS ND ND ND ND 
ND ND ND ND 
NH/CL ND ND ND ND 
ND ND ND ND 
RHIDM ND ND ND ND 
ND ND ND ND 
JH/DM ND ND ND ND 
ND ND ND ND 
JC/SP ND ND ND ND 
ND ND ND ND 
JMIBW ND ND ND ND 
ND ND ND ND 
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Appendix 2 continued. 
Pat/Don IL-2 IL-4 IL-10 IFN-y 
ALIBW ND ND ND ND 
ND ND ND ND 
SM/WH ND ND ND ND 
ND ND ND ND 
CW/WH ND ND ND ND 
ND ND ND ND 
DBR/JT ND ND ND ND 
ND ND ND ND 
BSIBJ ND ND ND ND 
ND ND ND ND 
JNIBJ ND ND ND ND 
ND ND ND ND 
PG/AP ND ND ND ND 
ND ND ND ND 
JT/NG ND ND ND ND 
ND ND ND ND 
JL/MB ND ND ND ND 
ND ND ND ND 
JA/MB ND ND ND ND 
ND ND ND ND 
VE/AJ ND ND ND ND 
ND ND ND ND 
CSIKB ND ND ND ND 
ND ND ND ND 
NW/JN ND ND ND ND 
ND ND ND ND 
WB/JN ND ND ND ND 
ND ND ND ND 
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Appendix 3 HLA typing data in HLA mismatched renal transplant pairs 
HLA Mismatch Patient/Donor HLA Types (Patient/Donor) 
A 8 DR 
6 antigen SJILF 2, 10 7, 14 l, I 
I, ll 57,27 4, 13 
5 antigen HC/AB l, 24 8,44 15, 4 
2,3 7,44 7, 16 
KR/AB l, 28 8,60 7, 17 
2,26 7,60 4, 12 
MT/BG 2,28 27,51 8, 13 
24,25 18, 51 l, 103 
MBIMP 2, 3 7,49 13, 15 
l, 2, 57,50 7,8 
RH/MP 2, 3, 44,49 13, 13 
l ,2 50,57 7, 8 
BW/DS l, 9 8,27 l, 17 
l 2 35,35 l, 4 
4 antigen JT/NG 3,28 7,27 4, 13 
2,32 44,61 4, 13 
JLIMB 2,26 5,62 4, 17 
l ,2 8, 61 11, ll 
JAIMB l, l 61, 61 17, 17 
l, 2 8, 61 ll' 11 
CS/KB 9,29 13,44 7, 11 
24,29 14,45 l' ll 
MP/AB 2, 2 44,44 4,4 
2,3 7,44 7, 16 
MK/GB 2,2 35,60 13, 15 
2,28 39,61 14, 15 
BC/AB l, 2 7,8 14, 17 
2,26 7,60 4, 12 
LFIMR 2, ll 35,51 4, 15 
2, 23, 44,62 4, 7 
SDNH 2,32 18, 35, 12, 17 
2,24 8,61 7, 17 
PD/JJ 2,2 35,44 l' l 
I, l 35,38 l' 16 
AB/TK I, 29 13,35 4, 15 
l, 3 44,44 4,9 
JPW/SJ 3,24 7,62 4, 13 
23,24 8,50 4, 17 
NH/CB 24,29 7, 44, 7, 13 
24,26 38,62 4, 13 
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Appendix 3 continued 
HLA Mismatch Patient/Donor HLA Types 
A B DR 
4 antigen JW/PL I, 24 7, 8, 15, 17 
2,29 7,62 15, 14 
3 antigen AL/BW 2,24 27,57 4, 7 
2,29 35,44 4, 7 
SMIWH 3,3 27,44 I, 13 
3,30 18,27 I, 17 
DBRJJT 2, 28, 44,37 11, 13 
I, 2 44,57 I, 11 
PG/AP 2,3 44,60 7; 14 
3,29 35,44 7, 13 
NW/JN 1 ,2 8,44 4,4 
2,26 44,45 4, 7 
WB/JN 2,2 44,44 4,4 
2,26 44,45 4, 7 
GE/LF 11, 28 27, 51 I, 4 
1' 11 27,57 4, 13 
SGNH I, 24 8,44 4, 17 
2, 24 8, 61 7, 17 
RE/CT 2, 11 49, 70 11' 13 
2,28 44,62 11' 13 
CHIJS A1, 2 8,62 9, 17 
1' 11 8, 51 4, 17 
JB/JS A1, 2 7,8 15, 17 
1' 11 8, 51 4, 17 
RJ/MB 32,32 5, 14 7, 7 
1, 32 8, 14 7, 17 
BP/CB 1, 24 8,62 4, 17 
24,26 ' 38,62 4, 13 
ES/GR 3,29 44 60 4, 15 
2,2 44,51 4, 15 
EC/PC 2, 11 35,44 I, 12 
2,3 7, 35 1' 15 
KB/EW 1, 30 35,35 I, 13 
AI, 24 8,24 I, 13 
TW/AG 3,30 7, 13 11' 15 
I, 28 7,44 15, 15 
ABIAG 2, 11 7, 13 15, 15 
I, 28 7,44 15, 15 
AR/PL 3,29 7,44 7, 15 
2,29 7,62 14, 15 
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Appendix 3 continued 
HLA Mismatch Patient/Donor HLA Types 
A 8 DR 
3 antigen PMIKS 2,3 14,44 I, I 
2,26 27,44 I, 16 
NH/CL 3, 3 15,44 I 0, 13 
I, 3 37,44 10, 12 
2 antigen JM/BW 2,29 44,44 7, 7 
2,29 35,44, 4, 7 
CWIWH 30,30 13, 18 I, 17 
3,30 18, 27 I, 17 
JNIBJ 2,2 8,62 4, 17 
I, 2 8,44 4, 17 
AD lLD 30,32 13,60 4, 7 
32,32 14, 61 4, 7 
JC/CT 2,28 44,53 4, 13 
2, 28 44,62 13, 11 
EE/DM I, 2 8, 8 7, 15 
2, II 7, 8 7, I5 
GN/PC 2, 3 35,44 I, 4 
2, 3 7,35 I, I5 
LW/JW I, 24 7, 8 9, 17 
I, 2 7,8 15, 17 
RHIDM I, 2 8,8 I7, 17 
I , I 8,44 13, 17 
JH/DM I, I 8,8 I7, 17 
I I 8,44 13, 17 
JC/SP I, 2 8,8 I7,52 
I, 2 8,60 13, 17 
I antigen VE/AJ I, 25 8,44 9, I7 
I, 3 8,8 9, 17 
JMIVS 24,24 7, 14 7, 15 
3,24 7, 7 7, 15 
MHIAH 2, 2 7,55 14, 15 
I, 2 7,55 14, 14 
0 antigen BS/BJ I, 2 8,44 4, I7 
I, 2 8,44 4, 17 
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Appendix 4 HLA typing data in identical sibling bone marrow transplant pairs 
Donor/Patient Pair HLA Types (Donor/Patient) 
A B DR DQ 
KG/JH 2,32 7, I5 4, I6 
2,32 7, I5 4, I6 
HJ/SJ 2,3 7, 13 I, 7, 2,5 
2,3 7, I3 I, 7 2,5 
PW/GW I, 30 55,57 13, I5 
I,30 55,57 I3, I5 
AWILP 3I, 32, 44,60 
3I 32 44,60 
NB/AD II, 32 27,44 I, I 5, 5 
II, 32 27,44 I, I 5, 5 
MBIDB 3,32 7, I4 4, I5 6, 8 
3,32 7, I4 4, I5 6,8 
NC/AC 2, 25 I8,44 4, I5 
2,25 18,44 4, 15 
IC/MC 2,32 7, 61 4,8 4,8 
2,32 7, 61 4, 8 4, 8 
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